<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Int. J. Mol. Med</journal-id>
<journal-id journal-id-type="publisher-id">IJMM</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1107-3756</issn>
<issn pub-type="epub">1791-244X</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28731148</article-id>
<article-id pub-id-type="pmc">5547940</article-id>
<article-id pub-id-type="doi">10.3892/ijmm.2017.3071</article-id>
<article-id pub-id-type="publisher-id">ijmm-40-03-0587</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Molecular genetics and targeted therapy of WNT-related human diseases (Review)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Katoh</surname>
<given-names>Masuko</given-names>
</name>
<xref ref-type="aff" rid="af1-ijmm-40-03-0587">1</xref>
<xref ref-type="corresp" rid="c1-ijmm-40-03-0587"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Katoh</surname>
<given-names>Masaru</given-names>
</name>
<xref ref-type="aff" rid="af2-ijmm-40-03-0587">2</xref>
</contrib>
</contrib-group>
<aff id="af1-ijmm-40-03-0587">
<label>1</label>M&amp;M Medical BioInformatics, Tokyo 113-0033</aff>
<aff id="af2-ijmm-40-03-0587">
<label>2</label>Department of Omics Network, National Cancer Center, Tokyo 104-0045, Japan</aff>
<author-notes>
<corresp id="c1-ijmm-40-03-0587">Correspondence to: Dr Masaru Katoh, Department of Omics Network, National Cancer Center, 5-1-1 Tsukiji, Chuo-Ward, Tokyo 104-0045, Japan, E-mail: <email>mkatoh-kkr@umin.ac.jp</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>19</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>19</day>
<month>7</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>40</volume>
<issue>3</issue>
<fpage>587</fpage>
<lpage>606</lpage>
<history>
<date date-type="received">
<day>03</day>
<month>4</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>7</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © Katoh et al.</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p>
</license>
</permissions>
<abstract>
<p>Canonical WNT signaling through Frizzled and LRP5/6 receptors is transduced to the WNT/β-catenin and WNT/stabilization of proteins (STOP) signaling cascades to regulate cell fate and proliferation, whereas non-canonical WNT signaling through Frizzled or ROR receptors is transduced to the WNT/planar cell polarity (PCP), WNT/G protein-coupled receptor (GPCR) and WNT/receptor tyrosine kinase (RTK) signaling cascades to regulate cytoskeletal dynamics and directional cell movement. WNT/β-catenin signaling cascade crosstalks with RTK/SRK and GPCR-cAMP-PKA signaling cascades to regulate β-catenin phosphorylation and β-catenin-dependent transcription. Germline mutations in WNT signaling molecules cause hereditary colorectal cancer, bone diseases, exudative vitreoretinopathy, intellectual disability syndrome and PCP-related diseases. <italic>APC</italic> or <italic>CTNNB1</italic> mutations in colorectal, endometrial and prostate cancers activate the WNT/β-catenin signaling cascade. <italic>RNF43</italic>, <italic>ZNRF3</italic>, <italic>RSPO2</italic> or <italic>RSPO3</italic> alterations in breast, colorectal, gastric, pancreatic and other cancers activate the WNT/β-catenin, WNT/STOP and other WNT signaling cascades. ROR1 upregulation in B-cell leukemia and solid tumors and ROR2 upregulation in melanoma induce invasion, metastasis and therapeutic resistance through Rho-ROCK, Rac-JNK, PI3K-AKT and YAP signaling activation. WNT signaling in cancer, stromal and immune cells dynamically orchestrate immune evasion and antitumor immunity in a cell context-dependent manner. Porcupine (PORCN), RSPO3, WNT2B, FZD5, FZD10, ROR1, tankyrase and β-catenin are targets of anti-WNT signaling therapy, and ETC-159, LGK974, OMP-18R5 (vantictumab), OMP-54F28 (ipafricept), OMP-131R10 (rosmantuzumab), PRI-724 and UC-961 (cirmtuzumab) are in clinical trials for cancer patients. Different classes of anti-WNT signaling therapeutics are necessary for the treatment of APC/CTNNB1-, RNF43/ZNRF3/RSPO2/RSPO3- and ROR1-types of human cancers. By contrast, Dickkopf-related protein 1 (DKK1), SOST and glycogen synthase kinase 3β (GSK3β) are targets of pro-WNT signaling therapy, and anti-DKK1 (BHQ880 and DKN-01) and anti-SOST (blosozumab, BPS804 and romosozumab) monoclonal antibodies are being tested in clinical trials for cancer patients and osteoporotic post-menopausal women. WNT-targeting therapeutics have also been applied as reagents for <italic>in vitro</italic> stem-cell processing in the field of regenerative medicine.</p>
</abstract>
<kwd-group>
<kwd>Alzheimer's disease</kwd>
<kwd>angiogenesis</kwd>
<kwd>cancer stem cells</kwd>
<kwd>epithelial-to-mesenchymal transition</kwd>
<kwd>FGF</kwd>
<kwd>myeloid-derived suppressor cells</kwd>
<kwd>Notch</kwd>
<kwd>regulatory T cells</kwd>
<kwd>tumor microenvironment</kwd>
<kwd>WNT5A</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec>
<title>1. Introduction</title>
<p>The WNT family of secreted glycoproteins consists of WNT1 (INT1), WNT2, WNT2B (WNT13), WNT3 (INT4), WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A (WNT14), WNT9B (WNT14B), WNT10A, WNT10B, WNT11 and WNT16 (<xref ref-type="bibr" rid="b1-ijmm-40-03-0587">1</xref>). WNT signals are transduced through the Frizzled family comprising seven-transmembrane receptors (FZD1, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9 and FZD10) and single-transmembrane co-receptors (LRP5, LRP6, ROR1 and ROR2) to initiate the canonical and non-canonical signaling cascades (<xref ref-type="bibr" rid="b2-ijmm-40-03-0587">2</xref>,<xref ref-type="bibr" rid="b3-ijmm-40-03-0587">3</xref>).</p>
<p>Canonical WNT signaling through Frizzled and LRP5/6 receptors promotes β-catenin-dependent transcription of TCF/LEF target genes (WNT/β-catenin signaling) (<xref ref-type="bibr" rid="b4-ijmm-40-03-0587">4</xref>) and β-catenin-independent de-repression of FOXM1, NRF2 (NFE2L2), YAP and other proteins [WNT/stabilization of proteins (STOP) signaling] (<xref ref-type="bibr" rid="b5-ijmm-40-03-0587">5</xref>,<xref ref-type="bibr" rid="b6-ijmm-40-03-0587">6</xref>) (<xref ref-type="fig" rid="f1-ijmm-40-03-0587">Fig. 1</xref>). By contrast, non-canonical WNT signaling through Frizzled or ROR receptors activates Dishevelled-dependent Rho-ROCK and Rac-JNK cascades [WNT/planar cell polarity (PCP) signaling] (<xref ref-type="bibr" rid="b7-ijmm-40-03-0587">7</xref>); G protein-dependent calcineurin-NFAT, CAMK2-NLK and PKC cascades [WNT/G protein-coupled receptor (GPCR) signaling] (<xref ref-type="bibr" rid="b2-ijmm-40-03-0587">2</xref>); and receptor tyrosine kinase (RTK)-dependent PI3K-AKT (<xref ref-type="bibr" rid="b8-ijmm-40-03-0587">8</xref>) and YAP/TAZ (<xref ref-type="bibr" rid="b9-ijmm-40-03-0587">9</xref>) cascades (WNT/RTK signaling) (<xref ref-type="fig" rid="f1-ijmm-40-03-0587">Fig. 1</xref>). WNT signals regulate self-renewal, metabolism, survival, proliferation and epithelial-to-mesenchymal transition (EMT) of target cells (<xref ref-type="bibr" rid="b10-ijmm-40-03-0587">10</xref>–<xref ref-type="bibr" rid="b13-ijmm-40-03-0587">13</xref>), and crosstalk with FGF, Hedgehog, Notch and transforming growth factor-β (TGF-β) signals (<xref ref-type="bibr" rid="b14-ijmm-40-03-0587">14</xref>–<xref ref-type="bibr" rid="b16-ijmm-40-03-0587">16</xref>). As the intracellular and intercellular WNT signaling networks orchestrate embryogenesis and homeostasis, genetic alterations in WNT signaling molecules are involved in the pathogenesis of various types of human cancers and noncancerous diseases (<xref ref-type="fig" rid="f2-ijmm-40-03-0587">Fig. 2</xref>).</p>
<p>Next-generation sequencing that produces huge amounts of genomic, epigenomic and transcriptomic data (<xref ref-type="bibr" rid="b17-ijmm-40-03-0587">17</xref>–<xref ref-type="bibr" rid="b20-ijmm-40-03-0587">20</xref>) and cell-based technologies, such as induced pluripotent stem cells (iPSCs) (<xref ref-type="bibr" rid="b21-ijmm-40-03-0587">21</xref>–<xref ref-type="bibr" rid="b23-ijmm-40-03-0587">23</xref>), direct reprogramming to somatic stem/progenitor cells (<xref ref-type="bibr" rid="b24-ijmm-40-03-0587">24</xref>) and CRISPR/Cas9-mediated genome editing (<xref ref-type="bibr" rid="b25-ijmm-40-03-0587">25</xref>,<xref ref-type="bibr" rid="b26-ijmm-40-03-0587">26</xref>), have been elucidating the mechanistic involvement of the WNT signaling cascades in human pathophysiology and opening up new therapeutics avenues for human diseases.</p>
<p>We carried out the Human WNTome and Post-WNTome Projects to construct a platform of medical WNT research in the late 1990s and early 2000s (<xref ref-type="bibr" rid="b1-ijmm-40-03-0587">1</xref>,<xref ref-type="bibr" rid="b2-ijmm-40-03-0587">2</xref>,<xref ref-type="bibr" rid="b7-ijmm-40-03-0587">7</xref> and references therein). Despite amazing progress in basic studies of WNT signaling and genetics, there is still a huge gap that must be addressed before WNT-targeted therapy for patients can be applied. A mechanistic understanding of the pathogenesis of WNT-related diseases is necessary to address the gap between basic research and clinical application. Here, human genetics and genomics of WNT-related diseases will be reviewed (<xref ref-type="table" rid="tI-ijmm-40-03-0587">Table I</xref>), and then, clinical application of WNT signaling-targeted therapy using small-molecule compounds, human/humanized monoclonal antibodies (mAb) and chimeric antigen receptor-modified T cells (CAR-T) will be discussed.</p>
</sec>
<sec>
<title>2. Hereditary colorectal cancer and various types of sporadic cancers</title>
<p>Germline mutations in the <italic>APC</italic> gene occur in patients with familial adenomatous polyposis, which is characterized by innumerable colorectal adenomas and predisposition to colorectal cancer (<xref ref-type="bibr" rid="b27-ijmm-40-03-0587">27</xref>), whereas germline mutations in the <italic>AXIN2</italic> and <italic>RNF43</italic> genes occur in patients with oligodontia-colorectal cancer syndrome (<xref ref-type="bibr" rid="b28-ijmm-40-03-0587">28</xref>) and sessile serrated polyposis cancer syndrome (<xref ref-type="bibr" rid="b29-ijmm-40-03-0587">29</xref>), respectively. Hereditary colorectal cancer is caused by loss-of-function mutations in the <italic>APC</italic>, <italic>AXIN2</italic> and <italic>RNF43</italic> genes (<xref ref-type="fig" rid="f2-ijmm-40-03-0587">Fig. 2</xref>).</p>
<p>Somatic <italic>APC</italic> mutations preferentially occur in non-hypermutated or conventional colorectal cancers, and somatic <italic>AXIN2</italic> and <italic>RNF43</italic> mutations preferentially occur in hypermutated or microsatellite-unstable colorectal cancers (<xref ref-type="bibr" rid="b30-ijmm-40-03-0587">30</xref>,<xref ref-type="bibr" rid="b31-ijmm-40-03-0587">31</xref>). Gain-of-function mutations in the <italic>CTNNB1</italic> gene encoding β-catenin (S33C, S37F/Y, T41A or S45F/P), <italic>EIF3E</italic>-<italic>RSPO2</italic> fusions and <italic>PTPRK</italic>-<italic>RSPO3</italic> fusions also occur in sporadic colorectal cancers (<xref ref-type="bibr" rid="b31-ijmm-40-03-0587">31</xref>,<xref ref-type="bibr" rid="b32-ijmm-40-03-0587">32</xref>). Loss-of-function <italic>APC</italic> mutations, gain-of-function <italic>CTNNB1</italic> mutations or loss-of-function <italic>RNF43</italic> or <italic>ZNRF3</italic> mutations have also been reported in breast cancer (<xref ref-type="bibr" rid="b33-ijmm-40-03-0587">33</xref>), gastric cancer (<xref ref-type="bibr" rid="b34-ijmm-40-03-0587">34</xref>), hepatocellular carcinoma (<xref ref-type="bibr" rid="b35-ijmm-40-03-0587">35</xref>), lung cancer (<xref ref-type="bibr" rid="b36-ijmm-40-03-0587">36</xref>), pancreatic cancer (<xref ref-type="bibr" rid="b37-ijmm-40-03-0587">37</xref>), prostate cancer (<xref ref-type="bibr" rid="b38-ijmm-40-03-0587">38</xref>) and uterine corpus endometrial carcinoma (<xref ref-type="bibr" rid="b39-ijmm-40-03-0587">39</xref>). Various types of human cancers are driven by somatic alterations in the canonical WNT signaling molecules, such as APC, AXIN2, β-catenin, RNF43, RSPO2 and RSPO3 (<xref ref-type="fig" rid="f2-ijmm-40-03-0587">Fig. 2</xref>).</p>
<p>In the adult intestine, WNT2B and WNT3 are secreted from pericryptal cells and Paneth cells, respectively, and transduce canonical WNT signaling through FZD7 for the maintenance of crypt base columnar (CBC) stem cells (<xref ref-type="bibr" rid="b40-ijmm-40-03-0587">40</xref>,<xref ref-type="bibr" rid="b41-ijmm-40-03-0587">41</xref>). Binding of canonical WNTs to the FZD and LRP5/6 receptors induces formation of the FZD-Dishevelled-AXIN-LRP5/6 complex and release of β-catenin from its degradation complex consisting of APC, AXIN, casein kinase 1 (CK1) and glycogen synthase kinase 3β (GSK3β), which results in nuclear translocation of stabilized β-catenin and subsequent transcriptional activation of TCF/LEF target genes, such as <italic>AXIN2</italic>, cyclin D1 (<italic>CCND1</italic>), <italic>FZD7</italic> and c-Myc (<italic>MYC</italic>) (<xref ref-type="fig" rid="f3-ijmm-40-03-0587">Fig. 3</xref>). Gain-of-function mutations in the <italic>CTNNB1</italic> gene, as well as loss-of-function mutations in the <italic>APC</italic> and <italic>AXIN2</italic> genes, activate the canonical WNT/β-catenin signaling cascade that regulates self-renewal, survival, proliferation and differentiation of tumor cells.</p>
<p>RNF43 and ZNRF3 are transmembrane-type E3-ubiquitin ligases that downregulate cell-surface FZD receptors through ubiquitylation and attenuate canonical and non-canonical WNT signaling, whereas RSPO2 and RSPO3 are RNF43/ZNRF3 ligands that de-repress FZD receptors from RNF43/ZNRF3-mediated degradation and enhance WNT signaling (<xref ref-type="bibr" rid="b3-ijmm-40-03-0587">3</xref>,<xref ref-type="bibr" rid="b42-ijmm-40-03-0587">42</xref>). Loss-of-function mutations in the <italic>RNF43</italic> and <italic>ZNRF3</italic> genes, as well as <italic>EIF3E</italic>-<italic>RSPO2</italic> and <italic>PTPRK</italic>-<italic>RSPO3</italic> fusions, potentiate the WNT/β-catenin signaling cascade and β-catenin-independent WNT signaling cascades (<xref ref-type="fig" rid="f4-ijmm-40-03-0587">Fig. 4</xref>).</p>
<p><italic>APC</italic> and <italic>CTNNB1</italic> alterations in conventional colorectal cancers induce WNT-independent activation of the β-catenin signaling cascade, whereas <italic>RNF43</italic>, <italic>RSPO2</italic> and <italic>RSPO3</italic> alterations in non-conventional colorectal cancers can activate the WNT/β-catenin and other WNT signaling cascades (<xref ref-type="fig" rid="f4-ijmm-40-03-0587">Fig. 4</xref>). To target different classes of genetic alterations in the WNT signaling molecules, several types of anti-WNT signaling therapeutics have been developed and are described later.</p>
</sec>
<sec>
<title>3. Intellectual disability syndrome, Alzheimer's disease and bipolar disorder</title>
<p>β-catenin, encoded by the <italic>CTNNB1</italic> gene, is a scaffold protein that interacts with WNT signaling components (including APC, AXIN, BCL9 and TCF/LEF), adhesion molecules (such as E-cadherin, N-cadherin and α-catenin) and epigenetic/transcriptional regulators (for example, CBP, p300, EZH2 and SMARCA4/BRG1) (<xref ref-type="bibr" rid="b43-ijmm-40-03-0587">43</xref>,<xref ref-type="bibr" rid="b44-ijmm-40-03-0587">44</xref>). Cadherin-bound β-catenin is stable and involved in the maintenance of cell-cell adhesion, whereas cytoplasmic free β-catenin is degraded in the proteasome through priming phosphorylation at S45 by CK1, following phosphorylation at S33, S37 and T41 by GSK3β, and subsequent poly-ubiquitylation at K19 by E3 ubiquitin ligase (<xref ref-type="bibr" rid="b45-ijmm-40-03-0587">45</xref>). Canonical WNT signaling activation leads to stabilization and nuclear translocation of cytoplasmic β-catenin as mentioned above (<xref ref-type="fig" rid="f3-ijmm-40-03-0587">Fig. 3</xref>). By contrast, activation of BCR-ABL, FLT3, KIT, SRC and RET tyrosine kinases (<xref ref-type="bibr" rid="b43-ijmm-40-03-0587">43</xref>,<xref ref-type="bibr" rid="b46-ijmm-40-03-0587">46</xref>–<xref ref-type="bibr" rid="b48-ijmm-40-03-0587">48</xref>) leads to release and nuclear translocation of cadherin-bound β-catenin through phosphorylation at Y654 and subsequent PKA-dependent phosphorylation at S675 (<xref ref-type="bibr" rid="b49-ijmm-40-03-0587">49</xref>). β-catenin is located at the crossroad of canonical WNT, tyrosine kinase and GPCR-cAMP-PKA signaling cascades for the regulation of cell adhesion, cell fate and cell functions (<xref ref-type="fig" rid="f3-ijmm-40-03-0587">Fig. 3</xref>).</p>
<p><italic>De novo</italic> loss-of-function mutations in the <italic>CTNNB1</italic> gene (for example, Q309X, S425fs and R515X) have been reported in patients with intellectual disability and other common features, such as microcephaly, speech disorder, truncal hypotonia and distal hypertonia (<xref ref-type="bibr" rid="b50-ijmm-40-03-0587">50</xref>). A loss-of-function <italic>CTNNB1</italic> mutation (P706fs) has also been reported in a patient presenting with intellectual disability, autism-like features, exudative vitreoretinopathy and lipomyelomeningocele (a closed form of neural tube defect) (<xref ref-type="bibr" rid="b51-ijmm-40-03-0587">51</xref>). WNT/β-catenin signals promote symmetrical and asymmetrical divisions of neural stem cells for their expansion and generation of neural progenitor cells, respectively, regulate proliferation and differentiation of neural progenitor cells in a context-dependent manner, and thus, maintain synaptic function (<xref ref-type="bibr" rid="b52-ijmm-40-03-0587">52</xref>). Therefore, loss-of-function mutations in the <italic>CTNNB1</italic> gene give rise to intellectual disability syndrome through impaired expansion and differentiation of neural stem/progenitor cells during embryonic, perinatal and postnatal brain development (<xref ref-type="fig" rid="f2-ijmm-40-03-0587">Fig. 2</xref>).</p>
<p>WNT/β-catenin signals are also necessary for adult neurogenesis or neuronal plasticity and synaptic maintenance (<xref ref-type="bibr" rid="b53-ijmm-40-03-0587">53</xref>). As WNT/β-catenin signaling induces the expression of the NeuroD1 transcription factor to promote neurogenesis in the hippocampus and olfactory bulb, Dickkopf-related protein 1 (Dkk1) upregulation in the hippocampus of SAMP8 mice is associated with decreased canonical WNT signaling and neuronal loss (<xref ref-type="bibr" rid="b54-ijmm-40-03-0587">54</xref>) and Wnt3 downregulation in the olfactory bulb of streptozotocin-induced diabetic rats is associated with impaired odor discrimination, cognitive dysfunction and increased anxiety (<xref ref-type="bibr" rid="b55-ijmm-40-03-0587">55</xref>). Dkk1 induction in the hippocampus of iDkk1 transgenic mice causes synaptic loss and memory defects through canonical WNT/β-catenin signaling inhibition and non-canonical WNT/RhoA-ROCK signaling activation, whereas Dkk1 repression reverts the Alzheimer's disease-like phenotypes in the iDkk1 transgenic mice (<xref ref-type="bibr" rid="b56-ijmm-40-03-0587">56</xref>). WNT/β-catenin signaling also induces expression of the REST silencing factor to protect neurons from oxidative stress and aggregated misfolded protein in aging brains; however, neuronal nuclear REST is lost in patients with Alzheimer's disease, frontotemporal dementia and Lewy-body dementia (<xref ref-type="bibr" rid="b57-ijmm-40-03-0587">57</xref>). By contrast, impaired canonical WNT/β-catenin signaling is involved in the pathogenesis of bipolar disorder through defective resilience to chronic stress (<xref ref-type="bibr" rid="b58-ijmm-40-03-0587">58</xref>). WNT7B downregulation in CXCR4<sup>+</sup> neural progenitor cells derived from bipolar-disease iPSCs is associated with a reduced proliferation potential, and canonical WNT/β-catenin signaling activation using GSK3 inhibitor (CHIR99021) restores the proliferation deficits (<xref ref-type="bibr" rid="b59-ijmm-40-03-0587">59</xref>), which explains the rationale why another GSK3 inhibitor, lithium, is utilized for the treatment of patients with bipolar disorder. Together, these facts indicate that impaired WNT/β-catenin signaling is involved in the pathogenesis of neuropsychiatric diseases, such as Alzheimer's disease and bipolar disorder.</p>
</sec>
<sec>
<title>4. Bone diseases</title>
<p>Bone homeostasis is maintained by mesenchymal stem cells that generate osteoblasts, osteoblast-derived osteocytes and other types of mesenchymal cells, as well as hematopoietic stem cells that give rise to monocytes, monocyte-derived osteoclasts and other types of blood cells. Canonical WNT/β-catenin signaling through Frizzled and LRP5/6 receptors promotes RUNX2-dependent osteoblastic differentiation of mesenchymal stem or progenitor cells (<xref ref-type="bibr" rid="b60-ijmm-40-03-0587">60</xref>,<xref ref-type="bibr" rid="b61-ijmm-40-03-0587">61</xref>). Canonical WNT signaling in osteoblast-lineage cells upregulates BMP2, and then BMP2 signaling through BMPR1A upregulates WNT7A/10B to synergistically potentiate osteoblastogenesis and bone formation (<xref ref-type="bibr" rid="b62-ijmm-40-03-0587">62</xref>,<xref ref-type="bibr" rid="b63-ijmm-40-03-0587">63</xref>). BMP2 signaling in osteoblast-lineage cells also upregulates the canonical WNT inhibitors DKK1 and sclerostin (SOST) to turn off canonical WNT signaling for the fine-tuning of bone mass (<xref ref-type="bibr" rid="b64-ijmm-40-03-0587">64</xref>,<xref ref-type="bibr" rid="b65-ijmm-40-03-0587">65</xref>). By contrast, parathyroid hormone (PTH) signaling through PTH1R in osteoblast-lineage cells downregulates SOST to promote bone formation and upregulates RANK ligand (RANKL) to induce osteoclastic differentiation of osteoclast progenitors (<xref ref-type="bibr" rid="b66-ijmm-40-03-0587">66</xref>). Non-canonical WNT5A signaling through ROR2 in osteoclast progenitors upregulates the RANK receptor to promote RANKL-induced osteoclastogenesis and bone resorption (<xref ref-type="bibr" rid="b67-ijmm-40-03-0587">67</xref>). WNT signaling cascades crosstalk with BMP, cytokine and PTH signaling cascades in a context-dependent manner to precisely control the balance of bone formation and resorption.</p>
<p>Aberrant canonical WNT signaling activation gives rise to bone-formation phenotypes (<xref ref-type="fig" rid="f2-ijmm-40-03-0587">Fig. 2</xref>). Loss-of-function mutation or deletion in the SOST gene occurs in patients with sclerosing skeletal dysplasias, such as craniodiaphyseal dysplasia (<xref ref-type="bibr" rid="b68-ijmm-40-03-0587">68</xref>), sclerosteosis (<xref ref-type="bibr" rid="b69-ijmm-40-03-0587">69</xref>) and van Buchem disease (<xref ref-type="bibr" rid="b70-ijmm-40-03-0587">70</xref>). Heterozygous mutations in the N-terminal signal peptide of SOST (V21M/L) are detected in patients with craniodiaphyseal dysplasia, the most severe form of SOST-defective disease, which is characterized by massive hyperostosis with leonine face and craniofacial foraminal stenosis. Homozygous missense mutation (Q24X) and enhancer deletion in the <italic>SOST</italic> gene are detected in patients with sclerosteosis and van Buchem disease, respectively, which are characterized by gigantism, facial palsy and hearing loss. Sclerosteosis is a severe form of SOST-defective disease frequently presenting with syndactyly, whereas van Buchem disease is a mild form of SOST-defective disease without syndactyly. By contrast, LRP5 mutations in the first β-propeller domain (for example, D111Y, G171R, A214T and A242T) have been reported in patients with high-bone-mass diseases, such as van Buchem disease type 2, endosteal hyperostosis and osteopetrosis type 1 (<xref ref-type="bibr" rid="b71-ijmm-40-03-0587">71</xref>). LRP5 mutations in the first β-propeller domain are gain-of-function mutations, as SOST and DKK1 bind to the first β-propeller domain of LRP5 to inhibit canonical WNT signaling (<xref ref-type="bibr" rid="b64-ijmm-40-03-0587">64</xref>,<xref ref-type="bibr" rid="b65-ijmm-40-03-0587">65</xref>). Loss-of-function SOST mutations and gain-of-function LRP5 mutations cause bone-formation phenotypes in patients with sclerosing skeletal dysplasias and high-bone-mass diseases, respectively.</p>
<p>Defects in canonical WNT signaling and/or aberrant activation of non-canonical WNT signaling cause bone-resorption phenotypes (<xref ref-type="fig" rid="f2-ijmm-40-03-0587">Fig. 2</xref>). Osteoporosis is characterized by low bone mineral density (BMD), deteriorated bone quality and susceptibility to fracture, whereas osteogenesis imperfecta is a prenatal-onset osteoporotic disease characterized by brittle bones (<xref ref-type="bibr" rid="b72-ijmm-40-03-0587">72</xref>,<xref ref-type="bibr" rid="b73-ijmm-40-03-0587">73</xref>). Homozygous loss-of-function mutations in the <italic>LRP5</italic> gene (such as R428X, E485X, D490fs and D718X) have been detected in patients with osteoporosis-pseudoglioma syndrome, which is characterized by osteoporosis and eye phenotypes (exudative vitreoretinopathy and susceptibility to blindness) (<xref ref-type="bibr" rid="b74-ijmm-40-03-0587">74</xref>). Heterozygous loss-of-function mutation in the <italic>LRP6</italic> gene (R611C) was found in patients with familial osteoporosis and early-onset coronary artery disease (<xref ref-type="bibr" rid="b75-ijmm-40-03-0587">75</xref>). Heterozygous loss-of-function WNT1 mutation (C218G) occurs in patients with early-onset osteoporosis, and homozygous loss-of-function WNT1 mutation (S295X) occurs in patients with osteogenesis imperfecta (<xref ref-type="bibr" rid="b73-ijmm-40-03-0587">73</xref>). By contrast, homozygous loss-of-function <italic>SFRP4</italic> mutations (V161fs, D167fs and R232X) give rise to Pyle disease, which is characterized by limb malformation, cortical-bone thinning and fracture, through enhanced non-canonical WNT5A signaling and osteoclastogenesis (<xref ref-type="bibr" rid="b76-ijmm-40-03-0587">76</xref>). In addition to the rare mutations mentioned above, BMD-associated single nucleotide polymorphisms (SNPs) in the <italic>CTNNB1</italic>, <italic>LRP5</italic>, <italic>SOST</italic>, <italic>WNT4</italic> and <italic>WNT16</italic> loci are also associated with slightly increased fracture risk (<xref ref-type="bibr" rid="b77-ijmm-40-03-0587">77</xref>). As rare mutations and common variations in the canonical WNT/β-catenin signaling molecules are involved in the pathogenesis of osteoporosis, pro-WNT/β-catenin signaling therapy is a rational option for the treatment of patients with osteoporosis.</p>
</sec>
<sec>
<title>5. Vascular diseases</title>
<p>Vascular development and homeostasis are coordinated by a network of VEGF, FGF, Notch, angiopoietin (ANGPT), WNT and other signaling cascades (<xref ref-type="bibr" rid="b78-ijmm-40-03-0587">78</xref>,<xref ref-type="bibr" rid="b79-ijmm-40-03-0587">79</xref>). Endothelial cells are involved in the maintenance of blood and lymphatic vessels as well as the support of somatic stem cells, such as gastric stem cells, hematopoietic stem cells, liver stem cells, mesenchymal stem cells and neural stem cells (<xref ref-type="bibr" rid="b80-ijmm-40-03-0587">80</xref>,<xref ref-type="bibr" rid="b81-ijmm-40-03-0587">81</xref>). VEGF signaling through VEGFR2 and FGF2 signaling through FGFR1/2 directly promote proliferation and migration of endothelial tip cells during angiogenic sprouting (<xref ref-type="bibr" rid="b82-ijmm-40-03-0587">82</xref>–<xref ref-type="bibr" rid="b84-ijmm-40-03-0587">84</xref>), and then, DLL and JAG signaling through Notch directly promote stabilization and elongation of endothelial stalk cells (<xref ref-type="bibr" rid="b85-ijmm-40-03-0587">85</xref>–<xref ref-type="bibr" rid="b87-ijmm-40-03-0587">87</xref>). ANGPT1 signaling through TIE2 in endothelial cells promotes vascular maturation and stability, whereas ANGPT2 signaling through TIE2 promotes vascular de-stabilization through ANGPT1 signaling inhibition (<xref ref-type="bibr" rid="b88-ijmm-40-03-0587">88</xref>). Aberrant canonical WNT/β-catenin signaling activation in cancer cells induces VEGF upregulation (<xref ref-type="bibr" rid="b89-ijmm-40-03-0587">89</xref>), which leads to unstable and leaky tumor angiogenesis. By contrast, non-canonical Wnt5a/PCP signaling downregulates Cskn1 and Bax to promote endothelial proliferation and survival, respectively, and upregulates Tie2 to promote vascular maturation and stability (<xref ref-type="bibr" rid="b90-ijmm-40-03-0587">90</xref>). Canonical and non-canonical WNT signaling cascades are directly or indirectly involved in vascular pathophysiology.</p>
<p>Familial exudative vitreoretinopathy is a hereditary disorder that is characterized by partial vascular agenesis, neovascularization and exudation in the retina and susceptibility to blindness owing to retinal detachment (<xref ref-type="bibr" rid="b91-ijmm-40-03-0587">91</xref>). We cloned and characterized the human <italic>FZD4</italic> gene in 1999 (<xref ref-type="bibr" rid="b92-ijmm-40-03-0587">92</xref>), and since then germline mutations in the <italic>FZD4</italic> gene (such as C45Y, Y58C, W226X and W496X) have been reported in patients with exudative vitreoretinopathy (<xref ref-type="bibr" rid="b93-ijmm-40-03-0587">93</xref>–<xref ref-type="bibr" rid="b95-ijmm-40-03-0587">95</xref>) (<xref ref-type="fig" rid="f2-ijmm-40-03-0587">Fig. 2</xref>). C45Y and Y58C FZD4 are missense mutations in the Frizzled-like domain that abolish NDP binding to FZD4, and W226X and W496X FZD4 are loss-of-function truncation mutations. <italic>NDP</italic> and <italic>LRP5</italic> mutations have also been reported in patients with exudative vitreoretinopathy (<xref ref-type="bibr" rid="b96-ijmm-40-03-0587">96</xref>,<xref ref-type="bibr" rid="b97-ijmm-40-03-0587">97</xref>). Loss-of-function <italic>LRP5</italic> mutations occur in patients with osteoporosis-pseudoglioma syndrome and present with similar eye phenotypes (<xref ref-type="bibr" rid="b74-ijmm-40-03-0587">74</xref>), and a loss-of-function <italic>CTNNB1</italic> mutation occurs in a patient with intellectual disability syndrome complicated with exudative vitreoretinopathy (<xref ref-type="bibr" rid="b51-ijmm-40-03-0587">51</xref>) as mentioned above. NDP is a secreted protein that binds to the extracellular Frizzled-like domain of FZD4 and activates the β-catenin signaling cascade through FZD4 and LRP5 receptors similar to canonical WNT ligands. Loss-of-function mutations in the <italic>NDP</italic>, <italic>FZD4</italic>, <italic>LRP5</italic> and <italic>CTNNB1</italic> genes in patients with exudative vitreoretinopathy indicate involvement of the NDP/β-catenin signaling defect in the pathogenesis of exudative vitreoretinopathy.</p>
<p>Ndp and Wnt7a/b are required for vascular development in the mouse retina and central nervous system, respectively (<xref ref-type="bibr" rid="b97-ijmm-40-03-0587">97</xref>,<xref ref-type="bibr" rid="b98-ijmm-40-03-0587">98</xref>), and lithium chloride treatment that stabilizes β-catenin through GSK3 inhibition upregulates the Vegf level to ameliorate retinal vascular phenotypes in an <italic>Lrp5</italic> knockout mouse model of familial exudative vitreoretinopathy (<xref ref-type="bibr" rid="b99-ijmm-40-03-0587">99</xref>). By contrast, Fzd4 signaling is required for retinal vascular stabilization and maturation (<xref ref-type="bibr" rid="b100-ijmm-40-03-0587">100</xref>), and WNT5A induces dissociation of Gα12/13 from FZD4 to promote p115RhoGEF-mediated activation of the RHO signaling cascade in endothelial cells (<xref ref-type="bibr" rid="b101-ijmm-40-03-0587">101</xref>). As canonical WNT or NDP signaling to the β-catenin cascade can promote angiogenic sprouting indirectly through transcriptional upregulation of VEGF and FGF family ligands and non-canonical WNT signaling through FZD4 can promote retinal vascular stability and maturation, fine-tuning of the canonical and non-canonical WNT signaling cascade may be necessary for the treatment of patients with familial exudative vitreoretinopathy.</p>
</sec>
<sec>
<title>6. Human diseases related to core PCP components</title>
<p>PCP is defined as cellular polarity within the epithelial plane perpendicular to the cellular apico-basal axis (<xref ref-type="bibr" rid="b7-ijmm-40-03-0587">7</xref>). The <italic>Drosophila</italic> PCP pathway coordinates orientation of sensory bristles and hairs and the rotation pattern of ommatidia (<xref ref-type="bibr" rid="b102-ijmm-40-03-0587">102</xref>,<xref ref-type="bibr" rid="b103-ijmm-40-03-0587">103</xref>), whereas the vertebrate PCP pathway regulates orientation of sensory hair cells in the inner ear, collective cell movements during embryogenesis (convergent extension movements during gastrulation and neural tube closure during neurulation) (<xref ref-type="bibr" rid="b104-ijmm-40-03-0587">104</xref>–<xref ref-type="bibr" rid="b107-ijmm-40-03-0587">107</xref>), directional movements of neural crest cells and tumor invasion (<xref ref-type="bibr" rid="b108-ijmm-40-03-0587">108</xref>–<xref ref-type="bibr" rid="b111-ijmm-40-03-0587">111</xref>). The PCP pathway is categorized as the Frizzled-Flamingo-dependent core PCP branch and Fat-Dachsous-dependent alternative or parallel PCP branch (<xref ref-type="bibr" rid="b112-ijmm-40-03-0587">112</xref>,<xref ref-type="bibr" rid="b113-ijmm-40-03-0587">113</xref>).</p>
<p>Flamingo (<italic>Drosophila</italic> ortholog of human CELSR1, CELSR2 and CELSR3), Frizzled (including FZD3, FZD6 and FZD7), Dishevelled (DVL1, DVL2 and DVL3), Prickle (PRICKLE1 and PRICKLE2) and Van Gogh/Vang (VANGL1 and VANGL2) are core PCP components that constitute the Flamingo-mediated interaction of the Flamingo-Frizzled-Dishevelled and Flamingo-Vang-Prickle complexes on the opposite sides of neighboring cells. The mammalian core PCP pathway overlaps with non-canonical WNT signaling through FZDs and DVLs to the Rac-JNK and RhoA-ROCK signaling cascades (<xref ref-type="fig" rid="f1-ijmm-40-03-0587">Fig. 1</xref>). We entered the PCP research field through molecular cloning and characterization of novel human PCP genes, such as <italic>FZD3</italic>, <italic>FZD6</italic>, <italic>FZD7</italic> and <italic>VANGL1</italic>, from 1998 to 2002 as fruits of the human WNTome project, and identification and characterization of <italic>PRICKLE1</italic> and <italic>PRICKLE2</italic> in 2003 as fruits of the Post-WNTome project (<xref ref-type="bibr" rid="b114-ijmm-40-03-0587">114</xref>). Dr Kibar's group opened up a new avenue for PCP genetics related to neural tube defects, and since then germline or <italic>de novo</italic> alterations in the core PCP components have been reported in human diseases, such as neural tube defects (<xref ref-type="bibr" rid="b115-ijmm-40-03-0587">115</xref>,<xref ref-type="bibr" rid="b116-ijmm-40-03-0587">116</xref>), epilepsy (<xref ref-type="bibr" rid="b117-ijmm-40-03-0587">117</xref>,<xref ref-type="bibr" rid="b118-ijmm-40-03-0587">118</xref>), autism (<xref ref-type="bibr" rid="b118-ijmm-40-03-0587">118</xref>,<xref ref-type="bibr" rid="b119-ijmm-40-03-0587">119</xref>) and Robinow syndrome (<xref ref-type="bibr" rid="b120-ijmm-40-03-0587">120</xref>).</p>
<p>Neural tube defects, including anencephaly, craniorachischisis and myelomeningocele (open spina bifida), are the second most common birth defects in humans, and they occur in ~1/1,000 established pregnancies (<xref ref-type="bibr" rid="b121-ijmm-40-03-0587">121</xref>). As the neural tube is generated through orchestrated extension, upward bending and fusion of the neural plate during embryogenesis, failure of the collective movement of neural crest precursors results in neural tube defects (<xref ref-type="bibr" rid="b122-ijmm-40-03-0587">122</xref>). Environmental factors, such as teratogenic chemicals, and no less than 200 genetic factors are involved in the susceptibility to neural tube defects (<xref ref-type="bibr" rid="b123-ijmm-40-03-0587">123</xref>). Mutations in the WNT signaling related genes, such as <italic>CELSR1</italic>, <italic>DVL2</italic>, <italic>FZD6</italic>, <italic>LRP6</italic>, <italic>PRICKLE1</italic>, <italic>VANGL1</italic> and <italic>VANGL2</italic>, occur in patients with neural tube defects (<xref ref-type="bibr" rid="b115-ijmm-40-03-0587">115</xref>). CELSR1, DVL2, FZD6, PRICKLE1, VANGL1 and VANGL2 are core PCP components that are involved in non-canonical WNT signaling cascades, whereas LRP6 is a canonical WNT receptor (<xref ref-type="table" rid="tI-ijmm-40-03-0587">Table I</xref>). LRP6 mutants (Y306H, Y373C and V1386L) repress Wnt3a-induced TCF/LEF-dependent transcription but potentiate Wnt5a-induced JNK-dependent transcription (<xref ref-type="bibr" rid="b116-ijmm-40-03-0587">116</xref>). In addition, a patient with intellectual disability syndrome caused by a loss-of-function <italic>CTNNB1</italic> mutation presented with exudative vitreoretinopathy and neural tube defect as mentioned above (<xref ref-type="bibr" rid="b51-ijmm-40-03-0587">51</xref>). Mutations in the core PCP signaling molecules, as well as loss-of-function mutations in the canonical WNT/β-catenin signaling molecules, give rise to neural tube defects.</p>
<p>The <italic>PRICKLE1</italic> and <italic>PRICKLE2</italic> genes are also mutated in patients with epilepsy and autism. Epilepsy is characterized by recurrent seizures, whereas autism is characterized by deficits in social interactions, communication and flexible behavior. Homozygous <italic>PRICKLE1</italic> mutation (R104Q) occurs in familial cases of progressive myoclonus epilepsy with early-onset ataxia (<xref ref-type="bibr" rid="b117-ijmm-40-03-0587">117</xref>). Heterozygous <italic>PRICKLE1</italic> mutations (R104Q, R144H and Y472H) and a <italic>PRICKLE2</italic> mutation (R148H) occur in sporadic cases of progressive myoclonus epilepsy (<xref ref-type="bibr" rid="b118-ijmm-40-03-0587">118</xref>), whereas heterozygous <italic>PRICKLE2</italic> mutations (E8Q and V153I) occur in autistic patients (<xref ref-type="bibr" rid="b119-ijmm-40-03-0587">119</xref>). Deletion of the <italic>PRICKLE2</italic> gene is detected in patients with 3p14 microdeletion syndrome, one type of which is characterized by autism, epilepsy and developmental delay and another type of which is characterized by autism, intellectual disability and language disorder (<xref ref-type="bibr" rid="b118-ijmm-40-03-0587">118</xref>,<xref ref-type="bibr" rid="b124-ijmm-40-03-0587">124</xref>). By contrast, loss-of-function mutation of the <italic>CTNNB1</italic> gene is reported in a patient with autism, neural tube defect, intellectual disability and exudative vitreoretinopathy as mentioned above (<xref ref-type="bibr" rid="b51-ijmm-40-03-0587">51</xref>). As the development and maintenance of neural tissues are orchestrated by the spatiotemporal fine-tuning of the canonical and non-canonical WNT signaling cascades, genetic alterations in WNT signaling molecules cause overlapping neuropsychiatric disorders, such as autism, epilepsy and intellectual disability.</p>
<p>Robinow syndrome is a hereditary disorder that presents with common features, such as brachydactyly, frontal bossing, genital hypoplasia, hemivertebra, hypertelorism and mesomelic limb shortening (<xref ref-type="bibr" rid="b125-ijmm-40-03-0587">125</xref>). In addition to <italic>DVL1</italic> and <italic>DVL3</italic> mutations in patients with the autosomal dominant form of Robinow syndrome (<xref ref-type="bibr" rid="b120-ijmm-40-03-0587">120</xref>), <italic>WNT5A</italic> and <italic>ROR2</italic> mutations occur in patients with autosomal dominant and autosomal recessive forms of Robinow syndrome, respectively (<xref ref-type="bibr" rid="b126-ijmm-40-03-0587">126</xref>,<xref ref-type="bibr" rid="b127-ijmm-40-03-0587">127</xref>). By contrast, autosomal dominant <italic>ROR2</italic> mutations occur in patients with brachydactyly type B1 (<xref ref-type="bibr" rid="b128-ijmm-40-03-0587">128</xref>). As WNT5A signaling through the ROR2 receptor activates DVL1/3-mediated RHO-ROCK and RAC1-JNK signaling cascades to regulate cell polarity and directional migration (<xref ref-type="bibr" rid="b129-ijmm-40-03-0587">129</xref>–<xref ref-type="bibr" rid="b132-ijmm-40-03-0587">132</xref>), loss-of-function mutations in the <italic>WNT5A</italic>, <italic>ROR2</italic>, <italic>DVL1</italic> and <italic>DVL3</italic> genes give rise to Robinow syndrome through impaired non-canonical WNT signaling (<xref ref-type="fig" rid="f2-ijmm-40-03-0587">Fig. 2</xref>). However, osteosclerotic phenotypes in a subset of patients with Robinow syndrome (<xref ref-type="bibr" rid="b133-ijmm-40-03-0587">133</xref>) suggest reciprocal WNT/β-catenin signaling activation in the bone, and Robinow syndrome-like phenotypes in mice with null and hypomorphic <italic>Prickle1</italic> alleles (<xref ref-type="bibr" rid="b134-ijmm-40-03-0587">134</xref>) suggest the involvement of core PCP components other than DVLs in Robinow syndrome. Signaling mechanisms and Robinow syndrome genes should be further investigated.</p>
<p>WNT/PCP or WNT5A/ROR/Frizzled signaling promotes invasion, survival and therapeutic resistance of human cancers (<xref ref-type="bibr" rid="b135-ijmm-40-03-0587">135</xref>–<xref ref-type="bibr" rid="b141-ijmm-40-03-0587">141</xref>), although WNT5A or non-canonical WNT/Ca<sup>2+</sup> signaling is context-dependently involved in tumor suppression (<xref ref-type="bibr" rid="b142-ijmm-40-03-0587">142</xref>–<xref ref-type="bibr" rid="b144-ijmm-40-03-0587">144</xref>). ROR1 is preferentially upregulated in B-cell leukemia, such as chronic lymphocytic leukemia (CLL) (<xref ref-type="bibr" rid="b145-ijmm-40-03-0587">145</xref>) and t(1;19) acute lymphoblastic leukemia (ALL) (<xref ref-type="bibr" rid="b146-ijmm-40-03-0587">146</xref>). WNT5A-dependent oligomerization of ROR1 and ROR2 on CLL cells induces recruitment of the guanine exchange factors ARHGEF1, ARHGEF2 and ARHGEF6 and subsequent activation of RhoA and Rac1 to promote chemotaxis and proliferation, respectively (<xref ref-type="bibr" rid="b147-ijmm-40-03-0587">147</xref>). ROR1 is also upregulated in breast cancer, gastric cancer and lung cancer, and ROR1 phosphorylation by MET and SRC promote tumor proliferation and invasion (<xref ref-type="bibr" rid="b148-ijmm-40-03-0587">148</xref>–<xref ref-type="bibr" rid="b150-ijmm-40-03-0587">150</xref>). ROR1 interacts with TCL1A (TCL1) to activate AKT in a mouse model of CLL (<xref ref-type="bibr" rid="b151-ijmm-40-03-0587">151</xref>); ROR1 interacts with HER3 and LLGL2 in breast cancer cells to inhibit STK4 (MST1) through K59 methylation, which leads to transcriptional upregulation of YAP/TAZ-target genes (<xref ref-type="bibr" rid="b150-ijmm-40-03-0587">150</xref>); and ROR1 interacts with caveolae components in lung cancer cells to promote survival and resistance to EGFR inhibitors through MET- or IGF1R-dependent PI3K-AKT signaling activation (<xref ref-type="bibr" rid="b152-ijmm-40-03-0587">152</xref>). ROR1 upregulation in B-cell leukemias and solid tumors promote malignant phenotypes through ROR1 phosphorylation and activation of WNT/PCP and WNT/RTK signaling cascades (<xref ref-type="fig" rid="f4-ijmm-40-03-0587">Fig. 4</xref>). By contrast, ROR2 is upregulated in invasive melanoma (<xref ref-type="bibr" rid="b153-ijmm-40-03-0587">153</xref>), and WNT5A/ROR2 signaling induces recruitment and activation of SRC to promote metastasis (<xref ref-type="bibr" rid="b154-ijmm-40-03-0587">154</xref>). WNT5A induces de-palmitoylation of MCAM adhesion molecules and subsequently polarizes localization of MCAM and CD44 to promote directional movement and invasion of melanoma cells (<xref ref-type="bibr" rid="b110-ijmm-40-03-0587">110</xref>). These facts clearly indicate that the WNT/PCP and WNT/RTK signaling cascades, as well as WNT/β-catenin signaling cascade, drive human carcinogenesis (<xref ref-type="fig" rid="f4-ijmm-40-03-0587">Fig. 4</xref>).</p>
</sec>
<sec>
<title>7. Other genetic diseases</title>
<p><italic>WNT3</italic> and <italic>WNT7A</italic> mutations are reported in patients with tetra-amelia syndrome and Fuhrmann syndrome, respectively (<xref ref-type="bibr" rid="b155-ijmm-40-03-0587">155</xref>,<xref ref-type="bibr" rid="b156-ijmm-40-03-0587">156</xref>) which are characterized by congenital limb malformations. Heterozygous E216G <italic>WNT4</italic> mutation causes mullerian aplasia and hyperandrogenism (<xref ref-type="bibr" rid="b157-ijmm-40-03-0587">157</xref>) whereas homozygous A114V <italic>WNT4</italic> mutation causes SERKAL syndrome presenting female-to-male sex reversal and dysgenesis of kidneys, adrenal glands and lungs (<xref ref-type="bibr" rid="b158-ijmm-40-03-0587">158</xref>). We cloned and characterized human <italic>WNT6</italic> and <italic>WNT10A</italic> in 2001 (<xref ref-type="bibr" rid="b159-ijmm-40-03-0587">159</xref>), and then, another group found a homozygous <italic>WNT10A</italic> E233X mutation in patients with odonto-onycho-dermal dysplasia characterized by severe hypodontia, onychodysplasia and keratoderma in 2007 (<xref ref-type="bibr" rid="b160-ijmm-40-03-0587">160</xref>). <italic>WNT10A</italic>, <italic>WNT10B</italic> and <italic>LRP6</italic> mutations occur in patients with selective tooth agenesis (<xref ref-type="bibr" rid="b161-ijmm-40-03-0587">161</xref>–<xref ref-type="bibr" rid="b163-ijmm-40-03-0587">163</xref>). By contrast, as porcupine (PORCN) is an O-acyltransferase that is involved in palmitoleoylation and subsequent secretion of WNT ligands (<xref ref-type="bibr" rid="b164-ijmm-40-03-0587">164</xref>), loss-of-function PORCN mutations lead to focal dermal hypoplasia characterized by patchy hypoplastic skin and other malformations (<xref ref-type="bibr" rid="b165-ijmm-40-03-0587">165</xref>).</p>
<p>In addition to <italic>FZD4</italic> and <italic>FZD6</italic> mutations in patients with exudative vitreoretinopathy (<xref ref-type="bibr" rid="b91-ijmm-40-03-0587">91</xref>) and neural tube defects (<xref ref-type="bibr" rid="b115-ijmm-40-03-0587">115</xref>), respectively, <italic>FZD5</italic> mutations in patients with ocular coloboma (<xref ref-type="bibr" rid="b166-ijmm-40-03-0587">166</xref>) and <italic>FZD6</italic> mutations in patients with nail dysplasia (<xref ref-type="bibr" rid="b167-ijmm-40-03-0587">167</xref>) have been reported. Loss-of-function <italic>RSPO1</italic> mutations cause palmoplantar hyperkeratosis with skin squamous cell carcinoma and sex reversal (<xref ref-type="bibr" rid="b168-ijmm-40-03-0587">168</xref>), whereas RSPO4 missense mutations occur in patients with congenital anonychia (<xref ref-type="bibr" rid="b169-ijmm-40-03-0587">169</xref>).</p>
<p>Heterozygous Ser1591fs mutation in the <italic>DAPLE</italic> (<italic>CCDC88C</italic>) gene has been reported in a patient with hydrocephalus (<xref ref-type="bibr" rid="b170-ijmm-40-03-0587">170</xref>). Wild-type DAPLE protein, containing the FZD-binding and Gα-binding/activation motifs in its C-terminal region, assembles FZD7 receptor and Gαi protein to transduce non-canonical WNT5A/Rac1 and PI3K-AKT signaling cascades and inhibit the canonical WNT/β-catenin signaling cascade (<xref ref-type="bibr" rid="b171-ijmm-40-03-0587">171</xref>), although the FZD7 receptor is involved in canonical WNT/β-catenin signaling activation in intestinal stem cells (<xref ref-type="bibr" rid="b41-ijmm-40-03-0587">41</xref>). As the Ser1591fs DAPLE mutant in a hydrocephalus patient is resistant to nonsense-mediated mRNA decay (<xref ref-type="bibr" rid="b170-ijmm-40-03-0587">170</xref>) and lacks the FZD-binding and Gα-binding/activation motifs, the truncating DAPLE mutation is predicted to impair non-canonical WNT/Rac1 and PI3K-AKT signaling cascades.</p>
</sec>
<sec>
<title>8. Therapeutics targeting WNT signaling cascades</title>
<p>Development of therapeutics that inhibit the WNT/β-catenin signaling cascade is a topic of great interest in the field of clinical oncology and medicinal chemistry (<xref ref-type="bibr" rid="b172-ijmm-40-03-0587">172</xref>–<xref ref-type="bibr" rid="b175-ijmm-40-03-0587">175</xref>). By contrast, as aberrant activation and inhibition of WNT signaling cascades are involved in the pathogenesis of cancer and non-cancerous diseases (<xref ref-type="table" rid="tI-ijmm-40-03-0587">Table I</xref>), therapeutics that inhibit or potentiate canonical or non-canonical WNT signaling cascades are necessary for the future implementation of genome-based medicine for human diseases. WNT-targeted therapy will be discussed in this section with emphases on PORCN, RSPO3, WNT ligands, FZD receptors, ROR1 receptor, tankyrase and β-catenin as targets for anti-WNT signaling therapy (<xref ref-type="table" rid="tII-ijmm-40-03-0587">Table II</xref>) and DKK1, SOST and GSK3β as targets for pro-WNT signaling therapy (<xref ref-type="table" rid="tIII-ijmm-40-03-0587">Table III</xref>).</p>
<p>PORCN is an endogenous WNT palmitoleoylase that promotes secretion of WNT family proteins and their interaction with FZD receptors (<xref ref-type="bibr" rid="b164-ijmm-40-03-0587">164</xref>), whereas NOTUM is an endogenous WNT de-palmitoleoylase that represses WNT-FZD interaction (<xref ref-type="bibr" rid="b176-ijmm-40-03-0587">176</xref>). Small-molecule inhibitors for PORCN and NOTUM are applicable to anti- and pro-WNT signaling therapies, respectively. ETC-159 (ETC-1922159) (<xref ref-type="bibr" rid="b177-ijmm-40-03-0587">177</xref>), IWP-2 (<xref ref-type="bibr" rid="b178-ijmm-40-03-0587">178</xref>), LGK974 (WNT974) (<xref ref-type="bibr" rid="b179-ijmm-40-03-0587">179</xref>) and WNT-C59 (<xref ref-type="bibr" rid="b180-ijmm-40-03-0587">180</xref>) are representative PORCN inhibitors that attenuate WNT signaling for <italic>in vivo</italic> treatment of colorectal cancer with <italic>RSPO</italic> translocations and pancreatic cancer with <italic>RNF43</italic> mutations (<xref ref-type="bibr" rid="b181-ijmm-40-03-0587">181</xref>–<xref ref-type="bibr" rid="b183-ijmm-40-03-0587">183</xref>) (<xref ref-type="fig" rid="f4-ijmm-40-03-0587">Fig. 4</xref>) as well as non-cancerous diseases, such as cardiac fibrosis (<xref ref-type="bibr" rid="b184-ijmm-40-03-0587">184</xref>) and kidney fibrosis (<xref ref-type="bibr" rid="b185-ijmm-40-03-0587">185</xref>). By contrast, OMP-131R10 is an anti-RSPO3 mAb that neutralizes RSPO3 to attenuate canonical WNT signaling through ubiquitylation-mediated FZD degradation (<xref ref-type="bibr" rid="b186-ijmm-40-03-0587">186</xref>). OMP-131R10 inhibits tumor growth in patient-derived xenograft models of colorectal cancers with <italic>RSPO3</italic> fusion or non-small cell lung cancers and ovarian cancers with RSPO3 upregulation (<xref ref-type="fig" rid="f4-ijmm-40-03-0587">Fig. 4</xref>). ETC-159, LGK974 and OMP-131R10 are in clinical trials for the treatment of cancer patients (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>; <ext-link ext-link-type="uri" xlink:href="https://clinical-trials.gov">https://clinical-trials.gov</ext-link>) (<xref ref-type="table" rid="tII-ijmm-40-03-0587">Table II</xref>).</p>
<p>Between 1996 and 2002, we cloned and characterized human <italic>WNT2B</italic>, <italic>WNT3A</italic>, <italic>WNT5B</italic>, <italic>WNT6</italic>, <italic>WNT7B</italic>, <italic>WNT8A</italic>, <italic>WNT9A</italic> (<italic>WNT14</italic>), <italic>WNT9B</italic> (<italic>WNT14B</italic>), <italic>WNT10A</italic>, <italic>FZD1</italic>, <italic>FZD3</italic>, <italic>FZD4</italic>, <italic>FZD5</italic>, <italic>FZD6</italic>, <italic>FZD7</italic>, <italic>FZD8</italic> and <italic>FZD10</italic> as the major products of the human WNTome project (1,2 and references therein). Some of these WNTs and FZDs are potential targets for cancer therapy (<xref ref-type="fig" rid="f4-ijmm-40-03-0587">Fig. 4</xref>). For example, as WNT2B is upregulated in diffuse-type gastric cancer, pancreatic cancer and nasopharyngeal carcinoma and involved in EMT, invasion and metastasis (<xref ref-type="bibr" rid="b187-ijmm-40-03-0587">187</xref>–<xref ref-type="bibr" rid="b190-ijmm-40-03-0587">190</xref>), WNT2B shRNAs have been used to inhibit tumorigenesis in mouse model experiments (<xref ref-type="bibr" rid="b191-ijmm-40-03-0587">191</xref>,<xref ref-type="bibr" rid="b192-ijmm-40-03-0587">192</xref>). FZD6 upregulation in colorectal cancer, neuroblastoma and triple-negative breast cancer is involved in stem-like features, EMT and drug resistance (<xref ref-type="bibr" rid="b193-ijmm-40-03-0587">193</xref>–<xref ref-type="bibr" rid="b196-ijmm-40-03-0587">196</xref>). Based on <italic>FZD5</italic> upregulation in solid tumors, including <italic>RNF43</italic>-mutated pancreatic cancer (<xref ref-type="bibr" rid="b197-ijmm-40-03-0587">197</xref>,<xref ref-type="bibr" rid="b198-ijmm-40-03-0587">198</xref>), <italic>FZD7</italic> upregulation in breast cancer, colorectal cancer, glioma and hepatocellular carcinoma (<xref ref-type="bibr" rid="b199-ijmm-40-03-0587">199</xref>–<xref ref-type="bibr" rid="b203-ijmm-40-03-0587">203</xref>) and <italic>FZD10</italic> upregulation in breast cancer, colorectal cancer and synovial sarcoma (<xref ref-type="bibr" rid="b204-ijmm-40-03-0587">204</xref>–<xref ref-type="bibr" rid="b207-ijmm-40-03-0587">207</xref>), anti-FZD5 IgG, anti-FZD7 mAb and anti-FZD10 mAbs have been developed for cancer therapy. Vantictumab (OMP-18R5), initially isolated as an FZD7-binding antibody, is a broad-spectrum anti-FZD mAb that reacts with FZD1, FZD2, FZD5, FZD7 and FZD8 (<xref ref-type="bibr" rid="b208-ijmm-40-03-0587">208</xref>), which all belong to the FZD1/2/7 or FZD5/8 subfamily among the FZD family (<xref ref-type="bibr" rid="b204-ijmm-40-03-0587">204</xref>). OTSA101-DPTA-90Y is a <sup>90</sup>Y-labeled anti-FZD10 mAb (<xref ref-type="bibr" rid="b209-ijmm-40-03-0587">209</xref>). By contrast, ipafricept (OMP-54F28) is a fusion protein that consists of the cysteine-rich domain of FZD8 and the Fc domain of immunoglobulin, and it functions as a trap for FZD8-binding WNT proteins (<xref ref-type="bibr" rid="b210-ijmm-40-03-0587">210</xref>). Vantictumab and OMP-54F28 are in clinical trials for the treatment of cancer patients (<xref ref-type="table" rid="tII-ijmm-40-03-0587">Table II</xref>). As the FZD7 receptor on intestinal stem cells, endothelial cells and solid tumors is involved in WNT signaling to the β-catenin, RhoA, Rac1, PI3K and Ca<sup>2+</sup> cascades (<xref ref-type="bibr" rid="b41-ijmm-40-03-0587">41</xref>,<xref ref-type="bibr" rid="b171-ijmm-40-03-0587">171</xref>,<xref ref-type="bibr" rid="b211-ijmm-40-03-0587">211</xref>,<xref ref-type="bibr" rid="b212-ijmm-40-03-0587">212</xref>), FZD7 blockade gives rise to various effects in a cell context-dependent manner. The effectiveness and adverse effects of anti-FZD mAb drugs may be determined by the selectivity of mAbs and the context-dependent functions of targeted FZDs.</p>
<p>ROR1 is a rational target of cancer therapeutics as ROR1 is upregulated in subsets of B-cell leukemia, breast cancer, gastric cancer and lung cancer but undetectable in most adult tissues except immature B-cells (<xref ref-type="fig" rid="f4-ijmm-40-03-0587">Fig. 4</xref>). In addition, ROR1 is involved in tumor proliferation, invasion and therapeutic resistance as mentioned above (<xref ref-type="bibr" rid="b145-ijmm-40-03-0587">145</xref>–<xref ref-type="bibr" rid="b152-ijmm-40-03-0587">152</xref>). ROR1, ROR2, NTRK1, NTRK2, NTRK3, MUSK, DDR1 and DDR2 constitute the ROR/NTRK subfamily among the RTKs, whereas small-molecule inhibitors and mAbs are established approaches to target RTKs (<xref ref-type="bibr" rid="b213-ijmm-40-03-0587">213</xref>,<xref ref-type="bibr" rid="b214-ijmm-40-03-0587">214</xref>). ROR1 is predicted to be a pseudokinase that lacks intrinsic tyrosine kinase activity (<xref ref-type="bibr" rid="b215-ijmm-40-03-0587">215</xref>), but ROR1 is phosphorylated by other tyrosine kinases, such as MET and SRC, and activates downstream signaling cascades (<xref ref-type="bibr" rid="b148-ijmm-40-03-0587">148</xref>,<xref ref-type="bibr" rid="b149-ijmm-40-03-0587">149</xref>). KAN 0439834 is a small-molecule ROR1 inhibitor that dephosphorylates ROR1 in B-cell leukemia, breast cancer and lung cancer and induces a cytotoxic effect on ROR1-expressing tumor cells (<xref ref-type="bibr" rid="b216-ijmm-40-03-0587">216</xref>). Cirmtuzumab (UC-961) is a humanized anti-ROR1 mAb that inhibits WNT5A-induced ROR1 signaling through ROR1 dephosphorylation and represses <italic>in vivo</italic> growth of ROR1-expressing CLL cells (<xref ref-type="bibr" rid="b147-ijmm-40-03-0587">147</xref>,<xref ref-type="bibr" rid="b217-ijmm-40-03-0587">217</xref>). ROR1-CD3-DART and APVO425 (ES425) are bispecific antibodies consisting of anti-ROR1 and anti-CD3 mAbs that redirect cytotoxic T cells to ROR1-expressing tumor cells (<xref ref-type="bibr" rid="b218-ijmm-40-03-0587">218</xref>,<xref ref-type="bibr" rid="b219-ijmm-40-03-0587">219</xref>). ROR1 CAR-T cells were also developed for cancer therapy, and the effectiveness and safety of ROR1 CAR-T cells have been demonstrated in rodent as well as non-human primate model experiments (<xref ref-type="bibr" rid="b220-ijmm-40-03-0587">220</xref>). Cirmtuzumab is in clinical trials for the treatment of cancer patients (<xref ref-type="table" rid="tII-ijmm-40-03-0587">Table II</xref>).</p>
<p>SOST and DKK1 are endogenous canonical WNT antagonists that induce direct inhibition of osteoblastogenesis as well as indirect promotion of osteoclastogenesis, and are involved in the pathogenesis of osteoporosis and cancer-associated osteolysis, respectively (<xref ref-type="bibr" rid="b64-ijmm-40-03-0587">64</xref>,<xref ref-type="bibr" rid="b221-ijmm-40-03-0587">221</xref>,<xref ref-type="bibr" rid="b222-ijmm-40-03-0587">222</xref>). As SOST and DKK1 are rational targets of pro-WNT signaling therapy for human diseases, anti-SOST mAbs (romosozumab, blosozumab and BPS804) (<xref ref-type="bibr" rid="b223-ijmm-40-03-0587">223</xref>–<xref ref-type="bibr" rid="b225-ijmm-40-03-0587">225</xref>), anti-DKK1 mAbs (BHQ880, DKN-01 and PF-04840082) (<xref ref-type="bibr" rid="b226-ijmm-40-03-0587">226</xref>–<xref ref-type="bibr" rid="b228-ijmm-40-03-0587">228</xref>) and a bispecific antibody against SOST and DKK1 (Hetero-DS) (<xref ref-type="bibr" rid="b229-ijmm-40-03-0587">229</xref>) have been developed. Romosozumab, blosozumab and BPS804 are in clinical trials for female postmenopausal patients with decreased BMD, whereas BHQ880 and DKN-01 are in clinical trials for patients with multiple myeloma and other solid tumors, such as cholangiocarcinoma, esophageal cancer and gastric cancer (<xref ref-type="table" rid="tIII-ijmm-40-03-0587">Table III</xref>).</p>
<p>Tankyrases (TNKS1/PARP5A and TNKS2/PARP5B), PARP1, PARP2, TIPARP (PARP7) and other PARPs are ADP-ribosyl transferases belonging to the PARP family (<xref ref-type="bibr" rid="b230-ijmm-40-03-0587">230</xref>–<xref ref-type="bibr" rid="b232-ijmm-40-03-0587">232</xref>), and ADP-ribosyl transferase inhibitors, such as olaparib, have been developed for cancer therapy (<xref ref-type="bibr" rid="b233-ijmm-40-03-0587">233</xref>–<xref ref-type="bibr" rid="b235-ijmm-40-03-0587">235</xref>). Tankyrases promote degradation of AXIN1 and AXIN2 through poly-ADP-ribosylation, and tankyrase inhibitors induce AXIN stabilization for canonical WNT/β-catenin signaling inhibition (<xref ref-type="bibr" rid="b236-ijmm-40-03-0587">236</xref>–<xref ref-type="bibr" rid="b238-ijmm-40-03-0587">238</xref>). AZ1366 (<xref ref-type="bibr" rid="b239-ijmm-40-03-0587">239</xref>), G007-LK (<xref ref-type="bibr" rid="b240-ijmm-40-03-0587">240</xref>), NVP-TNKS656 (<xref ref-type="bibr" rid="b241-ijmm-40-03-0587">241</xref>,<xref ref-type="bibr" rid="b242-ijmm-40-03-0587">242</xref>) and XAV939 (<xref ref-type="bibr" rid="b243-ijmm-40-03-0587">243</xref>,<xref ref-type="bibr" rid="b244-ijmm-40-03-0587">244</xref>) are investigational tankyrase inhibitors that can block canonical WNT/β-catenin signaling in model animal experiments to repress tumorigenesis (<xref ref-type="bibr" rid="b239-ijmm-40-03-0587">239</xref>–<xref ref-type="bibr" rid="b244-ijmm-40-03-0587">244</xref>), control neuropathic pain (<xref ref-type="bibr" rid="b245-ijmm-40-03-0587">245</xref>) and promote cardiac reprogramming from cardiac fibroblasts (<xref ref-type="bibr" rid="b24-ijmm-40-03-0587">24</xref>). As tankyrase inhibitors induce a variety of effects, such as canonical WNT/β-catenin signaling inhibition, YAP signaling inhibition, PI3K signaling inhibition and telomere shortening through defective poly-ADP-ribosylation of AXIN, AMOT, PTEN and TERF1, respectively (<xref ref-type="bibr" rid="b236-ijmm-40-03-0587">236</xref>–<xref ref-type="bibr" rid="b238-ijmm-40-03-0587">238</xref>), the tankyrase inhibitors mentioned above are not in clinical trials at present (<xref ref-type="table" rid="tII-ijmm-40-03-0587">Table II</xref>).</p>
<p>β-catenin is an effector of the WNT/β-catenin signaling cascade (<xref ref-type="bibr" rid="b2-ijmm-40-03-0587">2</xref>–<xref ref-type="bibr" rid="b4-ijmm-40-03-0587">4</xref>), and stabilized nuclear β-catenin associates with BCL9, CBP, p300, EZH2 and SMARCA4 to activate transcription of TCF/LEF-target genes (<xref ref-type="fig" rid="f3-ijmm-40-03-0587">Fig. 3</xref>). As β-catenin does not have intrinsic enzymatic activity, β-catenin inhibitors have been developed with a focus on its protein-protein interactions (<xref ref-type="bibr" rid="b175-ijmm-40-03-0587">175</xref>). BIO (<xref ref-type="bibr" rid="b246-ijmm-40-03-0587">246</xref>), CHIR99021 (<xref ref-type="bibr" rid="b247-ijmm-40-03-0587">247</xref>), LY2090314 (<xref ref-type="bibr" rid="b248-ijmm-40-03-0587">248</xref>) and TWS119 (<xref ref-type="bibr" rid="b249-ijmm-40-03-0587">249</xref>) are GSK3β or GSK3 inhibitors that can activate the WNT/β-catenin signaling cascade (<xref ref-type="table" rid="tIII-ijmm-40-03-0587">Table III</xref>). GSK3β inhibitors are applied as pro-WNT signaling reagents for cell processing in the field of regenerative medicine (<xref ref-type="bibr" rid="b250-ijmm-40-03-0587">250</xref>,<xref ref-type="bibr" rid="b251-ijmm-40-03-0587">251</xref>); however, clinical application of GSK3β inhibitors as pro-WNT signaling therapeutics for patients with impaired WNT/β-catenin signaling is too challenging. By contrast, BC2059 (<xref ref-type="bibr" rid="b252-ijmm-40-03-0587">252</xref>), CGP049090 (<xref ref-type="bibr" rid="b253-ijmm-40-03-0587">253</xref>), CWP232228 (<xref ref-type="bibr" rid="b254-ijmm-40-03-0587">254</xref>), ICG-001 (<xref ref-type="bibr" rid="b255-ijmm-40-03-0587">255</xref>), LF3 (<xref ref-type="bibr" rid="b256-ijmm-40-03-0587">256</xref>), MSAB (<xref ref-type="bibr" rid="b257-ijmm-40-03-0587">257</xref>), PKF115-584 (<xref ref-type="bibr" rid="b258-ijmm-40-03-0587">258</xref>), PRI-724 (<xref ref-type="bibr" rid="b259-ijmm-40-03-0587">259</xref>) and SAH-BCL9 (<xref ref-type="bibr" rid="b260-ijmm-40-03-0587">260</xref>) are β-catenin inhibitors that induce antitumor effects through repression of TCF/LEF-target genes, whereas some of these β-catenin inhibitors also show therapeutic effects in model animal experiments of non-cancerous diseases, such as pulmonary fibrosis and chronic kidney disease (<xref ref-type="bibr" rid="b261-ijmm-40-03-0587">261</xref>,<xref ref-type="bibr" rid="b262-ijmm-40-03-0587">262</xref>). PRI-724 is in clinical trials for cancer patients (<xref ref-type="table" rid="tII-ijmm-40-03-0587">Table II</xref>).</p>
<p>Cancer cells interact with immune cells and stromal cells to regulate antitumor immunity, angiogenesis and metabolism in the tumor microenvironment (<xref ref-type="bibr" rid="b78-ijmm-40-03-0587">78</xref>,<xref ref-type="bibr" rid="b213-ijmm-40-03-0587">213</xref>,<xref ref-type="bibr" rid="b263-ijmm-40-03-0587">263</xref>,<xref ref-type="bibr" rid="b264-ijmm-40-03-0587">264</xref>). WNT/β-catenin signaling activation in cancer cells indirectly regulates immunity through transcriptional regulation of CCL4 chemo-kine or ULBP ligands for dendritic cells and natural killer cells, respectively (<xref ref-type="bibr" rid="b265-ijmm-40-03-0587">265</xref>,<xref ref-type="bibr" rid="b266-ijmm-40-03-0587">266</xref>), whereas canonical or non-canonical WNT signaling activation in dendritic cells (<xref ref-type="bibr" rid="b267-ijmm-40-03-0587">267</xref>), macrophages (<xref ref-type="bibr" rid="b268-ijmm-40-03-0587">268</xref>), myeloid-derived suppressor cells (<xref ref-type="bibr" rid="b269-ijmm-40-03-0587">269</xref>) and T lymphocytes (<xref ref-type="bibr" rid="b270-ijmm-40-03-0587">270</xref>) directly regulates their functions and antitumor immunity. WNT/β-catenin signaling activation in dendritic cells can enhance immune evasion through accumulation of regulatory T cells (<xref ref-type="bibr" rid="b271-ijmm-40-03-0587">271</xref>–<xref ref-type="bibr" rid="b273-ijmm-40-03-0587">273</xref>), and anti-WNT signaling therapy using a PORCN inhibitor, tankyrase inhibitor or β-catenin inhibitor may be applicable for the treatment of immune evasion (<xref ref-type="fig" rid="f5-ijmm-40-03-0587">Fig. 5</xref>). By contrast, WNT/β-catenin signaling inhibition in cancer cells or tumor microenvironment owing to DKK1 upregulation can also lead to immune evasion through the accumulation of myeloid-derived suppressor cells and clearance of natural killer and cytotoxic T cells (<xref ref-type="bibr" rid="b266-ijmm-40-03-0587">266</xref>,<xref ref-type="bibr" rid="b269-ijmm-40-03-0587">269</xref>,<xref ref-type="bibr" rid="b274-ijmm-40-03-0587">274</xref>), and pro-WNT signaling therapy using an anti-DKK1 mAb may be applicable for the treatment of immune evasion in cancer patients with DKK1 upregulation (<xref ref-type="fig" rid="f5-ijmm-40-03-0587">Fig. 5</xref>). As WNT signaling cascades in cancer cells, stromal cells and immune cells regulate immune tolerance and antitumor immunity in a cell context-dependent manner, comprehensive understanding of WNT-dependent dynamic immune regulation based on precise immune monitoring is necessary before prescription of anti- or pro-WNT signaling therapeutics for cancer patients with immune evasion.</p>
</sec>
<sec>
<title>9. Conclusion</title>
<p>WNT signaling molecules are dysregulated in human diseases, such as cancer, bone diseases, cardiovascular diseases, neuropsychiatric diseases and other PCP-related diseases. Therapeutics targeting PORCN, RSPO3, FZD receptors, ROR1, β-catenin and DKK1 are in clinical trials for cancer patients, and SOST-targeting therapeutics are in clinical trials for osteoporotic patients. Fine-tuning of WNT-targeting therapeutics is necessary for the optimization of their clinical efficacy and safety, as WNT signals regulate a variety of pathophysiological conditions in a context-dependent manner. WNT-targeting therapeutics have also been applied as <italic>in vitro</italic> stem-cell processing reagents for regenerative medicine.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This study was financially supported in part by a Grant-in-Aid for the knowledge base project from M. Katoh's Fund.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="b1-ijmm-40-03-0587">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>WNT and FGF gene clusters (Review)</article-title>
<source/>Int J Oncol
          <volume>21</volume>
<fpage>1269</fpage>
<lpage>1273</lpage>
<year>2002</year>
<pub-id pub-id-type="pmid">12429977</pub-id>
</element-citation>
</ref>
<ref id="b2-ijmm-40-03-0587">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>WNT signaling pathway and stem cell signaling network</article-title>
<source/>Clin Cancer Res
          <volume>13</volume>
<fpage>4042</fpage>
<lpage>4045</lpage>
<year>2007</year>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2316</pub-id>
<pub-id pub-id-type="pmid">17634527</pub-id>
</element-citation>
</ref>
<ref id="b3-ijmm-40-03-0587">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niehrs</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>The complex world of WNT receptor signalling</article-title>
<source/>Nat Rev Mol Cell Biol
          <volume>13</volume>
<fpage>767</fpage>
<lpage>779</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1038/nrm3470</pub-id>
<pub-id pub-id-type="pmid">23151663</pub-id>
</element-citation>
</ref>
<ref id="b4-ijmm-40-03-0587">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Nan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mohammed</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Haydon</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Luu</surname>
<given-names>HH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: Implications in targeted cancer therapies</article-title>
<source/>Lab Invest
          <volume>96</volume>
<fpage>116</fpage>
<lpage>136</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1038/labinvest.2015.144</pub-id>
<!--<pub-id pub-id-type="pmcid">4731283</pub-id>-->
<pub-id pub-id-type="pmid">26618721</pub-id>
</element-citation>
</ref>
<ref id="b5-ijmm-40-03-0587">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Acebron</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Niehrs</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>β-catenin-independent roles of Wnt/LRP6 signaling</article-title>
<source/>Trends Cell Biol
          <volume>26</volume>
<fpage>956</fpage>
<lpage>967</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.tcb.2016.07.009</pub-id>
<pub-id pub-id-type="pmid">27568239</pub-id>
</element-citation>
</ref>
<ref id="b6-ijmm-40-03-0587">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rada</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rojo</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Offergeld</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Velasco-Martín</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>González-Sancho</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Valverde</surname>
<given-names>ÁM</given-names>
</name>
<name>
<surname>Dale</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Regadera</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cuadrado</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>WNT-3A regulates an Axin1/NRF2 complex that regulates antioxidant metabolism in hepatocytes</article-title>
<source/>Antioxid Redox Signal
          <volume>22</volume>
<fpage>555</fpage>
<lpage>571</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1089/ars.2014.6040</pub-id>
<!--<pub-id pub-id-type="pmcid">4333636</pub-id>-->
<pub-id pub-id-type="pmid">25336178</pub-id>
</element-citation>
</ref>
<ref id="b7-ijmm-40-03-0587">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>WNT/PCP signaling pathway and human cancer (Review)</article-title>
<source/>Oncol Rep
          <volume>14</volume>
<fpage>1583</fpage>
<lpage>1588</lpage>
<year>2005</year>
<pub-id pub-id-type="pmid">16273260</pub-id>
</element-citation>
</ref>
<ref id="b8-ijmm-40-03-0587">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang-Rodriguez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Basak</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Kipps</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth</article-title>
<source/>PLoS One
          <volume>7</volume>
<fpage>e31127</fpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1371/journal.pone.0031127</pub-id>
<!--<pub-id pub-id-type="pmcid">3293865</pub-id>-->
<pub-id pub-id-type="pmid">22403610</pub-id>
</element-citation>
</ref>
<ref id="b9-ijmm-40-03-0587">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhuo</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Lnc-ing ROR1-HER3 and Hippo signalling in metastasis</article-title>
<source/>Nat Cell Biol
          <volume>19</volume>
<fpage>81</fpage>
<lpage>83</lpage>
<year>2017</year>
<pub-id pub-id-type="doi">10.1038/ncb3467</pub-id>
<pub-id pub-id-type="pmid">28139652</pub-id>
</element-citation>
</ref>
<ref id="b10-ijmm-40-03-0587">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Medema</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Cancer stem cells: The challenges ahead</article-title>
<source/>Nat Cell Biol
          <volume>15</volume>
<fpage>338</fpage>
<lpage>344</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1038/ncb2717</pub-id>
<pub-id pub-id-type="pmid">23548926</pub-id>
</element-citation>
</ref>
<ref id="b11-ijmm-40-03-0587">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holland</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Klaus</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Garratt</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Birchmeier</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Wnt signaling in stem and cancer stem cells</article-title>
<source/>Curr Opin Cell Biol
          <volume>25</volume>
<fpage>254</fpage>
<lpage>264</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1016/j.ceb.2013.01.004</pub-id>
<pub-id pub-id-type="pmid">23347562</pub-id>
</element-citation>
</ref>
<ref id="b12-ijmm-40-03-0587">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamb</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bonuccelli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ozsvári</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Peiris-Pagès</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fiorillo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Bevilacqua</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mazzanti</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>McDonnell</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Naccarato</surname>
<given-names>AG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling</article-title>
<source/>Oncotarget
          <volume>6</volume>
<fpage>30453</fpage>
<lpage>30471</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.18632/oncotarget.5852</pub-id>
<!--<pub-id pub-id-type="pmcid">4741544</pub-id>-->
<pub-id pub-id-type="pmid">26421711</pub-id>
</element-citation>
</ref>
<ref id="b13-ijmm-40-03-0587">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tam</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>The epigenetics of epithelial-mesenchymal plasticity in cancer</article-title>
<source/>Nat Med
          <volume>19</volume>
<fpage>1438</fpage>
<lpage>1449</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1038/nm.3336</pub-id>
<!--<pub-id pub-id-type="pmcid">4190672</pub-id>-->
<pub-id pub-id-type="pmid">24202396</pub-id>
</element-citation>
</ref>
<ref id="b14-ijmm-40-03-0587">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranganathan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Capobianco</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Notch signalling in solid tumours: A little bit of everything but not all the time</article-title>
<source/>Nat Rev Cancer
          <volume>11</volume>
<fpage>338</fpage>
<lpage>351</lpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.1038/nrc3035</pub-id>
<pub-id pub-id-type="pmid">21508972</pub-id>
</element-citation>
</ref>
<ref id="b15-ijmm-40-03-0587">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Medici</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Signaling mechanisms of the epithelial-mesenchymal transition</article-title>
<source/>Sci Signal
          <volume>7</volume>
<fpage>re8</fpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1126/scisignal.2005189</pub-id>
<!--<pub-id pub-id-type="pmcid">4372086</pub-id>-->
<pub-id pub-id-type="pmid">25249658</pub-id>
</element-citation>
</ref>
<ref id="b16-ijmm-40-03-0587">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nakagama</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>FGF receptors: Cancer biology and therapeutics</article-title>
<source/>Med Res Rev
          <volume>34</volume>
<fpage>280</fpage>
<lpage>300</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1002/med.21288</pub-id>
<pub-id pub-id-type="pmid">23696246</pub-id>
</element-citation>
</ref>
<ref id="b17-ijmm-40-03-0587">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ting</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Stott</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Wittner</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Ozsolak</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ciciliano</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Smas</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Winokur</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gilman</surname>
<given-names>AJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis</article-title>
<source/>Nature
          <volume>487</volume>
<fpage>510</fpage>
<lpage>513</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1038/nature11217</pub-id>
<!--<pub-id pub-id-type="pmcid">3408856</pub-id>-->
<pub-id pub-id-type="pmid">22763454</pub-id>
</element-citation>
</ref>
<ref id="b18-ijmm-40-03-0587">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bozdag</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Riddick</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kotliarov</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Baysan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Iwamoto</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Cam</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Kotliarova</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fine</surname>
<given-names>HA</given-names>
</name>
</person-group>
<article-title>Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels</article-title>
<source/>PLoS One
          <volume>8</volume>
<fpage>e62982</fpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1371/journal.pone.0062982</pub-id>
<!--<pub-id pub-id-type="pmcid">3639162</pub-id>-->
<pub-id pub-id-type="pmid">23658659</pub-id>
</element-citation>
</ref>
<ref id="b19-ijmm-40-03-0587">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wittner</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Broderick</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Desai</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Brannigan</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Trautwein</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance</article-title>
<source/>Science
          <volume>349</volume>
<fpage>1351</fpage>
<lpage>1356</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1126/science.aab0917</pub-id>
<!--<pub-id pub-id-type="pmcid">4872391</pub-id>-->
<pub-id pub-id-type="pmid">26383955</pub-id>
</element-citation>
</ref>
<ref id="b20-ijmm-40-03-0587">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Churchman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>McCastlain</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Reshmi</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Payne-Turner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Iacobucci</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia</article-title>
<source/>Nat Commun
          <volume>7</volume>
<fpage>13331</fpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1038/ncomms13331</pub-id>
<!--<pub-id pub-id-type="pmcid">5105166</pub-id>-->
<pub-id pub-id-type="pmid">27824051</pub-id>
</element-citation>
</ref>
<ref id="b21-ijmm-40-03-0587">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettinato</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ramanathan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Mangino</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Scalable differentiation of human iPSCs in a multicellular spheroid-based 3D culture into hepatocyte-like cells through direct Wnt/β-catenin pathway inhibition</article-title>
<source/>Sci Rep
          <volume>6</volume>
<fpage>32888</fpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1038/srep32888</pub-id>
<pub-id pub-id-type="pmid">27616299</pub-id>
</element-citation>
</ref>
<ref id="b22-ijmm-40-03-0587">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Motono</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ioroi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ogura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>WNT-C59, a small-molecule WNT inhibitor, efficiently induces anterior cortex that includes cortical motor neurons from human pluripotent stem cells</article-title>
<source/>Stem Cells Transl Med
          <volume>5</volume>
<fpage>552</fpage>
<lpage>560</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.5966/sctm.2015-0261</pub-id>
<!--<pub-id pub-id-type="pmcid">4798742</pub-id>-->
<pub-id pub-id-type="pmid">26941358</pub-id>
</element-citation>
</ref>
<ref id="b23-ijmm-40-03-0587">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mae</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Toyoda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Uchida</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Osafune</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Redefining definitive endoderm subtypes by robust induction of human induced pluripotent stem cells</article-title>
<source/>Differentiation
          <volume>92</volume>
<fpage>281</fpage>
<lpage>290</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.diff.2016.04.002</pub-id>
<pub-id pub-id-type="pmid">27087651</pub-id>
</element-citation>
</ref>
<ref id="b24-ijmm-40-03-0587">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohamed</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Berry</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Radzinsky</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pratt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ang</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chemical enhancement of in vitro and in vivo direct cardiac reprogramming</article-title>
<source/>Circulation
          <volume>135</volume>
<fpage>978</fpage>
<lpage>995</lpage>
<year>2017</year>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.024692</pub-id>
<pub-id pub-id-type="pmid">27834668</pub-id>
</element-citation>
</ref>
<ref id="b25-ijmm-40-03-0587">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Meraner</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tovaglieri</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gerhard</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Stallcup</surname>
<given-names>WB</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Frizzled proteins are colonic epithelial receptors for C. difficile toxin B</article-title>
<source/>Nature
          <volume>538</volume>
<fpage>350</fpage>
<lpage>355</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1038/nature19799</pub-id>
<!--<pub-id pub-id-type="pmcid">5519134</pub-id>-->
<pub-id pub-id-type="pmid">27680706</pub-id>
</element-citation>
</ref>
<ref id="b26-ijmm-40-03-0587">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collery</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Volberding</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Bostrom</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Link</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Besharse</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Loss of zebrafish mfrp causes nanophthalmia, hyperopia, and accumulation of subretinal macrophages</article-title>
<source/>Invest Ophthalmol Vis Sci
          <volume>57</volume>
<fpage>6805</fpage>
<lpage>6814</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1167/iovs.16-19593</pub-id>
<!--<pub-id pub-id-type="pmcid">5215506</pub-id>-->
<pub-id pub-id-type="pmid">28002843</pub-id>
</element-citation>
</ref>
<ref id="b27-ijmm-40-03-0587">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kinzler</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Vogelstein</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Lessons from hereditary colorectal cancer</article-title>
<source/>Cell
          <volume>87</volume>
<fpage>159</fpage>
<lpage>170</lpage>
<year>1996</year>
<pub-id pub-id-type="doi">10.1016/S0092-8674(00)81333-1</pub-id>
<pub-id pub-id-type="pmid">8861899</pub-id>
</element-citation>
</ref>
<ref id="b28-ijmm-40-03-0587">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lammi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Arte</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Somer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jarvinen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lahermo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Thesleff</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Pirinen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nieminen</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer</article-title>
<source/>Am J Hum Genet
          <volume>74</volume>
<fpage>1043</fpage>
<lpage>1050</lpage>
<year>2004</year>
<pub-id pub-id-type="doi">10.1086/386293</pub-id>
<!--<pub-id pub-id-type="pmcid">1181967</pub-id>-->
<pub-id pub-id-type="pmid">15042511</pub-id>
</element-citation>
</ref>
<ref id="b29-ijmm-40-03-0587">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gala</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Mizukami</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Moriichi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lauwers</surname>
<given-names>GY</given-names>
</name>
<name>
<surname>Bardeesy</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas</article-title>
<source/>Gastroenterology
          <volume>146</volume>
<fpage>520</fpage>
<lpage>529</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1053/j.gastro.2013.10.045</pub-id>
<!--<pub-id pub-id-type="pmcid">3978775</pub-id>-->
<pub-id pub-id-type="pmid">24512911</pub-id>
</element-citation>
</ref>
<ref id="b30-ijmm-40-03-0587">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muzny</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Bainbridge</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dinh</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Drummond</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kovar</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Newsham</surname>
<given-names>IF</given-names>
</name>
<etal></etal>
<collab>Cancer Genome Atlas Network</collab>
</person-group>
<article-title>Comprehensive molecular characterization of human colon and rectal cancer</article-title>
<source/>Nature
          <volume>487</volume>
<fpage>330</fpage>
<lpage>337</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1038/nature11252</pub-id>
<pub-id pub-id-type="pmid">22810696</pub-id>
</element-citation>
</ref>
<ref id="b31-ijmm-40-03-0587">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giannakis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>XJ</given-names>
</name>
<name>
<surname>Shukla</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>ZR</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Nishihara</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bahl</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Amin-Mansour</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yamauchi</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genomic correlates of immune-cell infiltrates in colorectal carcinoma</article-title>
<source/>Cell Rep
          <volume>15</volume>
<fpage>857</fpage>
<lpage>865</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.celrep.2016.03.075</pub-id>
<!--<pub-id pub-id-type="pmcid">4850357</pub-id>-->
</element-citation>
</ref>
<ref id="b32-ijmm-40-03-0587">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seshagiri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stawiski</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Durinck</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Modrusan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Storm</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Conboy</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Chaudhuri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Janakiraman</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Jaiswal</surname>
<given-names>BS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recurrent R-spondin fusions in colon cancer</article-title>
<source/>Nature
          <volume>488</volume>
<fpage>660</fpage>
<lpage>664</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1038/nature11282</pub-id>
<!--<pub-id pub-id-type="pmcid">3690621</pub-id>-->
<pub-id pub-id-type="pmid">22895193</pub-id>
</element-citation>
</ref>
<ref id="b33-ijmm-40-03-0587">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciriello</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gatza</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Wilkerson</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Rhie</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Pastore</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>McLellan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yau</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kandoth</surname>
<given-names>C</given-names>
</name>
<etal></etal>
<collab>TCGA Research Network</collab>
</person-group>
<article-title>Comprehensive molecular portraits of invasive lobular breast cancer</article-title>
<source/>Cell
          <volume>163</volume>
<fpage>506</fpage>
<lpage>519</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.cell.2015.09.033</pub-id>
<!--<pub-id pub-id-type="pmcid">4603750</pub-id>-->
<pub-id pub-id-type="pmid">26451490</pub-id>
</element-citation>
</ref>
<ref id="b34-ijmm-40-03-0587">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bass</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Thorsson</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Shmulevich</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hinoue</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Laird</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Curtis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>H</given-names>
</name>
<etal></etal>
<collab>Cancer Genome Atlas Research Network</collab>
</person-group>
<article-title>Comprehensive molecular characterization of gastric adenocarcinoma</article-title>
<source/>Nature
          <volume>513</volume>
<fpage>202</fpage>
<lpage>209</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1038/nature13480</pub-id>
<!--<pub-id pub-id-type="pmcid">4170219</pub-id>-->
<pub-id pub-id-type="pmid">25079317</pub-id>
</element-citation>
</ref>
<ref id="b35-ijmm-40-03-0587">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guichard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Amaddeo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Imbeaud</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ladeiro</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pelletier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Maad</surname>
<given-names>IB</given-names>
</name>
<name>
<surname>Calderaro</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bioulac-Sage</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Letexier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Degos</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma</article-title>
<source/>Nat Genet
          <volume>44</volume>
<fpage>694</fpage>
<lpage>698</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1038/ng.2256</pub-id>
<!--<pub-id pub-id-type="pmcid">3819251</pub-id>-->
<pub-id pub-id-type="pmid">22561517</pub-id>
</element-citation>
</ref>
<ref id="b36-ijmm-40-03-0587">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Alexandrov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wala</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Pedamallu</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Shukla</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>BA</given-names>
</name>
<etal></etal>
<collab>Cancer Genome Atlas Research Network</collab>
</person-group>
<article-title>Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas</article-title>
<source/>Nat Genet
          <volume>48</volume>
<fpage>607</fpage>
<lpage>616</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1038/ng.3564</pub-id>
<!--<pub-id pub-id-type="pmcid">4884143</pub-id>-->
<pub-id pub-id-type="pmid">27158780</pub-id>
</element-citation>
</ref>
<ref id="b37-ijmm-40-03-0587">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bailey</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Nones</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Johns</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Patch</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Gingras</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Christ</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Bruxner</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>MC</given-names>
</name>
<etal></etal>
<collab>Australian Pancreatic Cancer Genome Initiative</collab>
</person-group>
<article-title>Genomic analyses identify molecular subtypes of pancreatic cancer</article-title>
<source/>Nature
          <volume>531</volume>
<fpage>47</fpage>
<lpage>52</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1038/nature16965</pub-id>
<pub-id pub-id-type="pmid">26909576</pub-id>
</element-citation>
</ref>
<ref id="b38-ijmm-40-03-0587">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robinson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Van Allen</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lonigro</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Mosquera</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Taplin</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Pritchard</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Attard</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrative clinical genomics of advanced prostate cancer</article-title>
<source/>Cell
          <volume>161</volume>
<fpage>1215</fpage>
<lpage>1228</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.cell.2015.05.001</pub-id>
<!--<pub-id pub-id-type="pmcid">4484602</pub-id>-->
<pub-id pub-id-type="pmid">26000489</pub-id>
</element-citation>
</ref>
<ref id="b39-ijmm-40-03-0587">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kandoth</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Cherniack</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Akbani</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Pashtan</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Benz</surname>
<given-names>CC</given-names>
</name>
<etal></etal>
<collab>Cancer Genome Atlas Research Network</collab>
</person-group>
<article-title>Integrated genomic characterization of endometrial carcinoma</article-title>
<source/>Nature
          <volume>497</volume>
<fpage>67</fpage>
<lpage>73</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1038/nature12113</pub-id>
<!--<pub-id pub-id-type="pmcid">3704730</pub-id>-->
<pub-id pub-id-type="pmid">23636398</pub-id>
</element-citation>
</ref>
<ref id="b40-ijmm-40-03-0587">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barker</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Adult intestinal stem cells: Critical drivers of epithelial homeostasis and regeneration</article-title>
<source/>Nat Rev Mol Cell Biol
          <volume>15</volume>
<fpage>19</fpage>
<lpage>33</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1038/nrm3721</pub-id>
<pub-id pub-id-type="pmid">24326621</pub-id>
</element-citation>
</ref>
<ref id="b41-ijmm-40-03-0587">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flanagan</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Phesse</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Schwab</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Malaterre</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stange</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Nowell</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Currie</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Saw</surname>
<given-names>JT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Frizzled7 functions as a Wnt receptor in intestinal epithelial Lgr5(+) stem cells</article-title>
<source/>Stem Cell Reports
          <volume>4</volume>
<fpage>759</fpage>
<lpage>767</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2015.03.003</pub-id>
<!--<pub-id pub-id-type="pmcid">4437483</pub-id>-->
<pub-id pub-id-type="pmid">25892522</pub-id>
</element-citation>
</ref>
<ref id="b42-ijmm-40-03-0587">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Cong</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Novel regulation of Wnt signaling at the proximal membrane level</article-title>
<source/>Trends Biochem Sci
          <volume>41</volume>
<fpage>773</fpage>
<lpage>783</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.tibs.2016.06.003</pub-id>
<pub-id pub-id-type="pmid">27377711</pub-id>
</element-citation>
</ref>
<ref id="b43-ijmm-40-03-0587">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valenta</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hausmann</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Basler</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>The many faces and functions of β-catenin</article-title>
<source/>EMBO J
          <volume>31</volume>
<fpage>2714</fpage>
<lpage>2736</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1038/emboj.2012.150</pub-id>
<!--<pub-id pub-id-type="pmcid">3380220</pub-id>-->
<pub-id pub-id-type="pmid">22617422</pub-id>
</element-citation>
</ref>
<ref id="b44-ijmm-40-03-0587">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy</article-title>
<source/>Epigenomics
          <volume>8</volume>
<fpage>285</fpage>
<lpage>305</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.2217/epi.15.89</pub-id>
<pub-id pub-id-type="pmid">26411517</pub-id>
</element-citation>
</ref>
<ref id="b45-ijmm-40-03-0587">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Inuzuka</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Roles of F-box proteins in cancer</article-title>
<source/>Nat Rev Cancer
          <volume>14</volume>
<fpage>233</fpage>
<lpage>247</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1038/nrc3700</pub-id>
<!--<pub-id pub-id-type="pmcid">4306233</pub-id>-->
<pub-id pub-id-type="pmid">24658274</pub-id>
</element-citation>
</ref>
<ref id="b46-ijmm-40-03-0587">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kajiguchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Katsumi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tanizaki</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kiyoi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Naoe</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Y654 of β-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of β-catenin</article-title>
<source/>Eur J Haematol
          <volume>88</volume>
<fpage>314</fpage>
<lpage>320</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1111/j.1600-0609.2011.01738.x</pub-id>
<pub-id pub-id-type="pmid">22126602</pub-id>
</element-citation>
</ref>
<ref id="b47-ijmm-40-03-0587">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling</article-title>
<source/>Mol Cancer Ther
          <volume>13</volume>
<fpage>1217</fpage>
<lpage>1230</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0397</pub-id>
<pub-id pub-id-type="pmid">24552773</pub-id>
</element-citation>
</ref>
<ref id="b48-ijmm-40-03-0587">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernández-Sánchez</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Barbier</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Whitehead</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Béalle</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Latorre-Ossa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rey</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fouassier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Claperon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brullé</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressure</article-title>
<source/>Nature
          <volume>523</volume>
<fpage>92</fpage>
<lpage>95</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1038/nature14329</pub-id>
<pub-id pub-id-type="pmid">25970250</pub-id>
</element-citation>
</ref>
<ref id="b49-ijmm-40-03-0587">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Veelen</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Helvensteijn</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Blonden</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Theeuwes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bakker</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Franken</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>van Gurp</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Meijlink</surname>
<given-names>F</given-names>
</name>
<name>
<surname>van der Valk</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>β-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis</article-title>
<source/>Gut
          <volume>60</volume>
<fpage>1204</fpage>
<lpage>1212</lpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.1136/gut.2010.233460</pub-id>
<!--<pub-id pub-id-type="pmcid">3152867</pub-id>-->
<pub-id pub-id-type="pmid">21307168</pub-id>
</element-citation>
</ref>
<ref id="b50-ijmm-40-03-0587">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuechler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Albrecht</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bacino</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Bartholomew</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>van Bokhoven</surname>
<given-names>H</given-names>
</name>
<name>
<surname>van den Boogaard</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bramswig</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Büttner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cremer</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations in β-catenin (CTNNB1) appear to be a frequent cause of intellectual disability: Expanding the mutational and clinical spectrum</article-title>
<source/>Hum Genet
          <volume>134</volume>
<fpage>97</fpage>
<lpage>109</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1007/s00439-014-1498-1</pub-id>
<pub-id pub-id-type="pmid">25326669</pub-id>
</element-citation>
</ref>
<ref id="b51-ijmm-40-03-0587">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dixon</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Stem</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Schuette</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Keegan</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Besirli</surname>
<given-names>CG</given-names>
</name>
</person-group>
<article-title>CTNNB1 mutation associated with familial exudative vitreoretinopathy (FEVR) phenotype</article-title>
<source/>Ophthalmic Genet
          <volume>37</volume>
<fpage>468</fpage>
<lpage>470</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.3109/13816810.2015.1120318</pub-id>
<pub-id pub-id-type="pmid">26967979</pub-id>
</element-citation>
</ref>
<ref id="b52-ijmm-40-03-0587">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lui</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>DV</given-names>
</name>
<name>
<surname>Kriegstein</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>Development and evolution of the human neocortex</article-title>
<source/>Cell
          <volume>146</volume>
<fpage>18</fpage>
<lpage>36</lpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.1016/j.cell.2011.06.030</pub-id>
<!--<pub-id pub-id-type="pmcid">3610574</pub-id>-->
<pub-id pub-id-type="pmid">21729779</pub-id>
</element-citation>
</ref>
<ref id="b53-ijmm-40-03-0587">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inestrosa</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Arenas</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Emerging roles of Wnts in the adult nervous system</article-title>
<source/>Nat Rev Neurosci
          <volume>11</volume>
<fpage>77</fpage>
<lpage>86</lpage>
<year>2010</year>
<pub-id pub-id-type="doi">10.1038/nrn2755</pub-id>
<pub-id pub-id-type="pmid">20010950</pub-id>
</element-citation>
</ref>
<ref id="b54-ijmm-40-03-0587">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bayod</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Felice</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Andrés</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rosa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Camins</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pallàs</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Canudas</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Downregulation of canonical Wnt signaling in hippocampus of SAMP8 mice</article-title>
<source/>Neurobiol Aging
          <volume>36</volume>
<fpage>720</fpage>
<lpage>729</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.09.017</pub-id>
<pub-id pub-id-type="pmid">25443287</pub-id>
</element-citation>
</ref>
<ref id="b55-ijmm-40-03-0587">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wakabayashi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hidaka</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fujimaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Asashima</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kuwabara</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Diabetes impairs Wnt3 protein-induced neurogenesis in olfactory bulbs via glutamate transporter 1 inhibition</article-title>
<source/>J Biol Chem
          <volume>291</volume>
<fpage>15196</fpage>
<lpage>15211</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1074/jbc.M115.672857</pub-id>
<!--<pub-id pub-id-type="pmcid">4946934</pub-id>-->
<pub-id pub-id-type="pmid">27226528</pub-id>
</element-citation>
</ref>
<ref id="b56-ijmm-40-03-0587">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marzo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Galli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lopes</surname>
<given-names>D</given-names>
</name>
<name>
<surname>McLeod</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Podpolny</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Segovia-Roldan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ciani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Purro</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cacucci</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gibb</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reversal of synapse degeneration by restoring Wnt signaling in the adult hippocampus</article-title>
<source/>Curr Biol
          <volume>26</volume>
<fpage>2551</fpage>
<lpage>2561</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.cub.2016.07.024</pub-id>
<!--<pub-id pub-id-type="pmcid">5070786</pub-id>-->
<pub-id pub-id-type="pmid">27593374</pub-id>
</element-citation>
</ref>
<ref id="b57-ijmm-40-03-0587">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Aron</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zullo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Drake</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>XS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>REST and stress resistance in ageing and Alzheimer's disease</article-title>
<source/>Nature
          <volume>507</volume>
<fpage>448</fpage>
<lpage>454</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1038/nature13163</pub-id>
<!--<pub-id pub-id-type="pmcid">4110979</pub-id>-->
<pub-id pub-id-type="pmid">24670762</pub-id>
</element-citation>
</ref>
<ref id="b58-ijmm-40-03-0587">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dias</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>NY</given-names>
</name>
<name>
<surname>Mazei-Robison</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Damez-Werno</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Scobie</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bagot</surname>
<given-names>R</given-names>
</name>
<name>
<surname>LaBonté</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ribeiro</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>β-catenin mediates stress resilience through Dicer1/microRNA regulation</article-title>
<source/>Nature
          <volume>516</volume>
<fpage>51</fpage>
<lpage>55</lpage>
<year>2014</year>
<!--<pub-id pub-id-type="pmcid">4257892</pub-id>-->
<pub-id pub-id-type="pmid">25383518</pub-id>
</element-citation>
</ref>
<ref id="b59-ijmm-40-03-0587">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madison</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nigam</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hussain</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Nehme</surname>
<given-names>R</given-names>
</name>
<name>
<surname>van der Ven</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fleishman</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of bipolar disorder patient-specific induced pluripotent stem cells from a family reveals neurodevelopmental and mRNA expression abnormalities</article-title>
<source/>Mol Psychiatry
          <volume>20</volume>
<fpage>703</fpage>
<lpage>717</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1038/mp.2015.7</pub-id>
<!--<pub-id pub-id-type="pmcid">4440839</pub-id>-->
<pub-id pub-id-type="pmid">25733313</pub-id>
</element-citation>
</ref>
<ref id="b60-ijmm-40-03-0587">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karantalis</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hare</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Use of mesenchymal stem cells for therapy of cardiac disease</article-title>
<source/>Circ Res
          <volume>116</volume>
<fpage>1413</fpage>
<lpage>1430</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.303614</pub-id>
<!--<pub-id pub-id-type="pmcid">4429294</pub-id>-->
<pub-id pub-id-type="pmid">25858066</pub-id>
</element-citation>
</ref>
<ref id="b61-ijmm-40-03-0587">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atashi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Modarressi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pepper</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>The role of reactive oxygen species in mesenchymal stem cell adipogenic and osteogenic differentiation: A review</article-title>
<source/>Stem Cells Dev
          <volume>24</volume>
<fpage>1150</fpage>
<lpage>1163</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1089/scd.2014.0484</pub-id>
<!--<pub-id pub-id-type="pmcid">4424969</pub-id>-->
<pub-id pub-id-type="pmid">25603196</pub-id>
</element-citation>
</ref>
<ref id="b62-ijmm-40-03-0587">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Alman</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Wnt pathway, an essential role in bone regeneration</article-title>
<source/>J Cell Biochem
          <volume>106</volume>
<fpage>353</fpage>
<lpage>362</lpage>
<year>2009</year>
<pub-id pub-id-type="doi">10.1002/jcb.22020</pub-id>
<pub-id pub-id-type="pmid">19127541</pub-id>
</element-citation>
</ref>
<ref id="b63-ijmm-40-03-0587">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Oyajobi</surname>
<given-names>BO</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tsao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts</article-title>
<source/>Bone
          <volume>52</volume>
<fpage>145</fpage>
<lpage>156</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1016/j.bone.2012.09.029</pub-id>
<pub-id pub-id-type="pmid">23032104</pub-id>
</element-citation>
</ref>
<ref id="b64-ijmm-40-03-0587">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ke</surname>
<given-names>HZ</given-names>
</name>
<name>
<surname>Richards</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ominsky</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases</article-title>
<source/>Endocr Rev
          <volume>33</volume>
<fpage>747</fpage>
<lpage>783</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1210/er.2011-1060</pub-id>
<pub-id pub-id-type="pmid">22723594</pub-id>
</element-citation>
</ref>
<ref id="b65-ijmm-40-03-0587">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boudin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fijalkowski</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Piters</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Van Hul</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases</article-title>
<source/>Semin Arthritis Rheum
          <volume>43</volume>
<fpage>220</fpage>
<lpage>240</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1016/j.semarthrit.2013.01.004</pub-id>
<pub-id pub-id-type="pmid">23433961</pub-id>
</element-citation>
</ref>
<ref id="b66-ijmm-40-03-0587">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silva</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Bilezikian</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Parathyroid hormone: Anabolic and catabolic actions on the skeleton</article-title>
<source/>Curr Opin Pharmacol
          <volume>22</volume>
<fpage>41</fpage>
<lpage>50</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.coph.2015.03.005</pub-id>
<!--<pub-id pub-id-type="pmcid">5407089</pub-id>-->
<pub-id pub-id-type="pmid">25854704</pub-id>
</element-citation>
</ref>
<ref id="b67-ijmm-40-03-0587">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maeda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Udagawa</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Uehara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ishihara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mizoguchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Takada</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kani</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis</article-title>
<source/>Nat Med
          <volume>18</volume>
<fpage>405</fpage>
<lpage>412</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1038/nm.2653</pub-id>
<pub-id pub-id-type="pmid">22344299</pub-id>
</element-citation>
</ref>
<ref id="b68-ijmm-40-03-0587">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Bieganski</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sohn</surname>
<given-names>YB</given-names>
</name>
<name>
<surname>Kozlowski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Semënov</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>YL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia</article-title>
<source/>Hum Genet
          <volume>129</volume>
<fpage>497</fpage>
<lpage>502</lpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.1007/s00439-011-0947-3</pub-id>
<pub-id pub-id-type="pmid">21221996</pub-id>
</element-citation>
</ref>
<ref id="b69-ijmm-40-03-0587">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brunkow</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Van Ness</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Paeper</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Kovacevich</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Proll</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Skonier</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sabo</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein</article-title>
<source/>Am J Hum Genet
          <volume>68</volume>
<fpage>577</fpage>
<lpage>589</lpage>
<year>2001</year>
<pub-id pub-id-type="doi">10.1086/318811</pub-id>
<!--<pub-id pub-id-type="pmcid">1274471</pub-id>-->
<pub-id pub-id-type="pmid">11179006</pub-id>
</element-citation>
</ref>
<ref id="b70-ijmm-40-03-0587">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balemans</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ebeling</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Van Hul</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wuyts</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lacza</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dioszegi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dikkers</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Hildering</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Willems</surname>
<given-names>PJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease</article-title>
<source/>J Med Genet
          <volume>39</volume>
<fpage>91</fpage>
<lpage>97</lpage>
<year>2002</year>
<pub-id pub-id-type="doi">10.1136/jmg.39.2.91</pub-id>
<!--<pub-id pub-id-type="pmcid">1735035</pub-id>-->
<pub-id pub-id-type="pmid">11836356</pub-id>
</element-citation>
</ref>
<ref id="b71-ijmm-40-03-0587">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Wesenbeeck</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cleiren</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gram</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beals</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Bénichou</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Scopelliti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Key</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Renton</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bartels</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density</article-title>
<source/>Am J Hum Genet
          <volume>72</volume>
<fpage>763</fpage>
<lpage>771</lpage>
<year>2003</year>
<pub-id pub-id-type="doi">10.1086/368277</pub-id>
<!--<pub-id pub-id-type="pmcid">1180253</pub-id>-->
<pub-id pub-id-type="pmid">12579474</pub-id>
</element-citation>
</ref>
<ref id="b72-ijmm-40-03-0587">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canalis</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Wnt signalling in osteoporosis: Mechanisms and novel therapeutic approaches</article-title>
<source/>Nat Rev Endocrinol
          <volume>9</volume>
<fpage>575</fpage>
<lpage>583</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1038/nrendo.2013.154</pub-id>
<pub-id pub-id-type="pmid">23938284</pub-id>
</element-citation>
</ref>
<ref id="b73-ijmm-40-03-0587">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laine</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Joeng</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Campeau</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Kiviranta</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tarkkonen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Grover</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Pekkinen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wessman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heino</surname>
<given-names>TJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta</article-title>
<source/>N Engl J Med
          <volume>368</volume>
<fpage>1809</fpage>
<lpage>1816</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1056/NEJMoa1215458</pub-id>
<!--<pub-id pub-id-type="pmcid">3709450</pub-id>-->
<pub-id pub-id-type="pmid">23656646</pub-id>
</element-citation>
</ref>
<ref id="b74-ijmm-40-03-0587">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Slee</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Fukai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Rawadi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Roman-Roman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Reginato</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cundy</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Glorieux</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Lev</surname>
<given-names>D</given-names>
</name>
<etal></etal>
<collab>Osteoporosis-Pseudoglioma Syndrome Collaborative Group</collab>
</person-group>
<article-title>LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development</article-title>
<source/>Cell
          <volume>107</volume>
<fpage>513</fpage>
<lpage>523</lpage>
<year>2001</year>
<pub-id pub-id-type="doi">10.1016/S0092-8674(01)00571-2</pub-id>
<pub-id pub-id-type="pmid">11719191</pub-id>
</element-citation>
</ref>
<ref id="b75-ijmm-40-03-0587">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Radhakrishnan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Nelson-Williams</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Carew</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Mane</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Najmabadi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>LRP6 mutation in a family with early coronary disease and metabolic risk factors</article-title>
<source/>Science
          <volume>315</volume>
<fpage>1278</fpage>
<lpage>1282</lpage>
<year>2007</year>
<pub-id pub-id-type="doi">10.1126/science.1136370</pub-id>
<!--<pub-id pub-id-type="pmcid">2945222</pub-id>-->
<pub-id pub-id-type="pmid">17332414</pub-id>
</element-citation>
</ref>
<ref id="b76-ijmm-40-03-0587">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simsek Kiper</surname>
<given-names>PO</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gori</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Unger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hesse</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Yamana</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kiviranta</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Solban</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brommage</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cortical-bone fragility: Insights from sFRP4 deficiency in Pyle's disease</article-title>
<source/>N Engl J Med
          <volume>374</volume>
<fpage>2553</fpage>
<lpage>2562</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1056/NEJMoa1509342</pub-id>
<pub-id pub-id-type="pmid">27355534</pub-id>
</element-citation>
</ref>
<ref id="b77-ijmm-40-03-0587">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Estrada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Styrkarsdottir</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Evangelou</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Duncan</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Ntzani</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Oei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Albagha</surname>
<given-names>OM</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>JP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture</article-title>
<source/>Nat Genet
          <volume>44</volume>
<fpage>491</fpage>
<lpage>501</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1038/ng.2249</pub-id>
<!--<pub-id pub-id-type="pmcid">3338864</pub-id>-->
<pub-id pub-id-type="pmid">22504420</pub-id>
</element-citation>
</ref>
<ref id="b78-ijmm-40-03-0587">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carmeliet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>RK</given-names>
</name>
</person-group>
<article-title>Molecular mechanisms and clinical applications of angiogenesis</article-title>
<source/>Nature
          <volume>473</volume>
<fpage>298</fpage>
<lpage>307</lpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.1038/nature10144</pub-id>
<!--<pub-id pub-id-type="pmcid">4049445</pub-id>-->
<pub-id pub-id-type="pmid">21593862</pub-id>
</element-citation>
</ref>
<ref id="b79-ijmm-40-03-0587">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review)</article-title>
<source/>Int J Mol Med
          <volume>32</volume>
<fpage>763</fpage>
<lpage>767</lpage>
<year>2013</year>
<!--<pub-id pub-id-type="pmcid">3812243</pub-id>-->
<pub-id pub-id-type="pmid">23863927</pub-id>
</element-citation>
</ref>
<ref id="b80-ijmm-40-03-0587">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayakawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ariyama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Stancikova</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sakitani</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Asfaha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Renz</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Dubeykovskaya</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Westphalen</surname>
<given-names>CB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mist1 expressing gastric stem cells maintain the normal and neoplastic gastric epithelium and are supported by a perivascular stem cell niche</article-title>
<source/>Cancer Cell
          <volume>28</volume>
<fpage>800</fpage>
<lpage>814</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.ccell.2015.10.003</pub-id>
<!--<pub-id pub-id-type="pmcid">4684751</pub-id>-->
<pub-id pub-id-type="pmid">26585400</pub-id>
</element-citation>
</ref>
<ref id="b81-ijmm-40-03-0587">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rafii</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>BS</given-names>
</name>
</person-group>
<article-title>Angiocrine functions of organ-specific endothelial cells</article-title>
<source/>Nature
          <volume>529</volume>
<fpage>316</fpage>
<lpage>325</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1038/nature17040</pub-id>
<!--<pub-id pub-id-type="pmcid">4878406</pub-id>-->
<pub-id pub-id-type="pmid">26791722</pub-id>
</element-citation>
</ref>
<ref id="b82-ijmm-40-03-0587">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goel</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Mercurio</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>VEGF targets the tumour cell</article-title>
<source/>Nat Rev Cancer
          <volume>13</volume>
<fpage>871</fpage>
<lpage>882</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1038/nrc3627</pub-id>
<!--<pub-id pub-id-type="pmcid">4011842</pub-id>-->
<pub-id pub-id-type="pmid">24263190</pub-id>
</element-citation>
</ref>
<ref id="b83-ijmm-40-03-0587">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Adamis</surname>
<given-names>AP</given-names>
</name>
</person-group>
<article-title>Ten years of anti-vascular endothelial growth factor therapy</article-title>
<source/>Nat Rev Drug Discov
          <volume>15</volume>
<fpage>385</fpage>
<lpage>403</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1038/nrd.2015.17</pub-id>
<pub-id pub-id-type="pmid">26775688</pub-id>
</element-citation>
</ref>
<ref id="b84-ijmm-40-03-0587">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Therapeutics targeting FGF signaling network in human diseases</article-title>
<source/>Trends Pharmacol Sci
          <volume>37</volume>
<fpage>1081</fpage>
<lpage>1096</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.tips.2016.10.003</pub-id>
<pub-id pub-id-type="pmid">27992319</pub-id>
</element-citation>
</ref>
<ref id="b85-ijmm-40-03-0587">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Regulation of angiogenesis via Notch signaling in breast cancer and cancer stem cells</article-title>
<source/>Biochim Biophys Acta
          <volume>1836</volume>
<fpage>304</fpage>
<lpage>320</lpage>
<year>2013</year>
<pub-id pub-id-type="pmid">24183943</pub-id>
</element-citation>
</ref>
<ref id="b86-ijmm-40-03-0587">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Notch signaling in blood vessels: From morphogenesis to homeostasis</article-title>
<source/>Sci China Life Sci
          <volume>57</volume>
<fpage>774</fpage>
<lpage>780</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1007/s11427-014-4716-0</pub-id>
<pub-id pub-id-type="pmid">25104449</pub-id>
</element-citation>
</ref>
<ref id="b87-ijmm-40-03-0587">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rostama</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Vary</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Liaw</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Notch signal integration in the vasculature during remodeling</article-title>
<source/>Vascul Pharmacol
          <volume>63</volume>
<fpage>97</fpage>
<lpage>104</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1016/j.vph.2014.10.003</pub-id>
<!--<pub-id pub-id-type="pmcid">4304902</pub-id>-->
<pub-id pub-id-type="pmid">25464152</pub-id>
</element-citation>
</ref>
<ref id="b88-ijmm-40-03-0587">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hilbert</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Klaschik</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The angiopoietin/TIE receptor system: Focusing its role for ischemia-reperfusion injury</article-title>
<source/>Cytokine Growth Factor Rev
          <volume>26</volume>
<fpage>281</fpage>
<lpage>291</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.cytogfr.2014.10.013</pub-id>
<pub-id pub-id-type="pmid">25466648</pub-id>
</element-citation>
</ref>
<ref id="b89-ijmm-40-03-0587">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gaspard</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia</article-title>
<source/>Cancer Res
          <volume>61</volume>
<fpage>6050</fpage>
<lpage>6054</lpage>
<year>2001</year>
<pub-id pub-id-type="pmid">11507052</pub-id>
</element-citation>
</ref>
<ref id="b90-ijmm-40-03-0587">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korn</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Scholz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wojtarowicz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Arnsperger</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Boutros</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Augustin</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Augustin</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Endothelial cell-derived non-canonical Wnt ligands control vascular pruning in angiogenesis</article-title>
<source/>Development
          <volume>141</volume>
<fpage>1757</fpage>
<lpage>1766</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1242/dev.104422</pub-id>
<pub-id pub-id-type="pmid">24715464</pub-id>
</element-citation>
</ref>
<ref id="b91-ijmm-40-03-0587">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilmour</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>Familial exudative vitreoretinopathy and related retinopathies</article-title>
<source/>Eye (Lond)
          <volume>29</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1038/eye.2014.70</pub-id>
<pub-id pub-id-type="pmid">25323851</pub-id>
</element-citation>
</ref>
<ref id="b92-ijmm-40-03-0587">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirikoshi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sagara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Koike</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sekihara</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hirai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Molecular cloning and characterization of human Frizzled-4 on chromosome 11q14-q21</article-title>
<source/>Biochem Biophys Res Commun
          <volume>264</volume>
<fpage>955</fpage>
<lpage>961</lpage>
<year>1999</year>
<pub-id pub-id-type="doi">10.1006/bbrc.1999.1612</pub-id>
<pub-id pub-id-type="pmid">10544037</pub-id>
</element-citation>
</ref>
<ref id="b93-ijmm-40-03-0587">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Shukla</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rajendran</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tawansy</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bedell</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>PX</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An essential role of the cysteine-rich domain of FZD4 in Norrin/Wnt signaling and familial exudative vitreoretinopathy</article-title>
<source/>J Biol Chem
          <volume>286</volume>
<fpage>10210</fpage>
<lpage>10215</lpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.1074/jbc.M110.194399</pub-id>
<!--<pub-id pub-id-type="pmcid">3060474</pub-id>-->
<pub-id pub-id-type="pmid">21177847</pub-id>
</element-citation>
</ref>
<ref id="b94-ijmm-40-03-0587">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Musada</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Syed</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jalali</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chakrabarti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Mutation spectrum of the FZD-4, TSPAN12 and ZNF408 genes in Indian FEVR patients</article-title>
<source/>BMC Ophthalmol
          <volume>16</volume>
<fpage>90</fpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1186/s12886-016-0236-y</pub-id>
<!--<pub-id pub-id-type="pmcid">4912735</pub-id>-->
<pub-id pub-id-type="pmid">27316669</pub-id>
</element-citation>
</ref>
<ref id="b95-ijmm-40-03-0587">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Novel mutations in FZD4 and phenotype-genotype correlation in Chinese patients with familial exudative vitreoretinopathy</article-title>
<source/>Mol Vis
          <volume>22</volume>
<fpage>917</fpage>
<lpage>932</lpage>
<year>2016</year>
<!--<pub-id pub-id-type="pmcid">4968609</pub-id>-->
<pub-id pub-id-type="pmid">27555740</pub-id>
</element-citation>
</ref>
<ref id="b96-ijmm-40-03-0587">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fei</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of two novel LRP5 mutations in families with familial exudative vitreoretinopathy</article-title>
<source/>Mol Vis
          <volume>20</volume>
<fpage>395</fpage>
<lpage>409</lpage>
<year>2014</year>
<!--<pub-id pub-id-type="pmcid">3976684</pub-id>-->
<pub-id pub-id-type="pmid">24715757</pub-id>
</element-citation>
</ref>
<ref id="b97-ijmm-40-03-0587">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nathans</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The Norrin/Frizzled4 signaling pathway in retinal vascular development and disease</article-title>
<source/>Trends Mol Med
          <volume>16</volume>
<fpage>417</fpage>
<lpage>425</lpage>
<year>2010</year>
<pub-id pub-id-type="doi">10.1016/j.molmed.2010.07.003</pub-id>
<!--<pub-id pub-id-type="pmcid">2963063</pub-id>-->
<pub-id pub-id-type="pmid">20688566</pub-id>
</element-citation>
</ref>
<ref id="b98-ijmm-40-03-0587">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stenman</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Rajagopal</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Ishibashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>AP</given-names>
</name>
</person-group>
<article-title>Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature</article-title>
<source/>Science
          <volume>322</volume>
<fpage>1247</fpage>
<lpage>1250</lpage>
<year>2008</year>
<pub-id pub-id-type="doi">10.1126/science.1164594</pub-id>
<pub-id pub-id-type="pmid">19023080</pub-id>
</element-citation>
</ref>
<ref id="b99-ijmm-40-03-0587">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Favazza</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Morss</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Saba</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Fredrick</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Akula</surname>
<given-names>JD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacologic activation of Wnt signaling by lithium normalizes retinal vasculature in a murine model of familial exudative vitreoretinopathy</article-title>
<source/>Am J Pathol
          <volume>186</volume>
<fpage>2588</fpage>
<lpage>2600</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.ajpath.2016.06.015</pub-id>
<!--<pub-id pub-id-type="pmcid">5222984</pub-id>-->
<pub-id pub-id-type="pmid">27524797</pub-id>
</element-citation>
</ref>
<ref id="b100-ijmm-40-03-0587">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birdsey</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Dufton</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Osuna Almagro</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Aspalter</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Dejana</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The endothelial transcription factor ERG promotes vascular stability and growth through Wnt/β-catenin signaling</article-title>
<source/>Dev Cell
          <volume>32</volume>
<fpage>82</fpage>
<lpage>96</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.devcel.2014.11.016</pub-id>
<!--<pub-id pub-id-type="pmcid">4292982</pub-id>-->
<pub-id pub-id-type="pmid">25584796</pub-id>
</element-citation>
</ref>
<ref id="b101-ijmm-40-03-0587">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arthofer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hot</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Strakova</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jäger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Grundmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kostenis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gutkind</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Schulte</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>WNT stimulation dissociates a Frizzled 4 inactive-state complex with Gα12/13</article-title>
<source/>Mol Pharmacol
          <volume>90</volume>
<fpage>447</fpage>
<lpage>459</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1124/mol.116.104919</pub-id>
<!--<pub-id pub-id-type="pmcid">5034691</pub-id>-->
<pub-id pub-id-type="pmid">27458145</pub-id>
</element-citation>
</ref>
<ref id="b102-ijmm-40-03-0587">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adler</surname>
<given-names>PN</given-names>
</name>
</person-group>
<article-title>The frizzled/stan pathway and planar cell polarity in the Drosophila wing</article-title>
<source/>Curr Top Dev Biol
          <volume>101</volume>
<fpage>1</fpage>
<lpage>31</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1016/B978-0-12-394592-1.00001-6</pub-id>
<!--<pub-id pub-id-type="pmcid">3575171</pub-id>-->
<pub-id pub-id-type="pmid">23140623</pub-id>
</element-citation>
</ref>
<ref id="b103-ijmm-40-03-0587">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mlodzik</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Wnt-Frizzled/planar cell polarity signaling: Cellular orientation by facing the wind (Wnt)</article-title>
<source/>Annu Rev Cell Dev Biol
          <volume>31</volume>
<fpage>623</fpage>
<lpage>646</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1146/annurev-cellbio-100814-125315</pub-id>
<!--<pub-id pub-id-type="pmcid">4673888</pub-id>-->
<pub-id pub-id-type="pmid">26566118</pub-id>
</element-citation>
</ref>
<ref id="b104-ijmm-40-03-0587">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bishop</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Elliot</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Garrett</surname>
<given-names>L</given-names>
</name>
<name>
<surname>English</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Andre</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sood</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Minami</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Wnt signaling gradients establish planar cell polarity by inducing Vangl2 phosphorylation through Ror2</article-title>
<source/>Dev Cell
          <volume>20</volume>
<fpage>163</fpage>
<lpage>176</lpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.1016/j.devcel.2011.01.001</pub-id>
<!--<pub-id pub-id-type="pmcid">3062198</pub-id>-->
<pub-id pub-id-type="pmid">21316585</pub-id>
</element-citation>
</ref>
<ref id="b105-ijmm-40-03-0587">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishimura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Honda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Takeichi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Planar cell polarity links axes of spatial dynamics in neural-tube closure</article-title>
<source/>Cell
          <volume>149</volume>
<fpage>1084</fpage>
<lpage>1097</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1016/j.cell.2012.04.021</pub-id>
<pub-id pub-id-type="pmid">22632972</pub-id>
</element-citation>
</ref>
<ref id="b106-ijmm-40-03-0587">
<label>106</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Sittaramane</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gurung</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chandrasekhar</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Structural and temporal requirements of Wnt/PCP protein Vangl2 function for convergence and extension movements and facial branchiomotor neuron migration in zebrafish</article-title>
<source/>Mech Dev
          <volume>131</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1016/j.mod.2013.12.001</pub-id>
<!--<pub-id pub-id-type="pmcid">4116749</pub-id>-->
<pub-id pub-id-type="pmid">24333599</pub-id>
</element-citation>
</ref>
<ref id="b107-ijmm-40-03-0587">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gödde</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Pearson</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Humbert</surname>
<given-names>PO</given-names>
</name>
</person-group>
<article-title>Dissecting the role of polarity regulators in cancer through the use of mouse models</article-title>
<source/>Exp Cell Res
          <volume>328</volume>
<fpage>249</fpage>
<lpage>257</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1016/j.yexcr.2014.08.036</pub-id>
<pub-id pub-id-type="pmid">25179759</pub-id>
</element-citation>
</ref>
<ref id="b108-ijmm-40-03-0587">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantrell</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Jessen</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>The planar cell polarity protein Van Gogh-Like 2 regulates tumor cell migration and matrix metalloproteinase-dependent invasion</article-title>
<source/>Cancer Lett
          <volume>287</volume>
<fpage>54</fpage>
<lpage>61</lpage>
<year>2010</year>
<pub-id pub-id-type="doi">10.1016/j.canlet.2009.05.041</pub-id>
<pub-id pub-id-type="pmid">19577357</pub-id>
</element-citation>
</ref>
<ref id="b109-ijmm-40-03-0587">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Connell</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Fiori</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Camilli</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>French</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Dissanayake</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Indig</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Bernier</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma</article-title>
<source/>Oncogene
          <volume>29</volume>
<fpage>34</fpage>
<lpage>44</lpage>
<year>2010</year>
<pub-id pub-id-type="doi">10.1038/onc.2009.305</pub-id>
<!--<pub-id pub-id-type="pmcid">2803338</pub-id>-->
<pub-id pub-id-type="pmid">19802008</pub-id>
</element-citation>
</ref>
<ref id="b110-ijmm-40-03-0587">
<label>110</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Runkle</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Terkowski</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Ekaireb</surname>
<given-names>RI</given-names>
</name>
<name>
<surname>Witze</surname>
<given-names>ES</given-names>
</name>
</person-group>
<article-title>Protein depalmitoylation is induced by Wnt5a and promotes polarized cell behavior</article-title>
<source/>J Biol Chem
          <volume>290</volume>
<fpage>15707</fpage>
<lpage>15716</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1074/jbc.M115.639609</pub-id>
<!--<pub-id pub-id-type="pmcid">4505481</pub-id>-->
<pub-id pub-id-type="pmid">25944911</pub-id>
</element-citation>
</ref>
<ref id="b111-ijmm-40-03-0587">
<label>111</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webster</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Kugel</surname>
<given-names>CH</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Weeraratna</surname>
<given-names>AT</given-names>
</name>
</person-group>
<article-title>The Wnts of change: How Wnts regulate phenotype switching in melanoma</article-title>
<source/>Biochim Biophys Acta
          <volume>1856</volume>
<fpage>244</fpage>
<lpage>251</lpage>
<year>2015</year>
<!--<pub-id pub-id-type="pmcid">4668201</pub-id>-->
<pub-id pub-id-type="pmid">26546268</pub-id>
</element-citation>
</ref>
<ref id="b112-ijmm-40-03-0587">
<label>112</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Function and cancer genomics of FAT family genes (Review)</article-title>
<source/>Int J Oncol
          <volume>41</volume>
<fpage>1913</fpage>
<lpage>1918</lpage>
<year>2012</year>
<!--<pub-id pub-id-type="pmcid">3583642</pub-id>-->
<pub-id pub-id-type="pmid">23076869</pub-id>
</element-citation>
</ref>
<ref id="b113-ijmm-40-03-0587">
<label>113</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Axelrod</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Regulation of PCP by the Fat signaling pathway</article-title>
<source/>Genes Dev
          <volume>27</volume>
<fpage>2207</fpage>
<lpage>2220</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1101/gad.228098.113</pub-id>
<!--<pub-id pub-id-type="pmcid">3814641</pub-id>-->
<pub-id pub-id-type="pmid">24142873</pub-id>
</element-citation>
</ref>
<ref id="b114-ijmm-40-03-0587">
<label>114</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Identification and characterization of human PRICKLE1 and PRICKLE2 genes as well as mouse Prickle1 and Prickle2 genes homologous to Drosophila tissue polarity gene prickle</article-title>
<source/>Int J Mol Med
          <volume>11</volume>
<fpage>249</fpage>
<lpage>256</lpage>
<year>2003</year>
<pub-id pub-id-type="pmid">12525887</pub-id>
</element-citation>
</ref>
<ref id="b115-ijmm-40-03-0587">
<label>115</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Marco</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Merello</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Piatelli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cama</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kibar</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Capra</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Planar cell polarity gene mutations contribute to the etiology of human neural tube defects in our population</article-title>
<source/>Birth Defects Res A Clin Mol Teratol
          <volume>100</volume>
<fpage>633</fpage>
<lpage>641</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1002/bdra.23255</pub-id>
<pub-id pub-id-type="pmid">24838524</pub-id>
</element-citation>
</ref>
<ref id="b116-ijmm-40-03-0587">
<label>116</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allache</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lachance</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Guyot</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Merello</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Justice</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Capra</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kibar</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Novel mutations in Lrp6 orthologs in mouse and human neural tube defects affect a highly dosage-sensitive Wnt non-canonical planar cell polarity pathway</article-title>
<source/>Hum Mol Genet
          <volume>23</volume>
<fpage>1687</fpage>
<lpage>1699</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1093/hmg/ddt558</pub-id>
<!--<pub-id pub-id-type="pmcid">3943515</pub-id>-->
<pub-id pub-id-type="pmid">24203697</pub-id>
</element-citation>
</ref>
<ref id="b117-ijmm-40-03-0587">
<label>117</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bassuk</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Buhr</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Buller</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Afawi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Shimojo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miyata</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gonzalez-Alegre</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Griesbach</surname>
<given-names>HL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A homozygous mutation in human PRICKLE1 causes an autosomal-recessive progressive myoclonus epilepsy-ataxia syndrome</article-title>
<source/>Am J Hum Genet
          <volume>83</volume>
<fpage>572</fpage>
<lpage>581</lpage>
<year>2008</year>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2008.10.003</pub-id>
<!--<pub-id pub-id-type="pmcid">2668041</pub-id>-->
<pub-id pub-id-type="pmid">18976727</pub-id>
</element-citation>
</ref>
<ref id="b118-ijmm-40-03-0587">
<label>118</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Manak</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Sowers</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Kiyonari</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dahdaleh</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in prickle orthologs cause seizures in flies, mice, and humans</article-title>
<source/>Am J Hum Genet
          <volume>88</volume>
<fpage>138</fpage>
<lpage>149</lpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2010.12.012</pub-id>
<!--<pub-id pub-id-type="pmcid">3035715</pub-id>-->
<pub-id pub-id-type="pmid">21276947</pub-id>
</element-citation>
</ref>
<ref id="b119-ijmm-40-03-0587">
<label>119</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sowers</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Loo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ulrich</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Paemka</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wassink</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bing</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disruption of the non-canonical Wnt gene PRICKLE2 leads to autism-like behaviors with evidence for hippocampal synaptic dysfunction</article-title>
<source/>Mol Psychiatry
          <volume>18</volume>
<fpage>1077</fpage>
<lpage>1089</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1038/mp.2013.71</pub-id>
<!--<pub-id pub-id-type="pmcid">4163749</pub-id>-->
<pub-id pub-id-type="pmid">23711981</pub-id>
</element-citation>
</ref>
<ref id="b120-ijmm-40-03-0587">
<label>120</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>White</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Mazzeu</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Hoischen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bayram</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Withers</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gezdirici</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kimonis</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Steehouwer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jhangiani</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Muzny</surname>
<given-names>DM</given-names>
</name>
<etal></etal>
<collab>Baylor-Hopkins Center for Mendelian Genomics</collab>
</person-group>
<article-title>DVL3 alleles resulting in a -1 frameshift of the last exon mediate autosomal-dominant Robinow syndrome</article-title>
<source/>Am J Hum Genet
          <volume>98</volume>
<fpage>553</fpage>
<lpage>561</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2016.01.005</pub-id>
<!--<pub-id pub-id-type="pmcid">4800044</pub-id>-->
<pub-id pub-id-type="pmid">26924530</pub-id>
</element-citation>
</ref>
<ref id="b121-ijmm-40-03-0587">
<label>121</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Copp</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>ND</given-names>
</name>
</person-group>
<article-title>Genetics and development of neural tube defects</article-title>
<source/>J Pathol
          <volume>220</volume>
<fpage>217</fpage>
<lpage>230</lpage>
<year>2010</year>
<pub-id pub-id-type="pmid">19918803</pub-id>
</element-citation>
</ref>
<ref id="b122-ijmm-40-03-0587">
<label>122</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muñoz-Soriano</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Belacortu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Paricio</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Planar cell polarity signaling in collective cell movements during morphogenesis and disease</article-title>
<source/>Curr Genomics
          <volume>13</volume>
<fpage>609</fpage>
<lpage>622</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.2174/138920212803759721</pub-id>
<!--<pub-id pub-id-type="pmcid">3492801</pub-id>-->
<pub-id pub-id-type="pmid">23730201</pub-id>
</element-citation>
</ref>
<ref id="b123-ijmm-40-03-0587">
<label>123</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Roles of planar cell polarity pathways in the development of neutral tube defects</article-title>
<source/>J Biomed Sci
          <volume>18</volume>
<fpage>66</fpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.1186/1423-0127-18-66</pub-id>
<!--<pub-id pub-id-type="pmcid">3175158</pub-id>-->
<pub-id pub-id-type="pmid">21864354</pub-id>
</element-citation>
</ref>
<ref id="b124-ijmm-40-03-0587">
<label>124</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de la Hoz</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Maortua</surname>
<given-names>H</given-names>
</name>
<name>
<surname>García-Rives</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Martínez-González</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Ezquerra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tejada</surname>
<given-names>MI</given-names>
</name>
</person-group>
<article-title>3p14 de novo interstitial microdeletion in a patient with intellectual disability and autistic features with language impairment: A comparison with similar cases</article-title>
<source/>Case Rep Genet
          <volume>2015</volume>
<fpage>876348</fpage>
<year>2015</year>
<!--<pub-id pub-id-type="pmcid">4446465</pub-id>-->
<pub-id pub-id-type="pmid">26075115</pub-id>
</element-citation>
</ref>
<ref id="b125-ijmm-40-03-0587">
<label>125</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazzeu</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Pardono</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vianna-Morgante</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Richieri-Costa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ae Kim</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brunoni</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Martelli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>de Andrade</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Colin</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Otto</surname>
<given-names>PA</given-names>
</name>
</person-group>
<article-title>Clinical characterization of autosomal dominant and recessive variants of Robinow syndrome</article-title>
<source/>Am J Med Genet A
          <volume>143</volume>
<fpage>320</fpage>
<lpage>325</lpage>
<year>2007</year>
<pub-id pub-id-type="doi">10.1002/ajmg.a.31592</pub-id>
<pub-id pub-id-type="pmid">17256787</pub-id>
</element-citation>
</ref>
<ref id="b126-ijmm-40-03-0587">
<label>126</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Person</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Beiraghi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sieben</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Hermanson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Robu</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Schleiffarth</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Billington</surname>
<given-names>CJ</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>van Bokhoven</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hoogeboom</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>WNT5A mutations in patients with autosomal dominant Robinow syndrome</article-title>
<source/>Dev Dyn
          <volume>239</volume>
<fpage>327</fpage>
<lpage>337</lpage>
<year>2010</year>
<pub-id pub-id-type="pmid">19918918</pub-id>
</element-citation>
</ref>
<ref id="b127-ijmm-40-03-0587">
<label>127</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Afzal</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Rajab</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fenske</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Oldridge</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Elanko</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ternes-Pereira</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tüysüz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Murday</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Patton</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Wilkie</surname>
<given-names>AO</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recessive Robinow syndrome, allelic to dominant brachydactyly type B, is caused by mutation of ROR2</article-title>
<source/>Nat Genet
          <volume>25</volume>
<fpage>419</fpage>
<lpage>422</lpage>
<year>2000</year>
<pub-id pub-id-type="doi">10.1038/78107</pub-id>
<pub-id pub-id-type="pmid">10932186</pub-id>
</element-citation>
</ref>
<ref id="b128-ijmm-40-03-0587">
<label>128</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oldridge</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fortuna</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Maringa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Propping</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mansour</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pollitt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>DeChiara</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Kimble</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Valenzuela</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Yancopoulos</surname>
<given-names>GD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dominant mutations in ROR2, encoding an orphan receptor tyrosine kinase, cause brachydactyly type B</article-title>
<source/>Nat Genet
          <volume>24</volume>
<fpage>275</fpage>
<lpage>278</lpage>
<year>2000</year>
<pub-id pub-id-type="doi">10.1038/73495</pub-id>
<pub-id pub-id-type="pmid">10700182</pub-id>
</element-citation>
</ref>
<ref id="b129-ijmm-40-03-0587">
<label>129</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Green</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Kuntz</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>PW</given-names>
</name>
</person-group>
<article-title>Ror receptor tyrosine kinases: Orphans no more</article-title>
<source/>Trends Cell Biol
          <volume>18</volume>
<fpage>536</fpage>
<lpage>544</lpage>
<year>2008</year>
<pub-id pub-id-type="doi">10.1016/j.tcb.2008.08.006</pub-id>
<!--<pub-id pub-id-type="pmcid">4672995</pub-id>-->
<pub-id pub-id-type="pmid">18848778</pub-id>
</element-citation>
</ref>
<ref id="b130-ijmm-40-03-0587">
<label>130</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minami</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Oishi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Endo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nishita</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: Their implications in developmental morphogenesis and human diseases</article-title>
<source/>Dev Dyn
          <volume>239</volume>
<fpage>1</fpage>
<lpage>15</lpage>
<year>2010</year>
<pub-id pub-id-type="pmid">19530173</pub-id>
</element-citation>
</ref>
<ref id="b131-ijmm-40-03-0587">
<label>131</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrova</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Malessy</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Verhaagen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fradkin</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Noordermeer</surname>
<given-names>JN</given-names>
</name>
</person-group>
<article-title>Wnt signaling through the Ror receptor in the nervous system</article-title>
<source/>Mol Neurobiol
          <volume>49</volume>
<fpage>303</fpage>
<lpage>315</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1007/s12035-013-8520-9</pub-id>
<pub-id pub-id-type="pmid">23990374</pub-id>
</element-citation>
</ref>
<ref id="b132-ijmm-40-03-0587">
<label>132</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Debebe</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Rathmell</surname>
<given-names>WK</given-names>
</name>
</person-group>
<article-title>Ror2 as a therapeutic target in cancer</article-title>
<source/>Pharmacol Ther
          <volume>150</volume>
<fpage>143</fpage>
<lpage>148</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2015.01.010</pub-id>
<pub-id pub-id-type="pmid">25614331</pub-id>
</element-citation>
</ref>
<ref id="b133-ijmm-40-03-0587">
<label>133</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bunn</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Al-Ani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Farella</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Craw</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>SP</given-names>
</name>
</person-group>
<article-title>An osteosclerotic form of Robinow syndrome</article-title>
<source/>Am J Med Genet A
          <volume>164A</volume>
<fpage>2638</fpage>
<lpage>2642</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1002/ajmg.a.36677</pub-id>
<pub-id pub-id-type="pmid">25045061</pub-id>
</element-citation>
</ref>
<ref id="b134-ijmm-40-03-0587">
<label>134</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>May-Simera</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Swaroop</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Null and hypomorph Prickle1 alleles in mice phenocopy human Robinow syndrome and disrupt signaling downstream of Wnt5a</article-title>
<source/>Biol Open
          <volume>3</volume>
<fpage>861</fpage>
<lpage>870</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1242/bio.20148375</pub-id>
<!--<pub-id pub-id-type="pmcid">4163663</pub-id>-->
<pub-id pub-id-type="pmid">25190059</pub-id>
</element-citation>
</ref>
<ref id="b135-ijmm-40-03-0587">
<label>135</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ford</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Qian Ma</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Quadir</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis</article-title>
<source/>Int J Cancer
          <volume>133</volume>
<fpage>779</fpage>
<lpage>787</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1002/ijc.27984</pub-id>
<pub-id pub-id-type="pmid">23233346</pub-id>
</element-citation>
</ref>
<ref id="b136-ijmm-40-03-0587">
<label>136</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asad</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>TZ</given-names>
</name>
<name>
<surname>Choolani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Virshup</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Thiery</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>RY</given-names>
</name>
</person-group>
<article-title>FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway</article-title>
<source/>Cell Death Dis
          <volume>5</volume>
<fpage>e1346</fpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1038/cddis.2014.302</pub-id>
<!--<pub-id pub-id-type="pmcid">4123093</pub-id>-->
<pub-id pub-id-type="pmid">25032869</pub-id>
</element-citation>
</ref>
<ref id="b137-ijmm-40-03-0587">
<label>137</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>LX</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>YN</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>XJ</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>YQ</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis</article-title>
<source/>Oncotarget
          <volume>6</volume>
<fpage>10239</fpage>
<lpage>10252</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.18632/oncotarget.3518</pub-id>
<!--<pub-id pub-id-type="pmcid">4496352</pub-id>-->
<pub-id pub-id-type="pmid">25823923</pub-id>
</element-citation>
</ref>
<ref id="b138-ijmm-40-03-0587">
<label>138</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thiele</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rachner</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Rauner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hofbauer</surname>
<given-names>LC</given-names>
</name>
</person-group>
<article-title>WNT5A and its receptors in the bone-cancer dialogue</article-title>
<source/>J Bone Miner Res
          <volume>31</volume>
<fpage>1488</fpage>
<lpage>1496</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1002/jbmr.2899</pub-id>
<pub-id pub-id-type="pmid">27355180</pub-id>
</element-citation>
</ref>
<ref id="b139-ijmm-40-03-0587">
<label>139</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumawat</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gosens</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>WNT-5A: Signaling and functions in health and disease</article-title>
<source/>Cell Mol Life Sci
          <volume>73</volume>
<fpage>567</fpage>
<lpage>587</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1007/s00018-015-2076-y</pub-id>
<!--<pub-id pub-id-type="pmcid">4713724</pub-id>-->
<pub-id pub-id-type="pmid">26514730</pub-id>
</element-citation>
</ref>
<ref id="b140-ijmm-40-03-0587">
<label>140</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Wnt-11 overexpression promoting the invasion of cervical cancer cells</article-title>
<source/>Tumour Biol
          <volume>37</volume>
<fpage>11789</fpage>
<lpage>11798</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1007/s13277-016-4953-x</pub-id>
<pub-id pub-id-type="pmid">27034261</pub-id>
</element-citation>
</ref>
<ref id="b141-ijmm-40-03-0587">
<label>141</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arabzadeh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hossein</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Salehi-Dulabi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zarnani</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>WNT5A-ROR2 is induced by inflammatory mediators and is involved in the migration of human ovarian cancer cell line SKOV-3</article-title>
<source/>Cell Mol Biol Lett
          <volume>21</volume>
<fpage>9</fpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1186/s11658-016-0003-3</pub-id>
<pub-id pub-id-type="pmid">28536612</pub-id>
</element-citation>
</ref>
<ref id="b142-ijmm-40-03-0587">
<label>142</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Crossman</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Sohn</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Crowley</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Serra</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>WNT5A inhibits metastasis and alters splicing of Cd44 in breast cancer cells</article-title>
<source/>PLoS One
          <volume>8</volume>
<fpage>e58329</fpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1371/journal.pone.0058329</pub-id>
<!--<pub-id pub-id-type="pmcid">3590134</pub-id>-->
<pub-id pub-id-type="pmid">23484019</pub-id>
</element-citation>
</ref>
<ref id="b143-ijmm-40-03-0587">
<label>143</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Easter</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Baxley</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Desmond</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Serra</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Wnt5a suppresses tumor formation and redirects tumor phenotype in MMTV-Wnt1 tumors</article-title>
<source/>PLoS One
          <volume>9</volume>
<fpage>e113247</fpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1371/journal.pone.0113247</pub-id>
<!--<pub-id pub-id-type="pmcid">4234660</pub-id>-->
<pub-id pub-id-type="pmid">25401739</pub-id>
</element-citation>
</ref>
<ref id="b144-ijmm-40-03-0587">
<label>144</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Holderfield</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Galeas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Delrosario</surname>
<given-names>R</given-names>
</name>
<name>
<surname>To</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Balmain</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McCormick</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>K-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling</article-title>
<source/>Cell
          <volume>163</volume>
<fpage>1237</fpage>
<lpage>1251</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.cell.2015.10.041</pub-id>
<pub-id pub-id-type="pmid">26590425</pub-id>
</element-citation>
</ref>
<ref id="b145-ijmm-40-03-0587">
<label>145</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fukuda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Endo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Castro</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Widhopf</surname>
<given-names>GF</given-names>
<suffix>II</suffix>
</name>
<name>
<surname>Rassenti</surname>
<given-names>LZ</given-names>
</name>
<name>
<surname>Cantwell</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Prussak</surname>
<given-names>CE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>105</volume>
<fpage>3047</fpage>
<lpage>3052</lpage>
<year>2008</year>
<pub-id pub-id-type="doi">10.1073/pnas.0712148105</pub-id>
<!--<pub-id pub-id-type="pmcid">2268582</pub-id>-->
<pub-id pub-id-type="pmid">18287027</pub-id>
</element-citation>
</ref>
<ref id="b146-ijmm-40-03-0587">
<label>146</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bicocca</surname>
<given-names>VT</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Masouleh</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Muschen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Loriaux</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Druker</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Tyner</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia</article-title>
<source/>Cancer Cell
          <volume>22</volume>
<fpage>656</fpage>
<lpage>667</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1016/j.ccr.2012.08.027</pub-id>
<!--<pub-id pub-id-type="pmcid">3500515</pub-id>-->
<pub-id pub-id-type="pmid">23153538</pub-id>
</element-citation>
</ref>
<ref id="b147-ijmm-40-03-0587">
<label>147</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Widhopf</surname>
<given-names>GF</given-names>
<suffix>II</suffix>
</name>
<name>
<surname>Shen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Briggs</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Kipps</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation</article-title>
<source/>J Clin Invest
          <volume>126</volume>
<fpage>585</fpage>
<lpage>598</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1172/JCI83535</pub-id>
<!--<pub-id pub-id-type="pmcid">4731190</pub-id>-->
<pub-id pub-id-type="pmid">26690702</pub-id>
</element-citation>
</ref>
<ref id="b148-ijmm-40-03-0587">
<label>148</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gentile</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lazzari</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Benvenuti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Trusolino</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Comoglio</surname>
<given-names>PM</given-names>
</name>
</person-group>
<article-title>The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells</article-title>
<source/>Int J Cancer
          <volume>135</volume>
<fpage>2305</fpage>
<lpage>2316</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1002/ijc.28879</pub-id>
<pub-id pub-id-type="pmid">24706440</pub-id>
</element-citation>
</ref>
<ref id="b149-ijmm-40-03-0587">
<label>149</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hojjat-Farsangi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moshfegh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Daneshmanesh</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Mikaelsson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Osterborg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mellstedt</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>The receptor tyrosine kinase ROR1 - an oncofetal antigen for targeted cancer therapy</article-title>
<source/>Semin Cancer Biol
          <volume>29</volume>
<fpage>21</fpage>
<lpage>31</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1016/j.semcancer.2014.07.005</pub-id>
<pub-id pub-id-type="pmid">25068995</pub-id>
</element-citation>
</ref>
<ref id="b150-ijmm-40-03-0587">
<label>150</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>PK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis</article-title>
<source/>Nat Cell Biol
          <volume>19</volume>
<fpage>106</fpage>
<lpage>119</lpage>
<year>2017</year>
<pub-id pub-id-type="doi">10.1038/ncb3464</pub-id>
<!--<pub-id pub-id-type="pmcid">5336186</pub-id>-->
<pub-id pub-id-type="pmid">28114269</pub-id>
</element-citation>
</ref>
<ref id="b151-ijmm-40-03-0587">
<label>151</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Widhopf</surname>
<given-names>GF</given-names>
<suffix>II</suffix>
</name>
<name>
<surname>Cui</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ghia</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Messer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Briggs</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Croce</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Kipps</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>111</volume>
<fpage>793</fpage>
<lpage>798</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1073/pnas.1308374111</pub-id>
<pub-id pub-id-type="pmid">24379361</pub-id>
</element-citation>
</ref>
<ref id="b152-ijmm-40-03-0587">
<label>152</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamaguchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ida</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yanagisawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Usukura</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hotta</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Isomura</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1</article-title>
<source/>Nat Commun
          <volume>7</volume>
<fpage>10060</fpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1038/ncomms10060</pub-id>
<!--<pub-id pub-id-type="pmcid">4777216</pub-id>-->
<pub-id pub-id-type="pmid">26725982</pub-id>
</element-citation>
</ref>
<ref id="b153-ijmm-40-03-0587">
<label>153</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Connell</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Marchbank</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Valiga</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vultur</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Herlyn</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Villanueva</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2</article-title>
<source/>Cancer Discov
          <volume>3</volume>
<fpage>1378</fpage>
<lpage>1393</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0005</pub-id>
<!--<pub-id pub-id-type="pmcid">3918498</pub-id>-->
<pub-id pub-id-type="pmid">24104062</pub-id>
</element-citation>
</ref>
<ref id="b154-ijmm-40-03-0587">
<label>154</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE</article-title>
<source/>Cancer Genet
          <volume>205</volume>
<fpage>552</fpage>
<lpage>562</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1016/j.cancergen.2012.09.002</pub-id>
<pub-id pub-id-type="pmid">23142633</pub-id>
</element-citation>
</ref>
<ref id="b155-ijmm-40-03-0587">
<label>155</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niemann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pascu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Stahl</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Aulepp</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Niswander</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous family</article-title>
<source/>Am J Hum Genet
          <volume>74</volume>
<fpage>558</fpage>
<lpage>563</lpage>
<year>2004</year>
<pub-id pub-id-type="doi">10.1086/382196</pub-id>
<!--<pub-id pub-id-type="pmcid">1182269</pub-id>-->
<pub-id pub-id-type="pmid">14872406</pub-id>
</element-citation>
</ref>
<ref id="b156-ijmm-40-03-0587">
<label>156</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woods</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Stricker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Seemann</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sherridan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Springell</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Karbani</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in WNT7A cause a range of limb malformations, including Fuhrmann syndrome and Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome</article-title>
<source/>Am J Hum Genet
          <volume>79</volume>
<fpage>402</fpage>
<lpage>408</lpage>
<year>2006</year>
<pub-id pub-id-type="doi">10.1086/506332</pub-id>
<!--<pub-id pub-id-type="pmcid">1559483</pub-id>-->
<pub-id pub-id-type="pmid">16826533</pub-id>
</element-citation>
</ref>
<ref id="b157-ijmm-40-03-0587">
<label>157</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biason-Lauber</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Konrad</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Navratil</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schoenle</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<article-title>A WNT4 mutation associated with Müllerian-duct regression and virilization in a 46, XX woman</article-title>
<source/>N Engl J Med
          <volume>351</volume>
<fpage>792</fpage>
<lpage>798</lpage>
<year>2004</year>
<pub-id pub-id-type="doi">10.1056/NEJMoa040533</pub-id>
<pub-id pub-id-type="pmid">15317892</pub-id>
</element-citation>
</ref>
<ref id="b158-ijmm-40-03-0587">
<label>158</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mandel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shemer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Borochowitz</surname>
<given-names>ZU</given-names>
</name>
<name>
<surname>Okopnik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Knopf</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Indelman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Drugan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tiosano</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gershoni-Baruch</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Choder</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SERKAL syndrome: An autosomal-recessive disorder caused by a loss-of-function mutation in WNT4</article-title>
<source/>Am J Hum Genet
          <volume>82</volume>
<fpage>39</fpage>
<lpage>47</lpage>
<year>2008</year>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2007.08.005</pub-id>
<!--<pub-id pub-id-type="pmcid">2253972</pub-id>-->
<pub-id pub-id-type="pmid">18179883</pub-id>
</element-citation>
</ref>
<ref id="b159-ijmm-40-03-0587">
<label>159</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirikoshi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sekihara</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>WNT10A and WNT6, clustered in human chromosome 2q35 region with head-to-tail manner, are strongly coexpressed in SW480 cells</article-title>
<source/>Biochem Biophys Res Commun
          <volume>283</volume>
<fpage>798</fpage>
<lpage>805</lpage>
<year>2001</year>
<pub-id pub-id-type="doi">10.1006/bbrc.2001.4855</pub-id>
<pub-id pub-id-type="pmid">11350055</pub-id>
</element-citation>
</ref>
<ref id="b160-ijmm-40-03-0587">
<label>160</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adaimy</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chouery</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Megarbane</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mroueh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Delague</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Nicolas</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Belguith</surname>
<given-names>H</given-names>
</name>
<name>
<surname>de Mazancourt</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Megarbane</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Mutation in WNT10A is associated with an autosomal recessive ectodermal dysplasia: The odonto-onycho-dermal dysplasia</article-title>
<source/>Am J Hum Genet
          <volume>81</volume>
<fpage>821</fpage>
<lpage>828</lpage>
<year>2007</year>
<pub-id pub-id-type="doi">10.1086/520064</pub-id>
<!--<pub-id pub-id-type="pmcid">1973944</pub-id>-->
<pub-id pub-id-type="pmid">17847007</pub-id>
</element-citation>
</ref>
<ref id="b161-ijmm-40-03-0587">
<label>161</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van den Boogaard</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Créton</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bronkhorst</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>van der Hout</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hennekam</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lindhout</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cune</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ploos van Amstel</surname>
<given-names>HK</given-names>
</name>
</person-group>
<article-title>Mutations in WNT10A are present in more than half of isolated hypodontia cases</article-title>
<source/>J Med Genet
          <volume>49</volume>
<fpage>327</fpage>
<lpage>331</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2012-100750</pub-id>
<pub-id pub-id-type="pmid">22581971</pub-id>
</element-citation>
</ref>
<ref id="b162-ijmm-40-03-0587">
<label>162</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in WNT10B are identified in individuals with oligodontia</article-title>
<source/>Am J Hum Genet
          <volume>99</volume>
<fpage>195</fpage>
<lpage>201</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2016.05.012</pub-id>
<!--<pub-id pub-id-type="pmcid">5005437</pub-id>-->
<pub-id pub-id-type="pmid">27321946</pub-id>
</element-citation>
</ref>
<ref id="b163-ijmm-40-03-0587">
<label>163</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massink</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Créton</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Spanevello</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fennis</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Cune</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Savelberg</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Nijman</surname>
<given-names>IJ</given-names>
</name>
<name>
<surname>Maurice</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>van den Boogaard</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>van Haaften</surname>
<given-names>G</given-names>
</name>
</person-group>
<comment>H and van Haaften G</comment>
<article-title>Loss-of-function mutations in the WNT co-receptor LRP6 cause autosomal-dominant oligodontia</article-title>
<source/>Am J Hum Genet
          <volume>97</volume>
<fpage>621</fpage>
<lpage>626</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2015.08.014</pub-id>
<!--<pub-id pub-id-type="pmcid">4596913</pub-id>-->
<pub-id pub-id-type="pmid">26387593</pub-id>
</element-citation>
</ref>
<ref id="b164-ijmm-40-03-0587">
<label>164</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poulsen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Alam</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jeyaraj</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Ang</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Cheong</surname>
<given-names>VW</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacophore model for Wnt/Porcupine inhibitors and its use in drug design</article-title>
<source/>J Chem Inf Model
          <volume>55</volume>
<fpage>1435</fpage>
<lpage>1448</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1021/acs.jcim.5b00159</pub-id>
<pub-id pub-id-type="pmid">26024410</pub-id>
</element-citation>
</ref>
<ref id="b165-ijmm-40-03-0587">
<label>165</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grzeschik</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Bornholdt</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Oeffner</surname>
<given-names>F</given-names>
</name>
<name>
<surname>König</surname>
<given-names>A</given-names>
</name>
<name>
<surname>del Carmen Boente</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Enders</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fritz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hertl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grasshoff</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Höfling</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia</article-title>
<source/>Nat Genet
          <volume>39</volume>
<fpage>833</fpage>
<lpage>835</lpage>
<year>2007</year>
<pub-id pub-id-type="doi">10.1038/ng2052</pub-id>
<pub-id pub-id-type="pmid">17546031</pub-id>
</element-citation>
</ref>
<ref id="b166-ijmm-40-03-0587">
<label>166</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Widen</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Ratnapriya</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gerth-Kahlert</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rainger</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Alur</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Strachan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Manjunath</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Balakrishnan</surname>
<given-names>A</given-names>
</name>
<etal></etal>
<collab>UK10K Consortium</collab>
</person-group>
<article-title>A secreted WNT-ligand-binding domain of FZD5 generated by a frameshift mutation causes autosomal dominant coloboma</article-title>
<source/>Hum Mol Genet
          <volume>25</volume>
<fpage>1382</fpage>
<lpage>1391</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1093/hmg/ddw020</pub-id>
<!--<pub-id pub-id-type="pmcid">4787907</pub-id>-->
<pub-id pub-id-type="pmid">26908622</pub-id>
</element-citation>
</ref>
<ref id="b167-ijmm-40-03-0587">
<label>167</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fröjmark</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Schuster</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sobol</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Entesarian</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kilander</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Gabrikova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nawaz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Baig</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Schulte</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Klar</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in Frizzled 6 cause isolated autosomal-recessive nail dysplasia</article-title>
<source/>Am J Hum Genet
          <volume>88</volume>
<fpage>852</fpage>
<lpage>860</lpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2011.05.013</pub-id>
<!--<pub-id pub-id-type="pmcid">3113248</pub-id>-->
<pub-id pub-id-type="pmid">21665003</pub-id>
</element-citation>
</ref>
<ref id="b168-ijmm-40-03-0587">
<label>168</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parma</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Radi</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Vidal</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Chaboissier</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Dellambra</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Valentini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Guerra</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schedl</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Camerino</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>R-spondin1 is essential in sex determination, skin differentiation and malignancy</article-title>
<source/>Nat Genet
          <volume>38</volume>
<fpage>1304</fpage>
<lpage>1309</lpage>
<year>2006</year>
<pub-id pub-id-type="doi">10.1038/ng1907</pub-id>
<pub-id pub-id-type="pmid">17041600</pub-id>
</element-citation>
</ref>
<ref id="b169-ijmm-40-03-0587">
<label>169</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brüchle</surname>
<given-names>NO</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Senderek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Akar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Koc</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rigopoulos</surname>
<given-names>D</given-names>
</name>
<name>
<surname>van Steensel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zerres</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bergmann</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>RSPO4 is the major gene in autosomal-recessive anonychia and mutations cluster in the furin-like cysteine-rich domains of the Wnt signaling ligand R-spondin 4</article-title>
<source/>J Invest Dermatol
          <volume>128</volume>
<fpage>791</fpage>
<lpage>796</lpage>
<year>2008</year>
<pub-id pub-id-type="doi">10.1038/sj.jid.5701088</pub-id>
<pub-id pub-id-type="pmid">17914448</pub-id>
</element-citation>
</ref>
<ref id="b170-ijmm-40-03-0587">
<label>170</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ekici</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Hilfinger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jatzwauk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thiel</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Wenzel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lorenz</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Boltshauser</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Goecke</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Staatz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Morris-Rosendahl</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disturbed Wnt signalling due to a mutation in CCDC88C causes an autosomal recessive non-syndromic hydrocephalus with medial diverticulum</article-title>
<source/>Mol Syndromol
          <volume>1</volume>
<fpage>99</fpage>
<lpage>112</lpage>
<year>2010</year>
<pub-id pub-id-type="doi">10.1159/000319859</pub-id>
<!--<pub-id pub-id-type="pmcid">2957845</pub-id>-->
<pub-id pub-id-type="pmid">21031079</pub-id>
</element-citation>
</ref>
<ref id="b171-ijmm-40-03-0587">
<label>171</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aznar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Midde</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Dunkel</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lopez-Sanchez</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Pavlova</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Marivin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Barbazán</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nitsche</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Janssen</surname>
<given-names>KP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Daple is a novel non-receptor GEF required for trimeric G protein activation in Wnt signaling</article-title>
<source/>eLife
          <volume>4</volume>
<fpage>e07091</fpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.7554/eLife.07091</pub-id>
<!--<pub-id pub-id-type="pmcid">4484057</pub-id>-->
<pub-id pub-id-type="pmid">26126266</pub-id>
</element-citation>
</ref>
<ref id="b172-ijmm-40-03-0587">
<label>172</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voronkov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krauss</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Wnt/β-catenin signaling and small molecule inhibitors</article-title>
<source/>Curr Pharm Des
          <volume>19</volume>
<fpage>634</fpage>
<lpage>664</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.2174/138161213804581837</pub-id>
<pub-id pub-id-type="pmid">23016862</pub-id>
</element-citation>
</ref>
<ref id="b173-ijmm-40-03-0587">
<label>173</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takebe</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Miele</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bando</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>SX</given-names>
</name>
<name>
<surname>Ivy</surname>
<given-names>SP</given-names>
</name>
</person-group>
<article-title>Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: Clinical update</article-title>
<source/>Nat Rev Clin Oncol
          <volume>12</volume>
<fpage>445</fpage>
<lpage>464</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1038/nrclinonc.2015.61</pub-id>
<!--<pub-id pub-id-type="pmcid">4520755</pub-id>-->
<pub-id pub-id-type="pmid">25850553</pub-id>
</element-citation>
</ref>
<ref id="b174-ijmm-40-03-0587">
<label>174</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tai</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Arcaroli</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vanderbilt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Aisner</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Messersmith</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Lieu</surname>
<given-names>CH</given-names>
</name>
</person-group>
<article-title>Targeting the WNT signaling pathway in cancer therapeutics</article-title>
<source/>Oncologist
          <volume>20</volume>
<fpage>1189</fpage>
<lpage>1198</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1634/theoncologist.2015-0057</pub-id>
<!--<pub-id pub-id-type="pmcid">4591954</pub-id>-->
<pub-id pub-id-type="pmid">26306903</pub-id>
</element-citation>
</ref>
<ref id="b175-ijmm-40-03-0587">
<label>175</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pelay-Gimeno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Glas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Grossmann</surname>
<given-names>TN</given-names>
</name>
</person-group>
<article-title>Structure-based design of inhibitors of protein-protein interactions: Mimicking peptide binding epitopes</article-title>
<source/>Angew Chem Int Ed Engl
          <volume>54</volume>
<fpage>8896</fpage>
<lpage>8927</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1002/anie.201412070</pub-id>
<!--<pub-id pub-id-type="pmcid">4557054</pub-id>-->
<pub-id pub-id-type="pmid">26119925</pub-id>
</element-citation>
</ref>
<ref id="b176-ijmm-40-03-0587">
<label>176</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kakugawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Langton</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Zebisch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Howell</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Feizi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bineva</surname>
<given-names>G</given-names>
</name>
<name>
<surname>O'Reilly</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Snijders</surname>
<given-names>AP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Notum deacylates Wnt proteins to suppress signalling activity</article-title>
<source/>Nature
          <volume>519</volume>
<fpage>187</fpage>
<lpage>192</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1038/nature14259</pub-id>
<!--<pub-id pub-id-type="pmcid">4376489</pub-id>-->
<pub-id pub-id-type="pmid">25731175</pub-id>
</element-citation>
</ref>
<ref id="b177-ijmm-40-03-0587">
<label>177</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Harmston</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Frois</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Alam</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jeyaraj</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Pendharkar</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Virshup</surname>
<given-names>IH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Wnt addiction of genetically defined cancers reversed by PORCN inhibition</article-title>
<source/>Oncogene
          <volume>35</volume>
<fpage>2197</fpage>
<lpage>2207</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1038/onc.2015.280</pub-id>
<pub-id pub-id-type="pmid">26257057</pub-id>
</element-citation>
</ref>
<ref id="b178-ijmm-40-03-0587">
<label>178</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dodge</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kilgore</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>NS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer</article-title>
<source/>Nat Chem Biol
          <volume>5</volume>
<fpage>100</fpage>
<lpage>107</lpage>
<year>2009</year>
<pub-id pub-id-type="doi">10.1038/nchembio.137</pub-id>
<!--<pub-id pub-id-type="pmcid">2628455</pub-id>-->
<pub-id pub-id-type="pmid">19125156</pub-id>
</element-citation>
</ref>
<ref id="b179-ijmm-40-03-0587">
<label>179</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kasibhatla</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schuller</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>110</volume>
<fpage>20224</fpage>
<lpage>20229</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1073/pnas.1314239110</pub-id>
<!--<pub-id pub-id-type="pmcid">3864356</pub-id>-->
<pub-id pub-id-type="pmid">24277854</pub-id>
</element-citation>
</ref>
<ref id="b180-ijmm-40-03-0587">
<label>180</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Proffitt</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Madan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Pendharkar</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Hannoush</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Virshup</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer</article-title>
<source/>Cancer Res
          <volume>73</volume>
<fpage>502</fpage>
<lpage>507</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2258</pub-id>
<pub-id pub-id-type="pmid">23188502</pub-id>
</element-citation>
</ref>
<ref id="b181-ijmm-40-03-0587">
<label>181</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van de Wetering</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Francies</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Bounova</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Iorio</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pronk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van Houdt</surname>
<given-names>W</given-names>
</name>
<name>
<surname>van Gorp</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Taylor-Weiner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kester</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prospective derivation of a living organoid biobank of colorectal cancer patients</article-title>
<source/>Cell
          <volume>161</volume>
<fpage>933</fpage>
<lpage>945</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.cell.2015.03.053</pub-id>
<pub-id pub-id-type="pmid">25957691</pub-id>
</element-citation>
</ref>
<ref id="b182-ijmm-40-03-0587">
<label>182</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Phoon</surname>
<given-names>YP</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chong</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Ip</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Lung</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>Wnt-C59 arrests stemness and suppresses growth of nasopharyngeal carcinoma in mice by inhibiting the Wnt pathway in the tumor microenvironment</article-title>
<source/>Oncotarget
          <volume>6</volume>
<fpage>14428</fpage>
<lpage>14439</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.18632/oncotarget.3982</pub-id>
<!--<pub-id pub-id-type="pmcid">4546477</pub-id>-->
<pub-id pub-id-type="pmid">25980501</pub-id>
</element-citation>
</ref>
<ref id="b183-ijmm-40-03-0587">
<label>183</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>ZD</given-names>
</name>
<name>
<surname>Oliver</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Oshima</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rozen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Virshup</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>NOTUM is a potential pharmacodynamic biomarker of Wnt pathway inhibition</article-title>
<source/>Oncotarget
          <volume>7</volume>
<fpage>12386</fpage>
<lpage>12392</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.18632/oncotarget.7157</pub-id>
<!--<pub-id pub-id-type="pmcid">4914292</pub-id>-->
<pub-id pub-id-type="pmid">26848981</pub-id>
</element-citation>
</ref>
<ref id="b184-ijmm-40-03-0587">
<label>184</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blyszczuk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Müller-Edenborn</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Valenta</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Osto</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Stellato</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Behnke</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Glatz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Basler</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lüscher</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Distler</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Transforming growth factor-β-dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis</article-title>
<source/>Eur Heart J
          <volume>38</volume>
<fpage>1413</fpage>
<lpage>1425</lpage>
<year>2017</year>
<pub-id pub-id-type="pmid">27099262</pub-id>
</element-citation>
</ref>
<ref id="b185-ijmm-40-03-0587">
<label>185</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bunte</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Rudemiller</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Griffiths</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Virshup</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Crowley</surname>
<given-names>SD</given-names>
</name>
</person-group>
<article-title>Experimental inhibition of porcupine-mediated Wnt O-acylation attenuates kidney fibrosis</article-title>
<source/>Kidney Int
          <volume>89</volume>
<fpage>1062</fpage>
<lpage>1074</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.kint.2016.01.017</pub-id>
<!--<pub-id pub-id-type="pmcid">4834146</pub-id>-->
<pub-id pub-id-type="pmid">27083283</pub-id>
</element-citation>
</ref>
<ref id="b186-ijmm-40-03-0587">
<label>186</label>
<element-citation publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Diamond</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Eckhardt</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Bendell</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Munster</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Kopetz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cattaruzza</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kapoun</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Dupont</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Faoro</surname>
<given-names>L</given-names>
</name>
</person-group>
<source/>A Phase 1a/b study of OMP-131R10, an anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC)
          <conf-name>Presented at: TAT 2016 Conference</conf-name>
<conf-loc>Washington DC</conf-loc>
<conf-date>21–23 March, 2016</conf-date>
</element-citation>
</ref>
<ref id="b187-ijmm-40-03-0587">
<label>187</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hirai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sugimura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Terada</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Cloning, expression and chromosomal localization of Wnt-13, a novel member of the Wnt gene family</article-title>
<source/>Oncogene
          <volume>13</volume>
<fpage>873</fpage>
<lpage>876</lpage>
<year>1996</year>
<pub-id pub-id-type="pmid">8761309</pub-id>
</element-citation>
</ref>
<ref id="b188-ijmm-40-03-0587">
<label>188</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kirikoshi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Terasaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shiokawa</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>WNT2B2 mRNA, upregulated in primary gastric cancer, is a positive regulator of the WNT- β-catenin-TCF signaling pathway</article-title>
<source/>Biochem Biophys Res Commun
          <volume>289</volume>
<fpage>1093</fpage>
<lpage>1098</lpage>
<year>2001</year>
<pub-id pub-id-type="doi">10.1006/bbrc.2001.6076</pub-id>
<pub-id pub-id-type="pmid">11741304</pub-id>
</element-citation>
</ref>
<ref id="b189-ijmm-40-03-0587">
<label>189</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Expression of Gli1 and Wnt2B correlates with progression and clinical outcome of pancreatic cancer</article-title>
<source/>Int J Clin Exp Pathol
          <volume>7</volume>
<fpage>4531</fpage>
<lpage>4538</lpage>
<year>2014</year>
<!--<pub-id pub-id-type="pmcid">4129084</pub-id>-->
<pub-id pub-id-type="pmid">25120849</pub-id>
</element-citation>
</ref>
<ref id="b190-ijmm-40-03-0587">
<label>190</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>MicroRNA-324-3p regulates nasopharyngeal carcinoma radioresistance by directly targeting WNT2B</article-title>
<source/>Eur J Cancer
          <volume>49</volume>
<fpage>2596</fpage>
<lpage>2607</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1016/j.ejca.2013.03.001</pub-id>
<pub-id pub-id-type="pmid">23583221</pub-id>
</element-citation>
</ref>
<ref id="b191-ijmm-40-03-0587">
<label>191</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>XN</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>HY</given-names>
</name>
</person-group>
<article-title>Antitumor effects of WNT2B silencing in GLUT1 overexpressing cisplatin resistant head and neck squamous cell carcinoma</article-title>
<source/>Am J Cancer Res
          <volume>5</volume>
<fpage>300</fpage>
<lpage>308</lpage>
<year>2014</year>
<pub-id pub-id-type="pmid">25628939</pub-id>
</element-citation>
</ref>
<ref id="b192-ijmm-40-03-0587">
<label>192</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobayashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Sonobe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Date</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Ad-shWnt2b vector therapy demonstrates antitumor activity in orthotopic intrapleural models as monitored with the in vitro imaging system (IVIS)</article-title>
<source/>Anticancer Res
          <volume>36</volume>
<fpage>5887</fpage>
<lpage>5893</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.21873/anticanres.11175</pub-id>
<pub-id pub-id-type="pmid">27793913</pub-id>
</element-citation>
</ref>
<ref id="b193-ijmm-40-03-0587">
<label>193</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tokuhara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hirai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Atomi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Terada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Molecular cloning of human Frizzled-6</article-title>
<source/>Biochem Biophys Res Commun
          <volume>243</volume>
<fpage>622</fpage>
<lpage>627</lpage>
<year>1998</year>
<pub-id pub-id-type="doi">10.1006/bbrc.1998.8143</pub-id>
<pub-id pub-id-type="pmid">9480858</pub-id>
</element-citation>
</ref>
<ref id="b194-ijmm-40-03-0587">
<label>194</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantilena</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pastorino</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pezzolo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chayka</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Pistoia</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ponzoni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sala</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Frizzled receptor 6 marks rare, highly tumourigenic stem-like cells in mouse and human neuroblastomas</article-title>
<source/>Oncotarget
          <volume>2</volume>
<fpage>976</fpage>
<lpage>983</lpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.18632/oncotarget.410</pub-id>
<pub-id pub-id-type="pmid">22249030</pub-id>
</element-citation>
</ref>
<ref id="b195-ijmm-40-03-0587">
<label>195</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>HI</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kim Yoon</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>FZD6 expression is negatively regulated by miR-199a-5p in human colorectal cancer</article-title>
<source/>BMB Rep
          <volume>48</volume>
<fpage>360</fpage>
<lpage>366</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.5483/BMBRep.2015.48.6.031</pub-id>
<!--<pub-id pub-id-type="pmcid">4578624</pub-id>-->
<pub-id pub-id-type="pmid">25772759</pub-id>
</element-citation>
</ref>
<ref id="b196-ijmm-40-03-0587">
<label>196</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corda</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sala</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lattanzio</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Iezzi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sallese</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fragassi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lamolinara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mirza</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Barcaroli</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ermler</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer</article-title>
<source/>J Pathol
          <volume>241</volume>
<fpage>350</fpage>
<lpage>361</lpage>
<year>2017</year>
<pub-id pub-id-type="doi">10.1002/path.4841</pub-id>
<!--<pub-id pub-id-type="pmcid">5248601</pub-id>-->
<pub-id pub-id-type="pmid">27859262</pub-id>
</element-citation>
</ref>
<ref id="b197-ijmm-40-03-0587">
<label>197</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saitoh</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hirai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Molecular cloning and characterization of human Frizzled-5 gene on chromosome 2q33.3-q34 region</article-title>
<source/>Int J Oncol
          <volume>19</volume>
<fpage>105</fpage>
<lpage>110</lpage>
<year>2001</year>
<pub-id pub-id-type="pmid">11408929</pub-id>
</element-citation>
</ref>
<ref id="b198-ijmm-40-03-0587">
<label>198</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinhart</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Pavlovic</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Chandrashekhar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Robitaille</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Jaksani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Overmeer</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors</article-title>
<source/>Nat Med
          <volume>23</volume>
<fpage>60</fpage>
<lpage>68</lpage>
<year>2017</year>
<pub-id pub-id-type="doi">10.1038/nm.4219</pub-id>
<pub-id pub-id-type="pmid">27869803</pub-id>
</element-citation>
</ref>
<ref id="b199-ijmm-40-03-0587">
<label>199</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sagara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Toda</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hirai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Terada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Molecular cloning, differential expression, and chromosomal localization of human frizzled-1, frizzled-2, and frizzled-7</article-title>
<source/>Biochem Biophys Res Commun
          <volume>252</volume>
<fpage>117</fpage>
<lpage>122</lpage>
<year>1998</year>
<pub-id pub-id-type="doi">10.1006/bbrc.1998.9607</pub-id>
<pub-id pub-id-type="pmid">9813155</pub-id>
</element-citation>
</ref>
<ref id="b200-ijmm-40-03-0587">
<label>200</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simmons</surname>
<given-names>GE</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Pandey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nedeljkovic-Kurepa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Saxena</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pruitt</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Frizzled 7 expression is positively regulated by SIRT1 and β-catenin in breast cancer cells</article-title>
<source/>PLoS One
          <volume>9</volume>
<fpage>e98861</fpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1371/journal.pone.0098861</pub-id>
<pub-id pub-id-type="pmid">24897117</pub-id>
</element-citation>
</ref>
<ref id="b201-ijmm-40-03-0587">
<label>201</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vincan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Flanagan</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Pouliot</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Brabletz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Spaderna</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Variable FZD7 expression in colorectal cancers indicates regulation by the tumour microenvironment</article-title>
<source/>Dev Dyn
          <volume>239</volume>
<fpage>311</fpage>
<lpage>317</lpage>
<year>2010</year>
<pub-id pub-id-type="pmid">19655379</pub-id>
</element-citation>
</ref>
<ref id="b202-ijmm-40-03-0587">
<label>202</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Overexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ</article-title>
<source/>Oncotarget
          <volume>7</volume>
<fpage>85987</fpage>
<lpage>85999</lpage>
<year>2016</year>
<!--<pub-id pub-id-type="pmcid">5349891</pub-id>-->
<pub-id pub-id-type="pmid">27852064</pub-id>
</element-citation>
</ref>
<ref id="b203-ijmm-40-03-0587">
<label>203</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gou</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MiR-199a regulates cell proliferation and survival by targeting FZD7</article-title>
<source/>PLoS One
          <volume>9</volume>
<fpage>e110074</fpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1371/journal.pone.0110074</pub-id>
<!--<pub-id pub-id-type="pmcid">4196968</pub-id>-->
<pub-id pub-id-type="pmid">25313882</pub-id>
</element-citation>
</ref>
<ref id="b204-ijmm-40-03-0587">
<label>204</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koike</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Takagi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Miwa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hirai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Terada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Molecular cloning of Frizzled-10, a novel member of the Frizzled gene family</article-title>
<source/>Biochem Biophys Res Commun
          <volume>262</volume>
<fpage>39</fpage>
<lpage>43</lpage>
<year>1999</year>
<pub-id pub-id-type="doi">10.1006/bbrc.1999.1161</pub-id>
<pub-id pub-id-type="pmid">10448064</pub-id>
</element-citation>
</ref>
<ref id="b205-ijmm-40-03-0587">
<label>205</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>XB</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Nie</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10</article-title>
<source/>Nat Commun
          <volume>5</volume>
<fpage>5406</fpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1038/ncomms6406</pub-id>
<pub-id pub-id-type="pmid">25406648</pub-id>
</element-citation>
</ref>
<ref id="b206-ijmm-40-03-0587">
<label>206</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terasaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Saitoh</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shiokawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Frizzled-10, upregulated in primary colorectal cancer, is a positive regulator of the WNT-β-catenin-TCF signaling pathway</article-title>
<source/>Int J Mol Med
          <volume>9</volume>
<fpage>107</fpage>
<lpage>112</lpage>
<year>2002</year>
<pub-id pub-id-type="pmid">11786918</pub-id>
</element-citation>
</ref>
<ref id="b207-ijmm-40-03-0587">
<label>207</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanaoka</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Katagiri</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fukukawa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yoshioka</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Iida</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Higuchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Oriuchi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Paudyal</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Paudyal</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: Therapeutic efficacy largely depends on radio-sensitivity</article-title>
<source/>Ann Nucl Med
          <volume>23</volume>
<fpage>479</fpage>
<lpage>485</lpage>
<year>2009</year>
<pub-id pub-id-type="doi">10.1007/s12149-009-0265-1</pub-id>
<pub-id pub-id-type="pmid">19412654</pub-id>
</element-citation>
</ref>
<ref id="b208-ijmm-40-03-0587">
<label>208</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gurney</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Axelrod</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bond</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Cain</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chartier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Donigan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chaudhari</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kapoun</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>109</volume>
<fpage>11717</fpage>
<lpage>11722</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1073/pnas.1120068109</pub-id>
<!--<pub-id pub-id-type="pmcid">3406803</pub-id>-->
<pub-id pub-id-type="pmid">22753465</pub-id>
</element-citation>
</ref>
<ref id="b209-ijmm-40-03-0587">
<label>209</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nielsen</surname>
<given-names>TO</given-names>
</name>
<name>
<surname>Poulin</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Ladanyi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Synovial sarcoma: Recent discoveries as a roadmap to new avenues for therapy</article-title>
<source/>Cancer Discov
          <volume>5</volume>
<fpage>124</fpage>
<lpage>134</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-1246</pub-id>
<!--<pub-id pub-id-type="pmcid">4320664</pub-id>-->
<pub-id pub-id-type="pmid">25614489</pub-id>
</element-citation>
</ref>
<ref id="b210-ijmm-40-03-0587">
<label>210</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Jimeno</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28</article-title>
<source/>Pharmacol Ther
          <volume>146</volume>
<fpage>1</fpage>
<lpage>11</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2014.08.005</pub-id>
<pub-id pub-id-type="pmid">25172549</pub-id>
</element-citation>
</ref>
<ref id="b211-ijmm-40-03-0587">
<label>211</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferreira Tojais</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Peghaire</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Franzl</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Larrieu-Lahargue</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jaspard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Reynaud</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moreau</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Couffinhal</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Duplàa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dufourcq</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Frizzled7 controls vascular permeability through the Wnt-canonical pathway and crosstalk with endothelial cell junction complexes</article-title>
<source/>Cardiovasc Res
          <volume>103</volume>
<fpage>291</fpage>
<lpage>303</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1093/cvr/cvu133</pub-id>
<pub-id pub-id-type="pmid">24866384</pub-id>
</element-citation>
</ref>
<ref id="b212-ijmm-40-03-0587">
<label>212</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phesse</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Flanagan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vincan</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Frizzled7: A promising Achilles' heel for targeting the Wnt receptor complex to treat cancer</article-title>
<source/>Cancers (Basel)
          <volume>8</volume>
<fpage>50</fpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.3390/cancers8050050</pub-id>
</element-citation>
</ref>
<ref id="b213-ijmm-40-03-0587">
<label>213</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)</article-title>
<source/>Int J Mol Med
          <volume>38</volume>
<fpage>3</fpage>
<lpage>15</lpage>
<year>2016</year>
<!--<pub-id pub-id-type="pmcid">4899036</pub-id>-->
<pub-id pub-id-type="pmid">27245147</pub-id>
</element-citation>
</ref>
<ref id="b214-ijmm-40-03-0587">
<label>214</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shabani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hojjat-Farsangi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Targeting receptor tyrosine kinases using monoclonal antibodies: The most specific tools for targeted-based cancer therapy</article-title>
<source/>Curr Drug Targets
          <volume>17</volume>
<fpage>1687</fpage>
<lpage>1703</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.2174/1389450116666151001104133</pub-id>
<pub-id pub-id-type="pmid">26424402</pub-id>
</element-citation>
</ref>
<ref id="b215-ijmm-40-03-0587">
<label>215</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gentile</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lazzari</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Benvenuti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Trusolino</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Comoglio</surname>
<given-names>PM</given-names>
</name>
</person-group>
<article-title>Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis</article-title>
<source/>Cancer Res
          <volume>71</volume>
<fpage>3132</fpage>
<lpage>3141</lpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2662</pub-id>
<pub-id pub-id-type="pmid">21487037</pub-id>
</element-citation>
</ref>
<ref id="b216-ijmm-40-03-0587">
<label>216</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mellstedt</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hojjat-Farsangi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Daneshmanesh</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Moshfegh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Byström</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Norin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Olin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vågberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Österborg</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>First generation of a small chemical molecule ROR1 RTK tyrosine kinase inhibitor</article-title>
<source/>Ann Oncol
          <volume>27</volume>
<issue>Suppl 6</issue>
<fpage>1533</fpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1093/annonc/mdw392.15</pub-id>
</element-citation>
</ref>
<ref id="b217-ijmm-40-03-0587">
<label>217</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Hojjat-Farsangi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Daneshmanesh</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Hansson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kokhaei</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Österborg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mellstedt</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Moshfegh</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia</article-title>
<source/>Tumour Biol
          <volume>37</volume>
<fpage>11947</fpage>
<lpage>11957</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1007/s13277-016-5039-5</pub-id>
<pub-id pub-id-type="pmid">27086035</pub-id>
</element-citation>
</ref>
<ref id="b218-ijmm-40-03-0587">
<label>218</label>
<element-citation id="b218-ijmm-40-03-0587-gen-2" publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Barat</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Chichili</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ciccarone</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Tamura</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gorlatov</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spliedt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Koenig</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bonvini</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<source/>Development of a humanized ROR1 × CD3 bispecific DART molecule for the treatment of solid and liquid tumors. (Abstract)
          <conf-name>Proceedings of the 107th Annual Meeting of the American Association for Cancer Research</conf-name>
<conf-date>Apr 16–20, 2016</conf-date>
<conf-loc>New Orleans, LA</conf-loc>
</element-citation>
<element-citation id="b218-ijmm-40-03-0587-gen-3" publication-type="journal">
<person-group person-group-type="author">
<collab>AACR</collab>
</person-group>
<source/>Cancer Res
          <volume>76</volume>
<issue>Suppl 14</issue>
<comment>Abstract 1489</comment>
<year>2016</year>
</element-citation>
</ref>
<ref id="b219-ijmm-40-03-0587">
<label>219</label>
<element-citation id="b219-ijmm-40-03-0587-gen-2" publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Blankenship</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Misher</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hoyos</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Ravikumar</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bader</surname>
<given-names>R</given-names>
</name>
<name>
<surname>McMahan</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>RE</given-names>
</name>
<etal></etal>
</person-group>
<source/>Anti-ROR1 × anti-CD3 ADAPTIR™ molecule, ES425, redirects T-cell cytotoxicity and inhibits tumor growth in preclinical models of triple-negative breast cancer. (Abstract)
          <conf-name>Proceedings of the 107th Annual Meeting of the American Association for Cancer Research</conf-name>
<conf-date>Apr 16–20, 2016</conf-date>
<conf-loc>New Orleans, LA. Philadelphia</conf-loc>
</element-citation>
<element-citation id="b219-ijmm-40-03-0587-gen-3" publication-type="journal">
<person-group person-group-type="author">
<collab>AACR</collab>
</person-group>
<source/>Cancer Res
          <volume>76</volume>
<issue>Suppl 14</issue>
<comment>Abstract 4995</comment>
<year>2016</year>
</element-citation>
</ref>
<ref id="b220-ijmm-40-03-0587">
<label>220</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sommermeyer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hudecek</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Balakrishnan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Paszkiewicz</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Kosasih</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Rader</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Riddell</surname>
<given-names>SR</given-names>
</name>
</person-group>
<article-title>Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells</article-title>
<source/>Cancer Immunol Res
          <volume>3</volume>
<fpage>206</fpage>
<lpage>216</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0163</pub-id>
<!--<pub-id pub-id-type="pmcid">4324006</pub-id>-->
<pub-id pub-id-type="pmid">25355068</pub-id>
</element-citation>
</ref>
<ref id="b221-ijmm-40-03-0587">
<label>221</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rasmussen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Barlogie</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shaughnessy</surname>
<given-names>JD</given-names>
<suffix>Jr</suffix>
</name>
</person-group>
<article-title>The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma</article-title>
<source/>N Engl J Med
          <volume>349</volume>
<fpage>2483</fpage>
<lpage>2494</lpage>
<year>2003</year>
<pub-id pub-id-type="doi">10.1056/NEJMoa030847</pub-id>
<pub-id pub-id-type="pmid">14695408</pub-id>
</element-citation>
</ref>
<ref id="b222-ijmm-40-03-0587">
<label>222</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voorzanger-Rousselot</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Goehrig</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Journe</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Doriath</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Body</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Clézardin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Garnero</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Increased Dickkopf-1 expression in breast cancer bone metastases</article-title>
<source/>Br J Cancer
          <volume>97</volume>
<fpage>964</fpage>
<lpage>970</lpage>
<year>2007</year>
<!--<pub-id pub-id-type="pmcid">2360424</pub-id>-->
<pub-id pub-id-type="pmid">17876334</pub-id>
</element-citation>
</ref>
<ref id="b223-ijmm-40-03-0587">
<label>223</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McClung</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Grauer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boonen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bolognese</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Diez-Perez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Langdahl</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Reginster</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Zanchetta</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Wasserman</surname>
<given-names>SM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Romosozumab in postmenopausal women with low bone mineral density</article-title>
<source/>N Engl J Med
          <volume>370</volume>
<fpage>412</fpage>
<lpage>420</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1056/NEJMoa1305224</pub-id>
<pub-id pub-id-type="pmid">24382002</pub-id>
</element-citation>
</ref>
<ref id="b224-ijmm-40-03-0587">
<label>224</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Recker</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Benson</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bolognese</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Robins</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Alam</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chiang</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Krege</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Sowa</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density</article-title>
<source/>J Bone Miner Res
          <volume>30</volume>
<fpage>216</fpage>
<lpage>224</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1002/jbmr.2351</pub-id>
<pub-id pub-id-type="pmid">25196993</pub-id>
</element-citation>
</ref>
<ref id="b225-ijmm-40-03-0587">
<label>225</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roschger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Roschger</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Keplingter</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Klaushofer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Abdullah</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kneissel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta</article-title>
<source/>Bone
          <volume>66</volume>
<fpage>182</fpage>
<lpage>188</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1016/j.bone.2014.06.015</pub-id>
<pub-id pub-id-type="pmid">24953712</pub-id>
</element-citation>
</ref>
<ref id="b226-ijmm-40-03-0587">
<label>226</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fulciniti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hideshima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vallet</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nanjappa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ettenberg</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Chauhan</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma</article-title>
<source/>Blood
          <volume>114</volume>
<fpage>371</fpage>
<lpage>379</lpage>
<year>2009</year>
<pub-id pub-id-type="doi">10.1182/blood-2008-11-191577</pub-id>
<!--<pub-id pub-id-type="pmcid">2714212</pub-id>-->
<pub-id pub-id-type="pmid">19417213</pub-id>
</element-citation>
</ref>
<ref id="b227-ijmm-40-03-0587">
<label>227</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bendell</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Mahalingam</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Halmos</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sirard</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Landau</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>DP</given-names>
</name>
</person-group>
<article-title>A Phase 1 study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (pac) in patients with DKK1 relapsed or refractory esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ)</article-title>
<source/>J Clin Oncol
          <volume>34</volume>
<issue>Suppl 4S</issue>
<comment>Abstract 111</comment>
<year>2016</year>
<pub-id pub-id-type="doi">10.1200/jco.2016.34.4_suppl.111</pub-id>
</element-citation>
</ref>
<ref id="b228-ijmm-40-03-0587">
<label>228</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Betts</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Treadway</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giovanelli</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Abdiche</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Paralkar</surname>
<given-names>VM</given-names>
</name>
</person-group>
<article-title>The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis</article-title>
<source/>J Pharmacol Exp Ther
          <volume>333</volume>
<fpage>2</fpage>
<lpage>13</lpage>
<year>2010</year>
<pub-id pub-id-type="doi">10.1124/jpet.109.164129</pub-id>
<pub-id pub-id-type="pmid">20089807</pub-id>
</element-citation>
</ref>
<ref id="b229-ijmm-40-03-0587">
<label>229</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Florio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gunasekaran</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Stolina</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tipton</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Salimi-Moosavi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Asuncion</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair</article-title>
<source/>Nat Commun
          <volume>7</volume>
<fpage>11505</fpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1038/ncomms11505</pub-id>
<!--<pub-id pub-id-type="pmcid">4894982</pub-id>-->
<pub-id pub-id-type="pmid">27230681</pub-id>
</element-citation>
</ref>
<ref id="b230-ijmm-40-03-0587">
<label>230</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>ADP-ribosyltransferases and poly ADP-ribosylation</article-title>
<source/>Curr Protein Pept Sci
          <volume>16</volume>
<fpage>491</fpage>
<lpage>501</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.2174/1389203716666150504122435</pub-id>
<!--<pub-id pub-id-type="pmcid">4725697</pub-id>-->
<pub-id pub-id-type="pmid">25938242</pub-id>
</element-citation>
</ref>
<ref id="b231-ijmm-40-03-0587">
<label>231</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Identification and characterization of human TIPARP gene within the CCNL amplicon at human chromosome 3q25.31</article-title>
<source/>Int J Oncol
          <volume>23</volume>
<fpage>541</fpage>
<lpage>547</lpage>
<year>2003</year>
<pub-id pub-id-type="pmid">12851707</pub-id>
</element-citation>
</ref>
<ref id="b232-ijmm-40-03-0587">
<label>232</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roper</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Chrysanthou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Senner</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Sienerth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gnan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Masutani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Latos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hemberger</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>ADP-ribosyltransferases Parp1 and Parp7 safeguard pluripotency of ES cells</article-title>
<source/>Nucleic Acids Res
          <volume>42</volume>
<fpage>8914</fpage>
<lpage>8927</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1093/nar/gku591</pub-id>
<!--<pub-id pub-id-type="pmcid">4132717</pub-id>-->
<pub-id pub-id-type="pmid">25034692</pub-id>
</element-citation>
</ref>
<ref id="b233-ijmm-40-03-0587">
<label>233</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haince</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Rouleau</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hendzel</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Masson</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Poirier</surname>
<given-names>GG</given-names>
</name>
</person-group>
<article-title>Targeting poly(ADP-ribosyl)ation: A promising approach in cancer therapy</article-title>
<source/>Trends Mol Med
          <volume>11</volume>
<fpage>456</fpage>
<lpage>463</lpage>
<year>2005</year>
<pub-id pub-id-type="doi">10.1016/j.molmed.2005.08.003</pub-id>
<pub-id pub-id-type="pmid">16154385</pub-id>
</element-citation>
</ref>
<ref id="b234-ijmm-40-03-0587">
<label>234</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gunderson</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>KN</given-names>
</name>
</person-group>
<article-title>Olaparib: An oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer</article-title>
<source/>Future Oncol
          <volume>11</volume>
<fpage>747</fpage>
<lpage>757</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.2217/fon.14.313</pub-id>
<pub-id pub-id-type="pmid">25757679</pub-id>
</element-citation>
</ref>
<ref id="b235-ijmm-40-03-0587">
<label>235</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nathubhai</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Haikarainen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Koivunen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Murthy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Koumanov</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lloyd</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Holman</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Pihlajaniemi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tosh</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lehtiö</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Highly potent and isoform selective dual site binding tankyrase/Wnt signaling inhibitors that increase cellular glucose uptake and have antiproliferative activity</article-title>
<source/>J Med Chem
          <volume>60</volume>
<fpage>814</fpage>
<lpage>820</lpage>
<year>2017</year>
<pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01574</pub-id>
<pub-id pub-id-type="pmid">27983846</pub-id>
</element-citation>
</ref>
<ref id="b236-ijmm-40-03-0587">
<label>236</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riffell</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Lord</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Ashworth</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Tankyrase-targeted therapeutics: Expanding opportunities in the PARP family</article-title>
<source/>Nat Rev Drug Discov
          <volume>11</volume>
<fpage>923</fpage>
<lpage>936</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1038/nrd3868</pub-id>
<pub-id pub-id-type="pmid">23197039</pub-id>
</element-citation>
</ref>
<ref id="b237-ijmm-40-03-0587">
<label>237</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Tankyrase inhibitors target YAP by stabilizing angiomotin family proteins</article-title>
<source/>Cell Rep
          <volume>13</volume>
<fpage>524</fpage>
<lpage>532</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.celrep.2015.09.014</pub-id>
<!--<pub-id pub-id-type="pmcid">4618173</pub-id>-->
<pub-id pub-id-type="pmid">26456820</pub-id>
</element-citation>
</ref>
<ref id="b238-ijmm-40-03-0587">
<label>238</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulak</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Holohan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>He</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Borek</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Otwinowski</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Garofalo</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disruption of Wnt/β-catenin signaling and telomeric shortening are inextricable consequences of tankyrase inhibition in human cells</article-title>
<source/>Mol Cell Biol
          <volume>35</volume>
<fpage>2425</fpage>
<lpage>2435</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1128/MCB.00392-15</pub-id>
<!--<pub-id pub-id-type="pmcid">4475917</pub-id>-->
<pub-id pub-id-type="pmid">25939383</pub-id>
</element-citation>
</ref>
<ref id="b239-ijmm-40-03-0587">
<label>239</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scarborough</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Helfrich</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Casás-Selves</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schuller</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Grosskurth</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zaberezhnyy</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition</article-title>
<source/>Clin Cancer Res
          <volume>23</volume>
<fpage>1531</fpage>
<lpage>1541</lpage>
<year>2017</year>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-1179</pub-id>
<pub-id pub-id-type="pmid">27663586</pub-id>
</element-citation>
</ref>
<ref id="b240-ijmm-40-03-0587">
<label>240</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lau</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Callow</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Waaler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Boggs</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Blake</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Magnuson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sambrone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schutten</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Firestein</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth</article-title>
<source/>Cancer Res
          <volume>73</volume>
<fpage>3132</fpage>
<lpage>3144</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-4562</pub-id>
<pub-id pub-id-type="pmid">23539443</pub-id>
</element-citation>
</ref>
<ref id="b241-ijmm-40-03-0587">
<label>241</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shultz</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Kirby</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Firestone</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Chin</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Dipietro</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fazal</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of NVP-TNKS656: The use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor</article-title>
<source/>J Med Chem
          <volume>56</volume>
<fpage>6495</fpage>
<lpage>6511</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1021/jm400807n</pub-id>
<pub-id pub-id-type="pmid">23844574</pub-id>
</element-citation>
</ref>
<ref id="b242-ijmm-40-03-0587">
<label>242</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arqués</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Chicote</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Puig</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Tenbaum</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Argilés</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dienstmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fernández</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Caratù</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Matito</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Silberschmidt</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tankyrase inhibition blocks Wnt/β-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer</article-title>
<source/>Clin Cancer Res
          <volume>22</volume>
<fpage>644</fpage>
<lpage>656</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-3081</pub-id>
<pub-id pub-id-type="pmid">26224873</pub-id>
</element-citation>
</ref>
<ref id="b243-ijmm-40-03-0587">
<label>243</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Mishina</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stegmeier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Michaud</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Charlat</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Wiellette</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wiessner</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling</article-title>
<source/>Nature
          <volume>461</volume>
<fpage>614</fpage>
<lpage>620</lpage>
<year>2009</year>
<pub-id pub-id-type="doi">10.1038/nature08356</pub-id>
<pub-id pub-id-type="pmid">19759537</pub-id>
</element-citation>
</ref>
<ref id="b244-ijmm-40-03-0587">
<label>244</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casás-Selves</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Helfrich</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Scarborough</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Bunn</surname>
<given-names>PA</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Chan</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>AC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition</article-title>
<source/>Cancer Res
          <volume>72</volume>
<fpage>4154</fpage>
<lpage>4164</lpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-2848</pub-id>
<!--<pub-id pub-id-type="pmcid">3673784</pub-id>-->
<pub-id pub-id-type="pmid">22738915</pub-id>
</element-citation>
</ref>
<ref id="b245-ijmm-40-03-0587">
<label>245</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Epigenetic modulation of Wnt signaling contributes to neuropathic pain in rats</article-title>
<source/>Mol Med Rep
          <volume>12</volume>
<fpage>4727</fpage>
<lpage>4733</lpage>
<year>2015</year>
<pub-id pub-id-type="pmid">26096038</pub-id>
</element-citation>
</ref>
<ref id="b246-ijmm-40-03-0587">
<label>246</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meijer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Skaltsounis</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Magiatis</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Polychronopoulos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Knockaert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leost</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>XP</given-names>
</name>
<name>
<surname>Vonica</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Brivanlou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dajani</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GSK-3-selective inhibitors derived from Tyrian purple indirubins</article-title>
<source/>Chem Biol
          <volume>10</volume>
<fpage>1255</fpage>
<lpage>1266</lpage>
<year>2003</year>
<pub-id pub-id-type="doi">10.1016/j.chembiol.2003.11.010</pub-id>
<pub-id pub-id-type="pmid">14700633</pub-id>
</element-citation>
</ref>
<ref id="b247-ijmm-40-03-0587">
<label>247</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ai</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>CHIR99021 promotes self-renewal of mouse embryonic stem cells by modulation of protein-encoding gene and long intergenic non-coding RNA expression</article-title>
<source/>Exp Cell Res
          <volume>319</volume>
<fpage>2684</fpage>
<lpage>2699</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1016/j.yexcr.2013.08.027</pub-id>
<pub-id pub-id-type="pmid">24021571</pub-id>
</element-citation>
</ref>
<ref id="b248-ijmm-40-03-0587">
<label>248</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atkinson</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Rank</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Capen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yadav</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Manro</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Engler</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Chedid</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Activating the Wnt/β-catenin pathway for the treatment of melanoma: Application of LY2090314, a novel selective inhibitor of glycogen synthase kinase-3</article-title>
<source/>PLoS One
          <volume>10</volume>
<fpage>e0125028</fpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1371/journal.pone.0125028</pub-id>
<pub-id pub-id-type="pmid">25915038</pub-id>
</element-citation>
</ref>
<ref id="b249-ijmm-40-03-0587">
<label>249</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>TY</given-names>
</name>
<name>
<surname>Brinker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Hur</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>PG</given-names>
</name>
</person-group>
<article-title>Synthetic small molecules that control stem cell fate</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>100</volume>
<fpage>7632</fpage>
<lpage>7637</lpage>
<year>2003</year>
<pub-id pub-id-type="doi">10.1073/pnas.0732087100</pub-id>
<!--<pub-id pub-id-type="pmcid">164638</pub-id>-->
<pub-id pub-id-type="pmid">12794184</pub-id>
</element-citation>
</ref>
<ref id="b250-ijmm-40-03-0587">
<label>250</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lalit</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Salick</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>DO</given-names>
</name>
<name>
<surname>Squirrell</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Shafer</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Saeed</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Schmuck</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Markandeya</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lineage reprogramming of fibroblasts into proliferative induced cardiac progenitor cells by defined factors</article-title>
<source/>Cell Stem Cell
          <volume>18</volume>
<fpage>354</fpage>
<lpage>367</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.stem.2015.12.001</pub-id>
<!--<pub-id pub-id-type="pmcid">4779406</pub-id>-->
<pub-id pub-id-type="pmid">26877223</pub-id>
</element-citation>
</ref>
<ref id="b251-ijmm-40-03-0587">
<label>251</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narcisi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Arikan</surname>
<given-names>OH</given-names>
</name>
<name>
<surname>Lehmann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ten Berge</surname>
<given-names>D</given-names>
</name>
<name>
<surname>van Osch</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>Differential effects of small molecule WNT agonists on the multilineage differentiation capacity of human mesenchymal stem cells</article-title>
<source/>Tissue Eng Part A
          <volume>22</volume>
<fpage>1264</fpage>
<lpage>1273</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1089/ten.tea.2016.0081</pub-id>
<pub-id pub-id-type="pmid">27633010</pub-id>
</element-citation>
</ref>
<ref id="b252-ijmm-40-03-0587">
<label>252</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiskus</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Saha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Devaraj</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Horrigan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Leveque</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Iyer</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells</article-title>
<source/>Leukemia
          <volume>29</volume>
<fpage>1267</fpage>
<lpage>1278</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1038/leu.2014.340</pub-id>
<pub-id pub-id-type="pmid">25482131</pub-id>
</element-citation>
</ref>
<ref id="b253-ijmm-40-03-0587">
<label>253</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trautmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sievers</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Aretz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kindler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Michels</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Friedrichs</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Renner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kirfel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huss</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma</article-title>
<source/>Oncogene
          <volume>33</volume>
<fpage>5006</fpage>
<lpage>5016</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1038/onc.2013.443</pub-id>
<pub-id pub-id-type="pmid">24166495</pub-id>
</element-citation>
</ref>
<ref id="b254-ijmm-40-03-0587">
<label>254</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>JU</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Wnt/β-catenin small-molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells</article-title>
<source/>Cancer Res
          <volume>75</volume>
<fpage>1691</fpage>
<lpage>1702</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-2041</pub-id>
<pub-id pub-id-type="pmid">25660951</pub-id>
</element-citation>
</ref>
<ref id="b255-ijmm-40-03-0587">
<label>255</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emami</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Eguchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Teo</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>SH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A small molecule inhibitor of β-catenin/CREB-binding protein transcription [corrected]</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>101</volume>
<fpage>12682</fpage>
<lpage>12687</lpage>
<year>2004</year>
<pub-id pub-id-type="doi">10.1073/pnas.0404875101</pub-id>
<pub-id pub-id-type="pmid">15314234</pub-id>
</element-citation>
</ref>
<ref id="b256-ijmm-40-03-0587">
<label>256</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Neuenschwander</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Specker</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wulf-Goldenberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weis</surname>
<given-names>WI</given-names>
</name>
<name>
<surname>von Kries</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Birchmeier</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>A small-molecule antagonist of the β-catenin/TCF4 interaction blocks the self-renewal of cancer stem cells and suppresses tumorigenesis</article-title>
<source/>Cancer Res
          <volume>76</volume>
<fpage>891</fpage>
<lpage>901</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-1519</pub-id>
<pub-id pub-id-type="pmid">26645562</pub-id>
</element-citation>
</ref>
<ref id="b257-ijmm-40-03-0587">
<label>257</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hwang</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Byun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Westover</surname>
<given-names>KD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Direct targeting of β-catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt/β-catenin signaling</article-title>
<source/>Cell Rep
          <volume>16</volume>
<fpage>28</fpage>
<lpage>36</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.celrep.2016.05.071</pub-id>
<!--<pub-id pub-id-type="pmcid">4957947</pub-id>-->
<pub-id pub-id-type="pmid">27320923</pub-id>
</element-citation>
</ref>
<ref id="b258-ijmm-40-03-0587">
<label>258</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sukhdeo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Dutta</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yasui</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rooney</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Carrasco</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>M</given-names>
</name>
<name>
<surname>He</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>YT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>104</volume>
<fpage>7516</fpage>
<lpage>7521</lpage>
<year>2007</year>
<pub-id pub-id-type="doi">10.1073/pnas.0610299104</pub-id>
<pub-id pub-id-type="pmid">17452641</pub-id>
</element-citation>
</ref>
<ref id="b259-ijmm-40-03-0587">
<label>259</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lenz</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Safely targeting cancer stem cells via selective catenin coactivator antagonism</article-title>
<source/>Cancer Sci
          <volume>105</volume>
<fpage>1087</fpage>
<lpage>1092</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.1111/cas.12471</pub-id>
<!--<pub-id pub-id-type="pmcid">4175086</pub-id>-->
<pub-id pub-id-type="pmid">24975284</pub-id>
</element-citation>
</ref>
<ref id="b260-ijmm-40-03-0587">
<label>260</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Sukhdeo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lemieux</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carrasco</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Horst</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling</article-title>
<source/>Sci Transl Med
          <volume>4</volume>
<fpage>148ra117</fpage>
<year>2012</year>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3003808</pub-id>
</element-citation>
</ref>
<ref id="b261-ijmm-40-03-0587">
<label>261</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henderson</surname>
<given-names>WR</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Chi</surname>
<given-names>EY</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tien</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Borok</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis</article-title>
<source/>Proc Natl Acad Sci USA
          <volume>107</volume>
<fpage>14309</fpage>
<lpage>14314</lpage>
<year>2010</year>
<pub-id pub-id-type="doi">10.1073/pnas.1001520107</pub-id>
<!--<pub-id pub-id-type="pmcid">2922550</pub-id>-->
<pub-id pub-id-type="pmid">20660310</pub-id>
</element-citation>
</ref>
<ref id="b262-ijmm-40-03-0587">
<label>262</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Nie</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>FF</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Multiple genes of the renin-angiotensin system are novel targets of Wnt/β-catenin signaling</article-title>
<source/>J Am Soc Nephrol
          <volume>26</volume>
<fpage>107</fpage>
<lpage>120</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1681/ASN.2014010085</pub-id>
<pub-id pub-id-type="pmid">25012166</pub-id>
</element-citation>
</ref>
<ref id="b263-ijmm-40-03-0587">
<label>263</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gajewski</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>YX</given-names>
</name>
</person-group>
<article-title>Innate and adaptive immune cells in the tumor microenvironment</article-title>
<source/>Nat Immunol
          <volume>14</volume>
<fpage>1014</fpage>
<lpage>1022</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1038/ni.2703</pub-id>
<!--<pub-id pub-id-type="pmcid">4118725</pub-id>-->
<pub-id pub-id-type="pmid">24048123</pub-id>
</element-citation>
</ref>
<ref id="b264-ijmm-40-03-0587">
<label>264</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Son</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Youn</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Youn</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The role of tumor microenvironment in therapeutic resistance</article-title>
<source/>Oncotarget
          <volume>8</volume>
<fpage>3933</fpage>
<lpage>3945</lpage>
<year>2017</year>
<!--<pub-id pub-id-type="pmcid">5354804</pub-id>-->
<pub-id pub-id-type="pmid">27965469</pub-id>
</element-citation>
</ref>
<ref id="b265-ijmm-40-03-0587">
<label>265</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spranger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gajewski</surname>
<given-names>TF</given-names>
</name>
</person-group>
<article-title>Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity</article-title>
<source/>Nature
          <volume>523</volume>
<fpage>231</fpage>
<lpage>235</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1038/nature14404</pub-id>
<pub-id pub-id-type="pmid">25970248</pub-id>
</element-citation>
</ref>
<ref id="b266-ijmm-40-03-0587">
<label>266</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malladi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Macalinao</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Basnet</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>de Stanchina</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Massagué</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Metastatic latency and immune evasion through autocrine Inhibition of WNT</article-title>
<source/>Cell
          <volume>165</volume>
<fpage>45</fpage>
<lpage>60</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.cell.2016.02.025</pub-id>
<!--<pub-id pub-id-type="pmcid">4808520</pub-id>-->
<pub-id pub-id-type="pmid">27015306</pub-id>
</element-citation>
</ref>
<ref id="b267-ijmm-40-03-0587">
<label>267</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Interactions between canonical Wnt signaling pathway and MAPK pathway regulate differentiation, maturation and function of dendritic cells</article-title>
<source/>Cell Immunol
          <volume>310</volume>
<fpage>170</fpage>
<lpage>177</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.cellimm.2016.09.006</pub-id>
<pub-id pub-id-type="pmid">27641635</pub-id>
</element-citation>
</ref>
<ref id="b268-ijmm-40-03-0587">
<label>268</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naskar</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Maiti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chakraborty</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chattopadhyay</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sen</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Wnt5a-Rac1-NF-κB homeostatic circuitry sustains innate immune functions in macrophages</article-title>
<source/>J Immunol
          <volume>192</volume>
<fpage>4386</fpage>
<lpage>4397</lpage>
<year>2014</year>
<pub-id pub-id-type="doi">10.4049/jimmunol.1302817</pub-id>
<pub-id pub-id-type="pmid">24706725</pub-id>
</element-citation>
</ref>
<ref id="b269-ijmm-40-03-0587">
<label>269</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D'Amico</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mahajan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Capietto</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zamani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ricci</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bumpass</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang-Gillam</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer</article-title>
<source/>J Exp Med
          <volume>213</volume>
<fpage>827</fpage>
<lpage>840</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1084/jem.20150950</pub-id>
<!--<pub-id pub-id-type="pmcid">4854727</pub-id>-->
<pub-id pub-id-type="pmid">27045006</pub-id>
</element-citation>
</ref>
<ref id="b270-ijmm-40-03-0587">
<label>270</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Staal</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Arens</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Wnt signaling as master regulator of T-lymphocyte responses: Implications for transplant therapy</article-title>
<source/>Transplantation
          <volume>100</volume>
<fpage>2584</fpage>
<lpage>2592</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1097/TP.0000000000001393</pub-id>
<pub-id pub-id-type="pmid">27861287</pub-id>
</element-citation>
</ref>
<ref id="b271-ijmm-40-03-0587">
<label>271</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swafford</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Manicassamy</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Wnt signaling in dendritic cells: Its role in regulation of immunity and tolerance</article-title>
<source/>Discov Med
          <volume>19</volume>
<fpage>303</fpage>
<lpage>310</lpage>
<year>2015</year>
<!--<pub-id pub-id-type="pmcid">4513356</pub-id>-->
<pub-id pub-id-type="pmid">25977193</pub-id>
</element-citation>
</ref>
<ref id="b272-ijmm-40-03-0587">
<label>272</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holtzhausen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Tsutsui</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Orabona</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tyler</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Hanks</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: Opportunities for pharmacologic enhancement of immunotherapy</article-title>
<source/>Cancer Immunol Res
          <volume>3</volume>
<fpage>1082</fpage>
<lpage>1095</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0167</pub-id>
<!--<pub-id pub-id-type="pmcid">4927300</pub-id>-->
<pub-id pub-id-type="pmid">26041736</pub-id>
</element-citation>
</ref>
<ref id="b273-ijmm-40-03-0587">
<label>273</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanks</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Immune evasion pathways and the design of dendritic cell-based cancer vaccines</article-title>
<source/>Discov Med
          <volume>21</volume>
<fpage>135</fpage>
<lpage>142</lpage>
<year>2016</year>
<!--<pub-id pub-id-type="pmcid">4934601</pub-id>-->
<pub-id pub-id-type="pmid">27011049</pub-id>
</element-citation>
</ref>
<ref id="b274-ijmm-40-03-0587">
<label>274</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaur</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Weeraratna</surname>
<given-names>AT</given-names>
</name>
</person-group>
<article-title>In the Wnt-er of life: Wnt signalling in melanoma and ageing</article-title>
<source/>Br J Cancer
          <volume>115</volume>
<fpage>1273</fpage>
<lpage>1279</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1038/bjc.2016.332</pub-id>
<!--<pub-id pub-id-type="pmcid">5129830</pub-id>-->
<pub-id pub-id-type="pmid">27764844</pub-id>
</element-citation>
</ref>
<ref id="b275-ijmm-40-03-0587">
<label>275</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Law</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Weck</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kyriss</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nilson</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Hunzicker-Dunn</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Lhcgr expression in granulosa cells: Roles for PKA-phosphorylated β-catenin, TCF3, and FOXO1</article-title>
<source/>Mol Endocrinol
          <volume>27</volume>
<fpage>1295</fpage>
<lpage>1310</lpage>
<year>2013</year>
<pub-id pub-id-type="doi">10.1210/me.2013-1025</pub-id>
<!--<pub-id pub-id-type="pmcid">3725343</pub-id>-->
<pub-id pub-id-type="pmid">23754802</pub-id>
</element-citation>
</ref>
<ref id="b276-ijmm-40-03-0587">
<label>276</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Habener</surname>
<given-names>JF</given-names>
</name>
</person-group>
<article-title>Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation</article-title>
<source/>J Biol Chem
          <volume>283</volume>
<fpage>8723</fpage>
<lpage>8735</lpage>
<year>2008</year>
<pub-id pub-id-type="doi">10.1074/jbc.M706105200</pub-id>
<!--<pub-id pub-id-type="pmcid">2417166</pub-id>-->
<pub-id pub-id-type="pmid">18216022</pub-id>
</element-citation>
</ref>
<ref id="b277-ijmm-40-03-0587">
<label>277</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellei</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pitisci</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Catricalà</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Larue</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Picardo</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Wnt/β-catenin signaling is stimulated by α-melanocyte-stimulating hormone in melanoma and melanocyte cells: Implication in cell differentiation</article-title>
<source/>Pigment Cell Melanoma Res
          <volume>24</volume>
<fpage>309</fpage>
<lpage>325</lpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.1111/j.1755-148X.2010.00800.x</pub-id>
<pub-id pub-id-type="pmid">21040502</pub-id>
</element-citation>
</ref>
<ref id="b278-ijmm-40-03-0587">
<label>278</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furuyashiki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Narumiya</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Stress responses: The contribution of prostaglandin E(2) and its receptors</article-title>
<source/>Nat Rev Endocrinol
          <volume>7</volume>
<fpage>163</fpage>
<lpage>175</lpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.1038/nrendo.2010.194</pub-id>
<pub-id pub-id-type="pmid">21116297</pub-id>
</element-citation>
</ref>
<ref id="b279-ijmm-40-03-0587">
<label>279</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brudvik</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Paulsen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Aandahl</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Roald</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Taskén</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Protein kinase A antagonist inhibits β-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in Apc(Min/+) mice</article-title>
<source/>Mol Cancer
          <volume>10</volume>
<fpage>149</fpage>
<year>2011</year>
<pub-id pub-id-type="doi">10.1186/1476-4598-10-149</pub-id>
<pub-id pub-id-type="pmid">22168384</pub-id>
</element-citation>
</ref>
<ref id="b280-ijmm-40-03-0587">
<label>280</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jansen</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Holman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hedemann</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Frankes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Elzinga</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Timens</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Gosens</surname>
<given-names>R</given-names>
</name>
<name>
<surname>de Bont</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Prostaglandin E<sub>2</sub> promotes MYCN non-amplified neuroblastoma cell survival via β-catenin stabilization</article-title>
<source/>J Cell Mol Med
          <volume>19</volume>
<fpage>210</fpage>
<lpage>226</lpage>
<year>2015</year>
<pub-id pub-id-type="doi">10.1111/jcmm.12418</pub-id>
<pub-id pub-id-type="pmid">25266063</pub-id>
</element-citation>
</ref>
<ref id="b281-ijmm-40-03-0587">
<label>281</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Estus</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Choudhary</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pilbeam</surname>
<given-names>CC</given-names>
</name>
</person-group>
<article-title>Prostaglandin-mediated inhibition of PTH-stimulated β-catenin signaling in osteoblasts by bone marrow macrophages</article-title>
<source/>Bone
          <volume>85</volume>
<fpage>123</fpage>
<lpage>130</lpage>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.bone.2016.01.023</pub-id>
<!--<pub-id pub-id-type="pmcid">4835216</pub-id>-->
<pub-id pub-id-type="pmid">26851123</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-ijmm-40-03-0587" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Overview of WNT signaling cascades. Canonical WNT signaling through Frizzled and LRP5/6 receptors promotes β-catenin-dependent transcription of <italic>CCND1</italic>, <italic>FZD7</italic>, <italic>MYC</italic> and other genes (WNT/β-catenin signaling) and β-catenin-independent stabilization of FOXM1, NRF2 (NFE2L2), YAP and other proteins (WNT/STOP signaling). Non-canonical WNT signaling through Frizzled or ROR receptors activates DVL-dependent Rho-ROCK and Rac-JNK cascades (WNT/PCP signaling), G protein-dependent calcineurin-NFAT, CAMK2-NLK and PKC cascades (WNT/GPCR signaling) and RTK-dependent PI3K-AKT and YAP/TAZ cascades (WNT/RTK signaling). Context-dependent WNT signaling through canonical and non-canonical signaling cascades regulates cell fate and proliferation, tissue or tumor microenvironment and whole-body homeostasis. GPCR, G protein-coupled receptor; PCP, planar cell polarity; RTK, receptor tyrosine kinase; STOP, stabilization of proteins.</p>
</caption>
<graphic xlink:href="IJMM-40-03-0587-g00"></graphic>
</fig>
<fig id="f2-ijmm-40-03-0587" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>WNT signaling dysregulation in cancer and non-cancerous diseases. Canonical WNT/β-catenin signaling cascade is aberrantly activated in hereditary colorectal cancer and various types of sporadic cancers owing to genetic alterations in the <italic>APC</italic>, <italic>AXIN2</italic>, <italic>CTNNB1</italic>, <italic>RNF43</italic>, <italic>RSPO2</italic> and <italic>RSPO3</italic> genes, and also in hereditary osteoblastic diseases owing to <italic>SOST</italic> and <italic>LRP5</italic> mutations (red boxes). The WNT/β-catenin signaling cascade is downergulated in intellectual disability syndrome owing to <italic>CTNNB1</italic> loss-of-function mutations, in familial exudative vitreoretinopathy owing to loss-of-function mutations in the <italic>FZD4</italic> and <italic>LRP5</italic> genes and in osteoporosis-associated syndromes owing to <italic>LRP5</italic>, <italic>LRP6</italic> and <italic>WNT1</italic> loss-of-function mutations (open box). By contrast, non-canonical WNT/RTK signaling cascade is aberrantly activated in B-cell leukemia and solid tumors as a result of ROR1 upregulation (blue box). Non-canonical WNT/PCP signaling cascade is dysregulated in PCP-related hereditary diseases, such as autism, epilepsy, neural tube defects and Robinow syndrome owing to mutations in the <italic>CELSR1</italic>, <italic>DVL1</italic>, <italic>DVL2</italic>, <italic>DVL3</italic>, <italic>FZD6</italic>, <italic>PRICKLE1</italic>, <italic>PRICKLE2</italic>, <italic>ROR2</italic>, <italic>VANGL1</italic>, <italic>VANGL2</italic> and <italic>WNT5A</italic> genes (open boxes). Genetic alterations in the WNT signaling molecules affect multiple WNT signaling cascades. For example, <italic>RNF43</italic>, <italic>RSPO2</italic> and <italic>RSPO3</italic> alterations activate WNT/β-catenin and other WNT signaling cascades, whereas loss-of-function <italic>LRP5</italic> mutations inactivate the WNT/β-catenin signaling cascade and reciprocally activate the WNT/PCP signaling cascade. PCP, planar cell polarity; RTK, receptor tyrosine kinase.</p>
</caption>
<graphic xlink:href="IJMM-40-03-0587-g01"></graphic>
</fig>
<fig id="f3-ijmm-40-03-0587" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>β-catenin at the crossroad of WNT, tyrosine kinase and GPCR-cAMP-PKA signaling cascades. WNT/β-catenin signaling activation induces stabilization and nuclear translocation of β-catenin and upregulation of β-catenin-TCF/LEF target genes. By contrast, activation of BCR-ABL, FLT3, KIT, SRC or RET tyrosine kinases and GPCR-mediated PKA activation induce β-catenin phosphorylation at Y654 and S675, respectively, which also promotes nuclear translocation of β-catenin and β-catenin-dependent transcription. FSHR (<xref ref-type="bibr" rid="b275-ijmm-40-03-0587">275</xref>), GLP1R (<xref ref-type="bibr" rid="b276-ijmm-40-03-0587">276</xref>), MC1R (<xref ref-type="bibr" rid="b277-ijmm-40-03-0587">277</xref>), PTGER2/EP2 (<xref ref-type="bibr" rid="b278-ijmm-40-03-0587">278</xref>,<xref ref-type="bibr" rid="b279-ijmm-40-03-0587">279</xref>), PTGER4/EP4 (<xref ref-type="bibr" rid="b278-ijmm-40-03-0587">278</xref>,<xref ref-type="bibr" rid="b280-ijmm-40-03-0587">280</xref>) and PTH1R (<xref ref-type="bibr" rid="b281-ijmm-40-03-0587">281</xref>) are GPCRs that are reported to induce cAMP-dependent PKA activation and subsequent β-catenin activation. <italic>AXIN2</italic>, <italic>CCND1</italic>, <italic>DKK1</italic>, <italic>FGF20</italic>, <italic>FZD7</italic>, <italic>JAG1</italic>, <italic>MYC</italic>, <italic>NEUROD1</italic> and <italic>NOTUM</italic> are representative targets of the WNT/β-catenin signaling cascade; however, β-catenin target genes are context-dependently upregulated owing to additional transcriptional regulation by the tyrosine kinase and PKA signaling cascades. GPCR, G protein-coupled receptor; PKA, protein kinase A, DKK1, Dickkopf-related protein 1.</p>
</caption>
<graphic xlink:href="IJMM-40-03-0587-g02"></graphic>
</fig>
<fig id="f4-ijmm-40-03-0587" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Mutations, downstream signaling and therapeutics of WNT-related human cancers. (Left) Loss-of-function APC mutations and gain-of-function <italic>CTNNB1</italic> mutations in human cancers, such as colorectal cancer, breast cancer and uterine cancer (uterine corpus endometrial carcinoma), lead to ligand-independent activation of the WNT/β-catenin signaling cascade, which can be treated with β-catenin inhibitors in preclinical model animal experiments. (Middle) Loss-of-function <italic>RNF43</italic> or <italic>ZNRF3</italic> mutations, <italic>RSPO2/3</italic> fusions and <italic>RSPO3</italic> upregulation in colorectal cancer, breast cancer, pancreatic cancer and other cancers activate the WNT/β-catenin signaling cascade as well as β-catenin-independent WNT signaling cascades, such as WNT/STOP and WNT/PCP signaling cascades. This type of cancers can be treated with anti-FZD5 mAb, anti-RSPO3 mAb or PORCN inhibitors. (Right) ROR1 upregulation in B-cell leukemia and solid tumors gives rise to WNT/PCP and WNT/RTK signaling activation, which can be treated with anti-ROR1 mAb, anti-ROR1 × anti-CD3 bispecific antibodies, ROR1 inhibitor and ROR1 CAR-T cells. PCP, planar cell polarity; ALL, acute lymphoblastic leukemia; CAR-T, chimeric antigen receptor-modified T cells; CLL, chronic lymphocytic leukemia; GoF, gain-of-function; LoF, loss-of-function; mAb, monoclonal antibody; Mut, mutation; RTK, receptor tyrosine kinase; STOP, stabilization of proteins; PORCN, porcupine.</p>
</caption>
<graphic xlink:href="IJMM-40-03-0587-g03"></graphic>
</fig>
<fig id="f5-ijmm-40-03-0587" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<p>Context-dependent WNT signaling and immune evasion. Cancer cells and CAFs dictate accumulation of M2-TAMs, MDSCs and regulatory T (Treg) cells in the tumor environment to give rise to immune evasion through clearance or functional inhibition of CD8<sup>+</sup> effector T cells and NK cells. WNT/β-catenin signaling activation in DCs can enhance immune evasion through Treg accumulation in the tumor microenvironment, whereas DKK1-induced WNT/β-catenin signaling inhibition in cancer cells or the tumor microenvironment can also enhance immune evasion through MDSC accumulation and NK clearance. Anti-WNT signaling therapy using PORCN inhibitor, tankyrase inhibitor or β-catenin inhibitor may be applicable for the treatment of immune evasion induced by WNT/β-catenin signaling activation. By contrast, pro-WNT signaling therapy using an anti-DKK1 monoclonal antibody may be applicable for the treatment of immune evasion associated with DKK1 upregulation. As WNT signaling cascades are involved in context-dependent immune evasion and antitumor immunity, precise immune monitoring and comprehensive understanding of WNT-dependent immune regulation are necessary to apply WNT-targeted therapy for cancer patients with immune evasion. CAFs, cancer-associated fibroblasts; M2-TAMs, M2-type tumor associated macrophages; NK, natural killer; DCs, dendritic cells; MDSCs, myeloid-derived suppressor cells; PORCN, porcupine; DKK1, Dickkopf-related protein 1.</p>
</caption>
<graphic xlink:href="IJMM-40-03-0587-g04"></graphic>
</fig>
<table-wrap id="tI-ijmm-40-03-0587" orientation="portrait" position="float">
<label>Table I</label>
<caption>
<p>Germline and somatic alterations in WNT signaling molecules in human diseases.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" valign="middle">Gene</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Function</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Germline</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Somatic</th>
<th align="center" colspan="1" rowspan="1" valign="middle">(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>APC</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">β-catenin degradation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hereditary colorectal cancer</td>
<td align="center" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b27-ijmm-40-03-0587">27</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>AXIN2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">β-catenin degradation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hereditary colorectal cancer</td>
<td align="center" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b28-ijmm-40-03-0587">28</xref>,<xref ref-type="bibr" rid="b30-ijmm-40-03-0587">30</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CELSR1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Core PCP component</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neural tube defects</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b115-ijmm-40-03-0587">115</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CTNNB1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">β-catenin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intellectual disability syndrome</td>
<td align="center" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b30-ijmm-40-03-0587">30</xref>,<xref ref-type="bibr" rid="b50-ijmm-40-03-0587">50</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>DAPLE</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">β-catenin degradation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hydrocephalus</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b170-ijmm-40-03-0587">170</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>DVL1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intracellular WNT signaling</td>
<td align="left" colspan="1" rowspan="1" valign="top">Robinow syndrome</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b120-ijmm-40-03-0587">120</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>DVL2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intracellular WNT signaling</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neural tube defects</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b115-ijmm-40-03-0587">115</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>DVL3</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Intracellular WNT signaling</td>
<td align="left" colspan="1" rowspan="1" valign="top">Robinow syndrome</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b120-ijmm-40-03-0587">120</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>FZD4</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">WNT receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Exudative vitreoretinopathy</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b91-ijmm-40-03-0587">91</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>FZD5</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">WNT receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ocular coloboma</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b166-ijmm-40-03-0587">166</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>FZD6</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">WNT receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nail dysplasia</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b167-ijmm-40-03-0587">167</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Neural tube defects</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b115-ijmm-40-03-0587">115</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>LRP5</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Canonical WNT receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Exudative vitreoretinopathy</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b91-ijmm-40-03-0587">91</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Osteoporosis-pseudoglioma syndrome</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b74-ijmm-40-03-0587">74</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">High-bone-mass diseases</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b71-ijmm-40-03-0587">71</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>LRP6</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Canonical WNT receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Osteoporosis and early-onset coronary artery disease</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b75-ijmm-40-03-0587">75</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Neural tube defects</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b115-ijmm-40-03-0587">115</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Selective tooth agenesis 7</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b163-ijmm-40-03-0587">163</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>NDP</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">FZD4 ligand</td>
<td align="left" colspan="1" rowspan="1" valign="top">Exudative vitreoretinopathy</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b91-ijmm-40-03-0587">91</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PORCN</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">WNT palmitoleoylation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Focal dermal hypoplasia</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b165-ijmm-40-03-0587">165</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PRICKLE1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Core PCP component</td>
<td align="left" colspan="1" rowspan="1" valign="top">Epilepsy</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b117-ijmm-40-03-0587">117</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Neural tube defects</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b115-ijmm-40-03-0587">115</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PRICKLE2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Core PCP component</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autism</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b119-ijmm-40-03-0587">119</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Epilepsy</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b118-ijmm-40-03-0587">118</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>RNF43</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">FZD ubiquitination</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hereditary colorectal cancer</td>
<td align="center" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b29-ijmm-40-03-0587">29</xref>,<xref ref-type="bibr" rid="b31-ijmm-40-03-0587">31</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ROR2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-canonical WNT receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Brachydactyly type B1</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b128-ijmm-40-03-0587">128</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Robinow syndrome</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b127-ijmm-40-03-0587">127</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>RSPO1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">RNF43/ZNRF3 antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">Palmoplantar hyperkeratosis with skin squamous cell carcinoma and sex reversal</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b168-ijmm-40-03-0587">168</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>RSPO2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">RNF43/ZNRF3 antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b32-ijmm-40-03-0587">32</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>RSPO3</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">RNF43/ZNRF3 antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b32-ijmm-40-03-0587">32</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>RSPO4</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">RNF43/ZNRF3 antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">Congenital anonychia</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b169-ijmm-40-03-0587">169</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SFRP4</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">WNT antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pyle disease</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b76-ijmm-40-03-0587">76</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SOST</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">WNT-LRP5/6 antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">Craniodiaphyseal dysplasia</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b68-ijmm-40-03-0587">68</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Sclerosteosis</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b69-ijmm-40-03-0587">69</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">van Buchem disease</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b70-ijmm-40-03-0587">70</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>VANGL1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Core PCP component</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neural tube defects</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b115-ijmm-40-03-0587">115</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>VANGL2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Core PCP component</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neural tube defects</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b115-ijmm-40-03-0587">115</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>WNT1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">WNT ligand</td>
<td align="left" colspan="1" rowspan="1" valign="top">Osteogenesis imperfecta</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b73-ijmm-40-03-0587">73</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Osteoporosis</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b73-ijmm-40-03-0587">73</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>WNT3</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">WNT ligand</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tetra-amelia syndrome</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b155-ijmm-40-03-0587">155</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>WNT4</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">WNT ligand</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mullerian aplasia and hyperandrogenism</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b157-ijmm-40-03-0587">157</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SERKAL syndrome</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b158-ijmm-40-03-0587">158</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>WNT5A</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">WNT ligand</td>
<td align="left" colspan="1" rowspan="1" valign="top">Robinow syndrome</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b126-ijmm-40-03-0587">126</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>WNT7A</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">WNT ligand</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fuhrmann syndrome</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b156-ijmm-40-03-0587">156</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>WNT10A</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">WNT ligand</td>
<td align="left" colspan="1" rowspan="1" valign="top">Odonto-onycho-dermal dysplasia</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b160-ijmm-40-03-0587">160</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Selective tooth agenesis 4</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b161-ijmm-40-03-0587">161</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>WNT10B</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">WNT ligand</td>
<td align="left" colspan="1" rowspan="1" valign="top">Selective tooth agenesis 8</td>
<td align="center" colspan="1" rowspan="1" valign="top"></td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b162-ijmm-40-03-0587">162</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="tII-ijmm-40-03-0587" orientation="portrait" position="float">
<label>Table II</label>
<caption>
<p>Anti-WNT signaling therapeutics.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" valign="middle">Target</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Mechanism of action</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Drug</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Stage of drug development</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Disease</th>
<th align="center" colspan="1" rowspan="1" valign="middle">(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">WNT</td>
<td align="left" colspan="1" rowspan="1" valign="top">PORCN inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">ETC-159</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase I</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b177-ijmm-40-03-0587">177</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">IWP-2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b178-ijmm-40-03-0587">178</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">LGK974</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase I</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b179-ijmm-40-03-0587">179</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">WNT-C59</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b180-ijmm-40-03-0587">180</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cardiac fibrosis</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b184-ijmm-40-03-0587">184</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Kidney fibrosis</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b185-ijmm-40-03-0587">185</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">WNT</td>
<td align="left" colspan="1" rowspan="1" valign="top">FZD8-binding WNT trap</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ipafricept</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase I</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b210-ijmm-40-03-0587">210</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">RSPO3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-RSPO3 mAb</td>
<td align="left" colspan="1" rowspan="1" valign="top">OMP-131R10</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase I</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b186-ijmm-40-03-0587">186</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">FZDs</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-FZD1/2/5/7/8 mAb</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vantictumab</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase I</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b208-ijmm-40-03-0587">208</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">FZD5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-FZD5 mAb</td>
<td align="left" colspan="1" rowspan="1" valign="top">IgG-2919</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b198-ijmm-40-03-0587">198</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">FZD10</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-FZD10 mAb</td>
<td align="left" colspan="1" rowspan="1" valign="top">OTSA101</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase I (terminated)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b209-ijmm-40-03-0587">209</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ROR1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ROR1 inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">KAN 0439834</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b216-ijmm-40-03-0587">216</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-ROR1 mAb</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cirmtuzumab</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase I</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b147-ijmm-40-03-0587">147</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-ROR1 × anti-CD3</td>
<td align="left" colspan="1" rowspan="1" valign="top">ROR1-CD3-DART</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b218-ijmm-40-03-0587">218</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">bispecific mAb</td>
<td align="left" colspan="1" rowspan="1" valign="top">APVO425</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b219-ijmm-40-03-0587">219</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ROR1 CAR-T cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">ROR1R-CAR-T</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b220-ijmm-40-03-0587">220</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">AXIN</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tankyrase inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">AZ1366</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b239-ijmm-40-03-0587">239</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">G007-LK</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b240-ijmm-40-03-0587">240</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">NVP-TNKS656</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b241-ijmm-40-03-0587">241</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">XAV939</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b243-ijmm-40-03-0587">243</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neuropathic pain</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b245-ijmm-40-03-0587">245</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">β-catenin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Blockade of β-catenin</td>
<td align="left" colspan="1" rowspan="1" valign="top">BC2059</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b252-ijmm-40-03-0587">252</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">protein-protein-interaction</td>
<td align="left" colspan="1" rowspan="1" valign="top">CGP049090</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b253-ijmm-40-03-0587">253</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">CWP232228</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b254-ijmm-40-03-0587">254</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ICG-001</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b255-ijmm-40-03-0587">255</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pulmonary fibrosis</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b261-ijmm-40-03-0587">261</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">CKD</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b262-ijmm-40-03-0587">262</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">LF3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b256-ijmm-40-03-0587">256</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">MSAB</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b257-ijmm-40-03-0587">257</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">PKF115-584</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b258-ijmm-40-03-0587">258</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">PRI-724</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase II</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b259-ijmm-40-03-0587">259</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">SAH-BCL9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b260-ijmm-40-03-0587">260</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-ijmm-40-03-0587">
<p>CKD, chronic kidney disease; OTSA101, OTSA101-DPTA-90Y; PORCN, porcupine.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tIII-ijmm-40-03-0587" orientation="portrait" position="float">
<label>Table III</label>
<caption>
<p>Pro-WNT signaling therapeutics.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" valign="middle">Target</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Mechanism of action</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Drug</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Stage of drug development</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Disease</th>
<th align="center" colspan="1" rowspan="1" valign="middle">(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">DKK1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-DKK1 mAb</td>
<td align="left" colspan="1" rowspan="1" valign="top">BHQ880</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase II</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b226-ijmm-40-03-0587">226</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DKN-01</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase I</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b227-ijmm-40-03-0587">227</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">PF-04840082</td>
<td align="left" colspan="1" rowspan="1" valign="top">Preclinical</td>
<td align="left" colspan="1" rowspan="1" valign="top">Osteoporosis</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b228-ijmm-40-03-0587">228</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SOST</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-SOST mAb</td>
<td align="left" colspan="1" rowspan="1" valign="top">Blosozumab</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase II</td>
<td align="left" colspan="1" rowspan="1" valign="top">Osteoporosis</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b224-ijmm-40-03-0587">224</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">BPS804</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase II</td>
<td align="left" colspan="1" rowspan="1" valign="top">Osteoporosis</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b225-ijmm-40-03-0587">225</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Romosozumab</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phase III</td>
<td align="left" colspan="1" rowspan="1" valign="top">Osteoporosis</td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b223-ijmm-40-03-0587">223</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">β-catenin</td>
<td align="left" colspan="1" rowspan="1" valign="top">GSK3β inhibitor or</td>
<td align="left" colspan="1" rowspan="1" valign="top">BIO</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reagent (<italic>in vitro</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b246-ijmm-40-03-0587">246</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">GSK3 inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">CHIR99021</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reagent <italic>(in vitro</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b247-ijmm-40-03-0587">247</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">LY2090314</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reagent (<italic>in vitro</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b248-ijmm-40-03-0587">248</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TWS119</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reagent (<italic>in vitro</italic>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="right" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="b249-ijmm-40-03-0587">249</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn2-ijmm-40-03-0587">
<p>DKK1, Dickkopf-related protein 1; GSK3β, glycogen synthase kinase 3β.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>